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Abstract 
 This research is focused on the development of novel photoassisted synthetic 
methodologies that provide straightforward access to complex and diverse libraries of 
polyheterocycles from modularly assembled precursors. All methods are based on the 
dearomative cycloadditions between two components: (i) o-azaxylylenes, generated by 
the excited-state intramolecular proton transfer, and (ii) tethered arene groups. 
We have demonstrated the synthetic utility of four new photoinduced processes that 
yield complex products amenable for post-photochemical modifications: 
• [4+4] Cycloaddition of o-azaxylylenes to 1,3,4-oxadiazoles with subsequent 
dinitrogen extrusion. This reaction furnishes compounds outfitted with 
epoxide fragments, which undergo ring-openings with various nucleophiles; 
furthermore, the oxidized products rearrange into triazocanoindolinones under 
Schmidt reaction conditions. 
• [4+2] Reaction between amino-o-azaxylylenes and tethered pyrroles. The 
primary pyrroline photoproducts are converted into stable polyheterocycles by 
1,3-dipolar cycloaddition with tosyl azide and an intramolecular Friedel–
Crafts reaction. 
• Photodearomatization of benzenoid arenes via [2+4] reactions with 
o-azaxylylenes. This process transforms readily available benzene units into 
 iii 
 
1,3-cyclohexadienes, which are reactive in acid-catalyzed modifications and 
thermal [4+2] cycloadditions. 
• Photocascade reaction involving [2+4] photocycloaddition of tethered 
anilines to o-azaxylylenes followed by secondary cyclization enabled by the 
oxalyl linker. This transformation permits strategic installation of specific 
functionalities into the photoproducts, with the purpose of further ring-
forming modifications. 
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Chapter One:  Introduction and General Background 
Progress in the field of drug discovery is seemingly never-ending, as illustrated by the 
fact that, every year since 1990, the U.S. Food and Drug Administration (FDA) has been 
steadily approving at least 17 new molecular entities for use as therapeutics [1] 
(Figure 1.1). Recent growth in the number of approvals is especially impressive: in 2018, 
the FDA has hit a new record by permitting 59 new drugs to enter the U.S. market [1, 2]. 
The majority of these novel therapies (38, or 64%) are small molecules, such as Pfizer’s 
Lorlatinib (1.1), designed to treat a certain type of lung cancer, and an anti-influenza 
agent Xofluza (1.2) developed by Shionogi and Genentech (Figure 1.2). All these 
observations indicate that the demand in new small-molecule drugs is persisting and will 
most likely keep growing. 
Figure 1.1: Annual FDA drug approvals for the 1990–2018 period [2]. 
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Figure 1.2: Examples of drugs approved by FDA in 2018 [1]. 
 
The process of drug discovery involves extensive screening of compound libraries. 
Biological evaluations required for the identification of a new therapeutic can be 
performed either on a focused library, which consists of drug candidates sharing common 
structural features that are known to facilitate binding to a specific target, or on a 
structurally complex and diverse library of molecules that are tested for their ability to 
perturbate a disease-related pathway without consideration of any particular target [3]. 
While the first approach relies on retrosynthetic analysis that allows efficient planning of 
routes towards specific compounds, the second strategy is implemented with the help of 
diversity-oriented synthesis (DOS) designed to probe a wide area of chemical space. This 
term is used to denote the imaginable multi-dimensional space encompassing all possible 
carbon-based small molecules, where the distance between each two points is directly 
proportional to the degree of dissimilarity between the molecules located at these points 
[4, 5]. An important feature of the DOS methodology is that it increases the chance of 
encountering unexplored regions of biologically relevant chemical space. In other words, 
it facilitates discovery of previously unknown structural elements responsible for the 
specific binding interactions between small molecules and biological targets, such as 
proteins, RNA and DNA. Therefore, the strategy of generating diverse libraries serves as 
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a powerful tool for the identification of new drug candidates, effectively complementing 
the target-oriented approach. 
Photochemical synthetic methods have not been widely utilized by modern medicinal 
chemists actively searching for novel therapeutics; however, recent “boom” in the 
discovery of powerful photoredox-based reactions seems to have started changing this 
situation [6]. At the same time, traditional metal-free photochemistry has an immense 
potential for applications in DOS, because it is capable of converting modularly 
assembled and easily diversifiable starting materials into reactive intermediates that can 
be involved in transformations leading to various complex molecular scaffolds 
(Scheme 1.1). An illustrative example is the recently developed methodology that takes 
advantage of transient species generated by the excited-state intramolecular proton 
transfer (ESIPT) [7-10] – a photoinduced process that has been well-studied by 
photophysicists but has long been overlooked by synthetic chemists. All relevant 
reactions will be discussed in detail in the Literature Review; a representative set of small 
molecules produced by the diversity-oriented ESIPT-based photochemistry is depicted in 
Scheme 1.1. 
 
 
 
 
 
Scheme 1.1: Utility of the photochemical ESIPT-based synthetic methodology [7-10] for 
DOS applications. 
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An important class of molecular transformations that can be achieved photo-
chemically and are suitable for DOS is dearomatization reactions [11]. These processes 
enable quick conversion of ubiquitous aromatic moieties, found in many feedstock 
chemicals, into complex scaffolds enriched with sp3-hybridized carbons. Lovering and 
co-workers have shown that compounds with a greater degree of three-dimensional 
complexity, which is quantified as a fraction of saturated carbons in the molecule, are 
more likely to become successful drug candidates [12]; therefore, dearomatized products 
are especially attractive from the medicinal chemistry standpoint. Even more complex 
structures, which would cover a larger region of chemical space, can be accessed through 
dearomative cycloadditions that produce polycyclic architectures with a high content of 
sp3 carbons. Furthermore, if this reaction is performed in intramolecular fashion, the 
tether linking two reactive components together transforms into an additional cycle in the 
product molecule (Scheme 1.2). 
 
 
 
 
 
 
 
 
Scheme 1.2: Hypothetical dearomatization reactions of various topologies. 
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The present work is aimed at the development of new synthetic methods based on 
intramolecular dearomative cycloadditions driven by ESIPT. Through the 
straightforward modular assembly of the starting materials, as well as structural diversity 
and complexity of the products, we intend to demonstrate that these novel strategies 
conform to the criteria of diversity-oriented synthesis – a powerful approach utilized to 
discover new small-molecule drugs demanded by modern society. 
 
 6 
Chapter Two:  Literature Review 
Excited-State Intramolecular Proton Transfer: a Photophysical Overview 
Excited-state intramolecular proton transfer (ESIPT) is a photoinduced relocation of a 
proton from an acidic site to a basic group within the same molecule [13]. Since the 
discovery of this phenomenon by Weller in the 1950s for salicylic acid (Scheme 2.1) 
[14], it has found a variety of applications, such as, fluorescent imaging probes utilized 
for the selective detection of biologically and environmentally important species [15], 
and in synthetic organic photochemistry, which is the focus of the present work. 
 
 
Scheme 2.1: ESIPT process in salicylic acid (simplified representation). 
 
ESIPT is feasible in the molecules where acidic and basic functionalities are situated 
in a close proximity to each other, so that an intramolecular hydrogen bond can be 
formed between two sites [13]. Typical proton donors are hydroxyl [13, 15-17] and 
amide groups [15-18], whereas proton acceptors are usually heterocyclic [13, 15, 17, 18] 
and imine nitrogen atoms [13, 15], as well as carbonyl oxygen [15-18]. Representative 
examples of the systems capable of ESIPT are shown in Figure 2.1. 
Energetics of a typical ESIPT and related processes are illustrated in the diagram for 
2-(2'-hydroxyphenyl)-benzothiazole (2.2-N; Figure 2.2) [17]. Photoexcitation promotes 
the molecule in its initial form, often referred to as normal or enol, from the ground state
 7 
 
 
 
 
 
Figure 2.1: Structures of selected ESIPT-reactive compounds. 
 
 
 
 
 
 
 
Figure 2.2: Energetic diagram of ESIPT for 2-(2'-hydroxyphenyl)-benzothiazole (2.2). 
Republished with permission of Royal Society of Chemistry, from ref. [17]; permission 
conveyed through Copyright Clearance Center, Inc. 
S0(N) to its first singlet excited state S1(N), which then converts into a lower energy 
tautomeric or keto excited state S1(T) through ESIPT. The resulting proton-transferred 
singlet has three main deactivation routes: 
• Changing the spin state by intersystem crossing (ISC) into T1(T); 
• Isomerization from E- to Z-form, where proton donor and acceptor are located 
on opposite sides of a newly formed double bond; 
• Relaxation to the ground state S0(T) that is subject to barrierless back proton 
transfer (BPT) to S0(N). 
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S0(T) → S0(N) transition process is radiative, i.e. accompanied by the emission of a 
photon, and therefore provides the opportunity to detect the presence of tautomerized 
species by fluorescence spectroscopy and to investigate the influence of various factors 
on the photophysical properties of ESIPT. 
Among numerous molecules where ESIPT is feasible, 1-(acylamino)anthraquinones 
constitute an instructive example, for which photophysics are well studied [19-21]. 
Furthermore, these compounds contain the same ESIPT-reactive o-amidoketone moieties 
that are present in all systems examined in this work (see “Results and Discussion” 
chapter). 
In their seminal work, Smith, Barbara and co-workers performed comprehensive 
photophysical investigations of the ESIPT mechanism in a series of four 1-(acylamino) 
anthraquinones, where electron-withdrawing properties of N-acyl group were 
successively increased (heptanoyl, chloroacetyl, dichloroacetyl and trifluoroacetyl 
derivatives, abbreviated as HPAQ, CAAQ, DCAQ and TFAQ, respectively; Figure 2.3a) 
[19]. Fluorescence spectroscopy studies revealed characteristic dual emission of these 
compounds (Figure 2.3b, c) consisting of: 
• Short-wavelength emission (SWE; ca. 510 nm) decreasing when moving from 
the most electron-rich HPAQ to the most electron-poor TFAQ; 
• Long-wavelength emission (LWE; ca. 635 nm) that experiences the opposite 
trend, increasing with the electron-withdrawing ability of an amide group. 
SWE is in the mirror-image relationship with absorption peak (Figure 2.3c), 
indicating the emission from the S1(N) state. The substantially Stokes-shifted LWE was  
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Figure 2.3: (a) Structures of studied 1-(acylamino)anthraquinones; 
(b) Emission spectra for cyclohexane solutions of HPAQ, CAAQ and TFAQ; 
(c) Absorption and emission spectra for cyclohexane solutions of HPAQ and TFAQ. 
Adapted with permission from ref. [19]. Copyright © 1991, American Chemical Society. 
assigned to the S1(T) → S0(T) transition, thus serving as experimental evidence for the 
ESIPT process in 1-(acylamino)anthraquinones.  
Authors noted that, in theory, there could be other possible explanations for the 
observed dual emission. For instance, twisted internal charge transfer (TICT) state is 
known to produce a similar effect [22]; however, TICT emission band is expected to 
undergo a red shift with the increase of solvent polarity, whereas the opposite trend was 
detected for LWE of aminoanthraquinone derivatives. Besides, photoionization of the 
S1(N) molecule could produce an excited-state anion responsible for LWE, although this 
emission would become weaker in less polar solvents and diminish in the presence of a 
(a) 
(b) 
(c) 
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strong acid, which is in disagreement with the experimental results. Another feasible 
rationale for the dual fluorescence could be emissions from two S1 states that are 
produced by exciting two different ground-state species, such as free analyte molecule 
and its complex with solvent. This possibility was ruled out by the fact that two excitation 
spectra, one with monitoring SWE and another with monitoring LWE, are identical and 
look similar to the absorption spectrum. Such crucial observation supports the ESIPT 
mechanism, where both SWE and LWE are derived from a common excited state S1(N): 
one is the direct S1(N) emission and the other is the emission from S1(T) produced by 
tautomerization of S1(N). 
By examination of the dual emission pattern, they established the influence of several 
internal and external factors on the ESIPT in 1-(acylamino)anthraquinones. As it was 
noted earlier, the LWE/SWE ratio increases with the electron-withdrawing character of 
an acyl substituent (Table 2.1), suggesting that enhancing NH acidity has a positive 
impact on ESIPT. The opposite trend (LWE/SWE decline) was observed in the series of  
 
Table 2.1: LWE/SWE Ratiosa for 1-(Acylamino)anthraquinones in Cyclohexane [19] 
Compound LWE/SWE Ratio 
HPAQ 0.34 
CAAQ 3.3 
DCAQ 14 
TFAQ 27 
a Defined as the emission intensity at 635 nm divided by the emission intensity at 510 nm. 
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spectra recorded in different solvents, going from less polar to more polar: cyclohexane 
→ dichloromethane → acetonitrile (Figure 2.4); this result indicates a stabilization of 
S1(N) relative to S1(T) in a more polar medium. 
 
 
 
 
 
 
 
Figure 2.4: Corrected fluorescence emission spectra for CAAQ in various solvents. 
Adapted with permission from ref. [19]. Copyright © 1991, American Chemical Society. 
While static fluorescence spectroscopy allows for detecting the existence of singlet 
excited tautomeric species and to study the influence of various factors on the extent of 
ESIPT, time-resolved emission experiments (performed by methods such as time-
correlated single-photon counting, TCSPC) provide the information about the dynamics 
of the process. For instance, by monitoring the rise in mostly tautomer-produced 
fluorescence at 593 nm of DCAQ with subpicosecond resolution, it was concluded that 
ESIPT process is extremely fast and is complete within 3 ps (Figure 2.5a). In addition, 
plotting the decay of emission at the same wavelength and performing exponential fitting 
(Figure 2.5b) gave the value for the lifetime of emitting S1(T) species, which is 82 ps in 
this case. 
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Figure 2.5: Time-resolved fluorescence emission of DCAQ in acetone monitored at 
593 nm: (a) Rise in emission, together with the instrument response function (arbitrary 
zero of time); (b) Emission decay curve monitored over longer period. Adapted with 
permission from ref. [19]. Copyright © 1991, American Chemical Society. 
Importantly, the ESIPT process in 1-(acylamino)anthraquinones can also occur in the 
triplet manifold, as suggested by Nagaoka et al. who probed the T1 states of the same 
series of compounds (Figure 2.3a) by transient absorption spectroscopy [20]. Given that 
the data was obtained at 2 µs after photoexcitation (six orders of magnitude longer than 
the typical singlet lifetime), and that the spectra were quenched by oxygen, the authors 
concluded that observed absorption was produced by triplet species. In most cases, two 
bands were detected: short-wavelength absorption (SWA; ca. 450 nm) and long-
wavelength absorption (LWA; ca. 480 nm), which were ascribed to T1(N) and T1(T) 
respectively. Assignments were made based on the same trends reported for singlet 
states: namely, decrease in the amount of tautomerized species in more polar solvents and 
for compounds with less electron-withdrawing acyl groups (Figure 2.6). The authors 
concluded that both ESIPT and back proton transfer take place in the triplet state, due to 
the following observations: 
(a) (b) 
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• The absorption spectrum of TFAQ obtained after triplet photosensitization 
with benzophenone, which is supposed to produce T1(N) exclusively0F
1, 
contains both SWA and LWA, indicating the formation of T1(T); 
• Spectrum of TFAQ in acetonitrile has only SWA arising from the 
untautomerized form; given the high propensity of this compound for singlet 
ESIPT [19], it was proposed that back proton transfer predominates in the 
triplet state. 
 
 
 
 
 
 
 
Figure 2.6: Transient absorption spectra of TFAQ (a) and CAAQ (b) obtained in various 
solvents at room temperature. Reprinted from ref. [20], Copyright © 1997, with 
permission from Elsevier. 
In addition to amidoanthraquinones, a number of other systems deserve brief 
discussion, because they allowed revelation of several crucial trends in ESIPT reactivity. 
Chou and co-workers investigated thermodynamics and kinetics of ESIPT in a series 
of 2-(2′-aminophenyl)benzothiazole (ABT) derivatives by fluorescence spectroscopy and 
                                                 
1 It is, however, challenging to induce selective photoexcitation of benzophenone in presence of 
TFAQ, since both compounds absorb in the same region (250–300 nm) [19, 23]. If TFAQ gets excited to 
S1(N), then the formation of T1(T) is possible via singlet ESIPT followed by ISC. 
(a) (b) 
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DFT calculations [24]. They found that stronger acidic character of NH proton correlates 
not only with greater exergonicity of the proton transfer, but also with a smaller energy 
barrier for the process (Figure 2.7). At the same time, in the case of 2-(imidazo[1,2-
a]pyridin-2-yl)aniline-based (IPA) compounds, the effect of NH acidity on the ESIPT 
rate was almost the opposite, with trifluoroacetyl derivative being the slowest (Figure 
2.8) [25]. This apparent abnormality was rationalized by proposing a highly charge-
separated non-planar transition state 2.6 leading to the formation of zwitter-ionic  
Figure 2.7: Thermodynamic and kinetic correlations for ESIPT in the series of ABT 
compounds 2.4a–h. kpt is the proton-transfer rate constant. The potential energy curves 
(dashed lines) are qualitative. Adapted with permission from ref. [24]. Copyright © 2015, 
American Chemical Society. 
Figure 2.8: Thermodynamic and kinetic correlations for ESIPT in the series of IPA 
compounds 2.5a–e. kpt and k–pt are the proton-transfer and back proton-transfer rate 
constants respectively. ΔEexp* and ΔEcal* are experimental and calculated energy 
differences between the normal form and tautomer form species in S1 excited states. 
Republished with permission of Royal Society of Chemistry, from ref. [25]; permission 
conveyed through Copyright Clearance Center, Inc. 
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Scheme 2.2: ESIPT of IPA system via a plausible non-planar transition state [25]. 
 
tautomer 2.5-S1(T) (Scheme 2.2), as opposed to ABT systems where ESIPT proceeds 
through flat semi-π-conjugated structure. Presumably, increase in the electron-
withdrawing character of R group provides stronger stabilization of a negative charge on 
the amide nitrogen, forcing it to adopt non-planar geometry. This distortion destabilizes 
the transition state 2.6 by reducing the amount of π-conjugation in it, and therefore results 
in a slower ESIPT. 
For 2-(2'-benzamidophenyl)benzimidazole (2-BAPBI; Figure 2.9), effect of the 
solvent on the singlet tautomer lifetime was studied (Table 2.2) [26]. In less polar 
cyclohexane and dioxane, monoexponential decays were observed and gave lifetimes 
around 2 ns. In contrast, fitting the data measured in more polar media (acetonitrile, 
methanol and water) produced biexponential decays, suggesting the presence of two 
different emitting species in these solvents. The authors proposed that the major short-
lived species is a “closed” tautomer with intramolecular hydrogen bond 2.7-T, whereas 
the minor long-lived fluorescence, which was detected exclusively in polar solvents, was 
assigned to an “open” tautomer bound to a solvent molecule 2.7-T'. Lifetime of the 
“closed” species decreases with the solvent polarity; however, this trend is broken in 
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water, so it was suggested that this emission component belongs to an untautomerized 
form 2.7-N'. At the same time, a stronger hydrogen bonding capacity of the solvent 
results in greater stabilization of the “open” tautomer 2.7-T', increasing its proportion and 
extending its lifetime. 
 
 
 
Figure 2.9: 2-BAPBI and derived species detected by time-resolved fluorescence [26]. 
 
Table 2.2: Fluorescence Lifetimes (τ, ns) for 2-BAPBI in Different Solvents 
(Reprinted from ref. [26], Copyright © 1999, with permission from Elsevier) 
Solvent Fit 1 (single exp. decay)  Fit 2 (double exp. decay) 
 τ χ2 a  τ1 τ2 χ2 
Cyclohexane 2.1 1.2     
Dioxane 2.0 1.2     
Acetonitrile 0.28 1.6  0.28 (96.2b) 7.2 (3.8) 1.2 
Methanol 3.6 2.5  0.21 (84.7) 5.4 (15.3) 1.3 
Water 4.6 4.2  1.8 (52.1) 9.1 (47.9) 1.1 
a χ2 is the measure of goodness of fit. b Numbers in parentheses are amplitudes which represent relative 
proportions of species decaying with the corresponding lifetimes. 
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Excited-State Intramolecular Proton Transfer: Synthetic Applications 
Short-lived tautomers produced by ESIPT are highly energetic, and therefore are 
expected to be very reactive. One can envision taking advantage of their reactivity and 
engaging them in chemical transformations that would create new C–C and/or C–hetero-
atom bonds. However, the number of synthetic methods employing ESIPT has been 
limited, presumably due to short lifetimes of photogenerated excited tautomers that suffer 
from a multitude of fast decay pathways, such as back proton transfer (BPT; Scheme 2.3). 
 
 
 
Scheme 2.3: Hypothetical “trapping” reaction of ESIPT-generated tautomer. 
 
One of the earliest examples of an ESIPT-based transformation that irreversibly leads 
to a new compound is the alkyne photohydration in o-hydroxy-substituted phenylethylene 
2.10 discovered by Yates in 1984 (Scheme 2.4, reaction a); yield of the resulting 
acetophenone 2.11 was not reported [27]. It was suggested that the OH group protonates 
a triple bond in the excited state species 2.10-N*, and subsequent nucleophilic addition of 
water to the carbocation 2.10-T* leads to the ketone product 2.11. The newer study 
shows that utilizing the primary amine 2.12, as a trapping agent in this reaction, provides 
access to imine 2.13 in 56% yield (Scheme 2.4, reaction b) [28]. A similar process is also 
feasible for alkene substrates: photohydration of o-hydroxystyrene 2.14 affords benzyl 
alcohol 2.15 (Scheme 2.4, reaction c) [29]. 
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Scheme 2.4 
In addition, some systems with a more distant location of the double bond are ESIPT-
reactive as well [30, 31]. For example, formation of products 2.18 and 2.20 from 
2-(2′-cyclohexenyl)phenol 2.16 was rationalized by proposing transfer of a proton to the 
proximal olefinic carbon, followed by ring opening of the secondary cyclohexyl 
carbocation forming the key o-quinone methide intermediate 2.17 (Scheme 2.5) [30]. 
Subsequent trapping of this species by nucleophilic addition of methanol and by Diels–
Alder reaction with ethyl vinyl ether 2.19 yields methoxy-adduct 2.18 and 
dihydrobenzopyran 2.20, respectively. 
 
 
 
 
 
Scheme 2.5 
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Wan and co-workers extended the applicability of ESIPT to a carbon atom onto the 
systems where a proton is transferred to a polyaromatic moiety. Irradiation of the 
naphthyl-substituted phenol 2.21 triggered ESIPT to the 7'-position, followed by 
6π-electrocyclization of the quinone methide 2.21-T* yielding product 20, which was 
readily oxidized to the stable 1,9-benzoxanthene 2.23 (Scheme 2.6) [32]. Since no 
reaction was observed in neat acetonitrile, the authors concluded that ESIPT to a distant 
carbon atom in this system is water-mediated. 
 
Scheme 2.6 
Interestingly, introduction of a second OH group into the para-position to phenol 
forced the proton transfer to occur under anhydrous conditions (Scheme 2.7) [33]. In this 
case, ipso-carbon of the naphthalene ring in 2.24 undergoes direct protonation, and the 
resulting zwitterionic intermediate 2.24-T* rearranges to the more stable benzylic 
carbocation 2.25 via 1,2-shift of phenyl group; reverse proton transfer gives the product 
2.26. Photolysis of the phenylanthracene analogue 2.27 in neat acetonitrile induces the 
same ESIPT; however, the produced carbocation 2.27-T* is stabilized by three adjacent 
phenyl rings, and instead of rearranging, it cyclizes to the ether 2.28. 
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Scheme 2.7 
It has been found that there is a much larger number of synthetic applications in 
ESIPT-reactive compounds where the oxygen acts as a proton acceptor. One important 
class of transformations involving these systems is based on the formation of o-quinone 
methide intermediate 2.30 produced by elimination of water or alcohol, which 
presumably takes place simultaneously with the ESIPT (Scheme 2.8). 
 
 
Scheme 2.8 
Kostikov and Popik took advantage of this process for the development of photolabile 
protecting groups [34, 35]. Irradiation of 2,5-dihydroxybenzyl ethers 2.31 and their 
naphthalene analogues 2.32 induces ESIPT accompanied by clean elimination of alcohol 
substrates 2.34 (Scheme 2.9) [34]. 
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Scheme 2.9 
In another example, the same mechanism enables traceless photorelease of various 
diols 2.39 from corresponding acetals of 5-methoxy- or 5-hydroxysalicylaldehydes 2.35: 
transfer of a proton to the acetal oxygen concurrent with the departure of alcohol leads to 
2.37 that hydrolyzes to aldehyde 2.38 and diol 2.39 (Scheme 2.10) [35]. 
 
 
 
 
 
 
 
Scheme 2.10 
A group of researchers led by Basarić studied a number of ESIPT-driven quinone 
methide formations in hydroxyadamantyl-substituted phenols and naphthols [36, 37]. For 
instance, photolysis of alcohol 2.40 gives rise to the intermediate 2.41 which is trapped 
by ethanolamine 2.42 (Scheme 2.11, reaction a) [37]. A different reactivity was observed 
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for the biphenyl alcohol 2.44, where two hydroxyl groups are separated with a longer 
bridge: the resulting quinone methide 2.45 contains an additional double bond, which 
makes the system perfectly arranged for the 6π-electrocyclic ring closure delivering 
chromane 2.46 (Scheme 2.11, reaction b) [36]. 
 
 
 
 
 
 
Scheme 2.11 
2-Hydroxychalcones are also amenable for ESIPT/electrocyclization cascade [38]. In 
this case, transfer of a proton to the carbonyl oxygen in substrate 2.47 directly provides 
quinone methide Z-2.47-T*, which after Z-E isomerization of the exocyclic double bond 
undergoes pericyclic reaction that furnishes flavanone 2.48 (Scheme 2.12). 
 
 
 
 
 
 
Scheme 2.12 
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A prominent example of a synthetically useful system where ESIPT to oxygen plays a 
central role in its reactivity is 3-hydroxyflavone; its photochemistry has been thoroughly 
studied in Porco’s lab [39-43]. They discovered that the zwitterionic 3-oxidopyryllium 
species 2.49-T*, which is produced as a result of a proton transfer in this photoactive 
core (2.49) can be efficiently engaged in 1,3-dipolar cycloaddition with an alkene, such 
as methyl cinnamate 2.50 (Scheme 2.13) – the process that conceivably takes place in the 
biosynthesis of numerous cyclopenta[bc]benzopyran derivatives occurring in Aglaia 
plants [44, 45]. Remarkably, this one-pot ESIPT/cycloaddition sequence proceeds with 
high regioselectivity and good endo/exo diastereoselectivity, which was rationalized by 
plausible π-stacking interactions between aryl groups in the dipolarophile and 3-oxido-
pyryllium in the proposed transition state endo-2.51 [42]. 
 
 
Scheme 2.13 
The novel transformation enabled exceptionally concise biomimetic synthesis of the 
natural product (±)-methyl rocaglate endo-2.57 (Scheme 2.14) [39]. After irradiation of 
the 3-hydroxyflavone 2.53, two compounds were isolated: the major adduct 2.54 and the 
product of the acid-catalyzed α-ketol shift 2.55 that formed during silica gel purification. 
Treatment of the resulting mixture with base induced 1,2-shift of dimethoxyphenyl group 
in 2.54 and expansion of cyclobutane ring in 2.55, yielding the single tetrahydro-
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benzofuran 2.56. Subsequent hydroxy-directed reduction of α-ketol afforded the desired 
(±)-methyl rocaglate endo-2.57, as well as its stereoisomer exo-2.57. 
 
 
 
 
 
 
 
 
 
 
Scheme 2.14 
Furthermore, extending the scope of the process on a wide range of dipolarophiles 
(predominantly β-aryl and β-hetaryl-substituted acrylates and acrylamides) allowed for 
generating a library of 16 rocaglate derivatives used for in vitro and in vivo biological 
evaluations [42]. 
Importantly, Porco’s group developed an enantioselective version of the 
transformation, utilizing chiral TADDOL-based reagents and applied this approach for 
the asymmetric total syntheses of (–)-rocaglaol 2.60 and (–)-rocaglamide 2.61 [40], as 
well as (–)-silvestrol 2.62 [41] and (+)-foveoglin A 2.63 [43] (Scheme 2.15). The high 
 25 
degree of enantiocontrol (up to 96% ee for the final product) is presumably achieved 
through the hydrogen bonding of the chiral mediator 2.58 to 3-oxidopyryllium; this 
stereospecific interaction effectively blocks one stereoface from the attack of the 
dipolarophile (transition state 2.59). 
 
 
 
 
 
 
 
 
 
 
Scheme 2.15 
Certain mechanistic aspects of the photoinduced cycloaddition in 3-hydroxyflavone 
systems were also investigated [42, 43]. The importance of the ESIPT process in the 
mechanism of the transformation was emphasized by the fact that protic solvents (e.g. 
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methanol) and additives (e.g. trifluoroethanol) improve the product yield and enhance the 
intensity of long-wavelength fluorescence emission attributed to the tautomerized species 
2.53-T* (Figure 2.10). Based on these observations, it was proposed that protic 
compounds facilitate ESIPT through the formation of hydrogen-bonded complexes and 
acting as “proton shuttles.” Besides the ESIPT pathway, the authors did not exclude the 
possibility of the excited-state charge transfer (ESICT) form 2.53-N*' participating in the 
cycloaddition: in the fluorescence spectra of 3-hydroxyflavone 2.53, a short-wavelength 
shoulder band around 440 nm was detected; given that a similar peak was observed in the 
spectrum of ESIPT-inactive 3-methoxyflavone 2.64, this emission was assigned to the 
ESICT species 2.53-N*'. 
 
 
 
 
 
 
 
 
 
Figure 2.10: Fluorescence emission of 3-hydroxyflavone 2.53 and 3-methoxyflavone 
2.64 indicating both ESICT and ESIPT processes with presumed charge transfer (CT) in 
both excited states from phototautomers 2.53-N*/2.53-N*' and 2.53-T*/2.53-T*'. 
Light blue: 2.53 in CHCl3; orange: 2.53 in CHCl3/TFE (95:5); red: 2.53 in CHCl3/TFE 
(70:30); green: 2.53 in TFE; purple: 2.64 in TFE. Adapted from ref. [42], Copyright © 
2010, with permission from John Wiley and Sons, Inc. 
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With regard to the spin multiplicity of excited-state intermediates involved in the 
ESIPT/cycloaddition process, several results support the participation of triplet 
biradicaloids [43]: 
• Addition of the triplet quencher 9,10-dibromoanthracene completely 
suppressed the reaction; 
• Running the irradiation in presence of the triplet sensitizer benzophenone lead 
to increase in the product yield (from 40 to 56%). 
In view of these observations, the authors slightly revised the mechanism and 
proposed a stepwise cycloaddition pathway, where proton-transferred 3-oxidopyryllium 
is represented as a triplet biradical resonance form 2.53-T*-BR (Scheme 2.16). This 
species reacts with dipolarophile 2.65 either through the direct radical addition, or via 
photoinduced electron transfer (PET) that forms radical ion pair 2.66 collapsing into the 
semi-adduct 2.67; subsequent ISC and recombination afford product 2.68. 
 
 
 
 
 
 
 
 
 
Scheme 2.16 
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In addition to 3-hydroxyflavones, Porco’s group engaged their aza-analogues, 
3-hydroxyquinolinones, into the same ESIPT-driven transformation [46, 47]. 
Fluorescence studies performed on the simplest derivative 2.69 revealed that S1(T) 
species 2.69-T* (Scheme 2.17), which produces largely Stokes-shifted emission band 
around 475 nm (Figure 2.11), is formed with a high quantum yield and has a relatively 
long lifetime: for instance, the values obtained in dioxane are 0.65 and 16.8 ns, 
respectively. Therefore, it was envisioned that the excited-state tautomer 2.69-T* can be 
efficiently captured with various dipolarophiles, and this hypothesis found experimental 
verification: irradiating quinolinone 2.69 with various unsaturated compounds (e.g. 2.70, 
2.72, 2.74) afforded expected cycloadducts in good yields (Scheme 2.17) [46]. 
Interestingly, the product of the alkyne addition 2.75 spontaneously converted into the 
indolino-cyclopentenone 2.76 by α-ketol shift. 
 
 
 
 
 
 
 
 
 
Scheme 2.17 
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Figure 2.11: Absorption and normalized fluorescence spectra of 2.69. Reprinted with 
permission from ref. [46]. Copyright © 2011, American Chemical Society. 
The strategy of utilizing ESIPT-generated species for cycloaddition reactions, which 
are especially appealing from the complexity building standpoint, was successfully 
implemented by Kutateladze’s group for o-carbonyl-functionalized anilides (2.77a,b, 
Scheme 2.18) and anilines (2.77c) [7-10, 48-50]. The main challenge associated with 
these systems is that their excited-state tautomers (called o-azaxylylenes, 
2.77a–c-T*) are extremely short-lived: for instance, fluorescence lifetimes measured for 
LWE in N-acetyl- and N-trifluoroacetyl-substituted o-aminoacetophenones 2.77d,e are 
only 45 and 409 ps, respectively [51] – at least 1000 times less than the values obtained 
for previously discussed 3-hydroxyquinolinones [46]. This apparent obstacle, however, 
was surmounted by tying two cycloaddition components together in one molecule: 
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intramolecular processes, such as [4+4] and [4+2] reactions with the attached 
heterocyclic moieties, turned out to be fast enough to effectively compete with the decay 
of the o-azaxylylene species. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.18 
Even though the intramolecular aspect of the photocycloaddition required additional 
synthetic manipulations in order to make the precursor molecules, the assembly of the 
substrates was achieved through simple and high-yielding methods (e.g. amide coupling). 
As a result, the scope of the novel process was expanded on a vast number of systems 
(representative examples are depicted in Scheme 2.19); all of them consist of three main 
parts: 
 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.19 
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• Photoactive core based on o-amino-substituted aromatic carbonyl compounds: 
benzaldehyde (2.79a–c), acetophenones (either with plain methyl group, 
2.79d, or α-functionalized, 2.79e,i), benzophenone (2.79f), or cyclic ketones 
(2.79g,h); 
• Linker attached to ESIPT-reactive moiety either through the amide bond 
(“south” bridge, 2.79a–d,f–i) or via the ketone arm (“north” bridge, 2.79e); 
• Unsaturated pendant responsible for intercepting the photogenerated 
o-azaxylylene; cycloaddition-competent groups include electron-rich 
heterocycles, e.g. furan (2.79a,c,e,g,i), thiophene (2.79d) and pyrrole (2.79h), 
as well as all-carbon cyclopentene (2.79b) and norbornene (2.79f). 
Variations in all these fragments, combined with the availability of two cycloaddition 
channels, enabled rapid access to a diverse collection of N,O,S-polyheterocyclic 
scaffolds. Irradiation of furan-containing precursors afforded products with O-bridged 
benzazocine (anti-2.80a, syn-2.80c, anti-2.80e, syn-2.80g) and furo[2,3-b]quinoline cores 
(syn-2.81a, anti-2.81g) formed by [4+4] and [4+2] pathways, respectively. At the same 
time, thiophene and N-linked pyrrole rings participate only in [4+2] addition, leading to 
dihydrothiophene anti-2.81d and 2-pyrroline syn-2.81h, respectively (due to its 
instability, syn-2.81h was converted to the isolable N-sulfonyl amidine 2.82). Additional 
heterocyclic rings in the photoproducts are introduced as a result of linker folding: for 
instance, by selecting appropriate spacers between photoactive units and unsaturated 
pendants, important pharmacophore moieties were installed, such as β-lactam 
(Scheme 2.19, reaction a) and 2,5-diketopiperazine (Scheme 2.19, reaction c). 
Furthermore, a special precursor system with the “double” photoactive core was 
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designed, which enabled the cascade sequence of two [4+2] reactions furnishing 
exceptionally complex structures with a fully saturated furan (Scheme 2.19, reaction i). 
Overall, the photocycloaddition process is highly diastereoselective; however, due to 
substantial variety of photoprecursor structure topologies, the unified model that would 
consistently rationalize all observed stereochemical outcomes was not suggested. For the 
reactions with furans, thiophenes and pyrroles linked to the rest of the precursor at 
2-position, endo approach of an unsaturated ring to the azaxylylene was proposed 
(Scheme 2.20). If the hydroxy group in the reactive intermediate is positioned “in”, i.e. 
towards the amide nitrogen – e.g. in case of the tetralone-based photoprecursor 2.79j 
having non-rotatable carbonyl group – the resulting [4+4] product has syn relationship 
between OH and the newly formed heteroatom-containing bridge (syn-2.80j), whereas 
[4+2] cycloadduct is anti (anti-2.81j) [7]. 
 
 
 
 
 
 
 
Scheme 2.20: endo-Addition of furan to in-OH-o-azaxylylene. 
 34 
The opposite stereoconfiguration is obtained in the presence of hydrogen-bonding 
additives, such as HMPA or water, which are used to accelerate the reaction by providing 
stabilization to hydroxy-o-azaxylylene (Scheme 2.21) [48]. Binding of the additive to the 
hydroxy group forces a precursor with a rotatable carbonyl (e.g. 2.79k) to form 
azaxylylene with out-OH (2.79k-T*), and consequently leads to anti-[4+4] product 
anti-2.80k [48]. 
 
 
 
 
Scheme 2.21: endo-Addition of furan to out-OH-o-azaxylylene bound to HMPA. 
 
While this endo-cycloaddition model generally works well, in some cases it fails to 
explain diastereoselectivity. For instance, irradiation of 2.79c in presence of HMPA 
afforded syn-[4+4] photoproduct syn-2.80c (Scheme 2.19, reaction c) [7], even though 
the reaction is predicted to proceed via “out”-OH intermediate. 
Also, the model is not applicable to the systems containing the pyrrole pendant 
attached through the heteroatom: reaction of the photoprecursor 2.79h yields syn-[4+2] 
cycloadduct syn-2.81h [49], suggesting the preference of exo-approach (Scheme 2.22). 
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Scheme 2.22: exo-Addition of pyrrole to in-OH-o-azaxylylene. 
 
For the systems with “north” linker topology, a reactive conformation rationalizing 
the observed formation of anti-[4+4] products was proposed (Scheme 2.23) [8]. Such 
folding places the phenyl group (or another bulky substituent) in the less sterically 
hindered pseudo-equatorial position; however, the exo-orientation of furan with respect to 
azaxylylene does not agree with the endo-cycloaddition hypothesis suggested for “south-
bridged” systems. 
 
 
 
 
Scheme 2.23: exo-Addition of furan in systems with “north” linkers. 
 
The o-azaxylylene-based diversity-oriented methodology was adapted for the 
preparation of enantiopure molecules [7, 48, 49]. By using amino acids as starting 
materials, chiral center can be easily embedded into the linker; photolysis of the resulting 
precursors, such as proline-derived 2.79c and phenylalanine-based 2.79h, leads to 
diastereoselective cycloaddition, where the chiral information is transferred from the 
tether to the rest of the molecule (Scheme 2.19, reactions c and h). 
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Furthermore, an asymmetric variant of the photocycloaddition was demonstrated for 
the systems where the primary source of chirality can be tracelessly removed after the 
irradiation [50]. For example, employing L-tert-leucinol-derived 2-oxazoline as a 
surrogate for the aldehyde group in the photoactive core enabled a stereocontrolled 
reaction, which afforded product 2.84 with 90% ee after hydrolytic removal of the chiral 
auxiliary (Scheme 2.24). Another remarkable feature of this system is that an oxazoline-
based photoprecursor undergoes ESIPT to the nitrogen atom, as opposed to previously 
covered cases, where carbonyl oxygen plays a role of proton acceptor. 
 
 
 
 
 
Scheme 2.24 
In order to maintain low reaction temperature that is essential for obtaining high ee, 
this process required a “cool” UV light source (365 nm) instead of heat-generating 
Hanovia lamps with a wide emission spectrum. Due to weak absorption of oxazoline-
functionalized anilides at this wavelength (their λmax is blue-shifted to 320−330 nm), the 
photocycloaddition proceeded extremely slowly; however, it is significantly accelerated 
in the presence of 4,4′-dimethoxybenzophenone (DMBP), a known triplet sensitizer that 
is highly absorbing up to 400 nm. This crucial observation strongly suggests that the 
ESIPT in azaxylylene precursors can occur in the triplet manifold, because selective 
production of T1(N) species is induced under these conditions. 
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Numerous experimental observations indicate that the cycloaddition step, most likely, 
proceeds via triplet intermediates as well [52]: 
• Bromine-substituted precursor 2.79n reacts more than 4 times faster than the 
corresponding non-halogenated compound 2.79m, as evidenced by their 
photocycloaddition quantum yields (Table 2.3). In addition, bromine 
significantly suppresses LWE from S1(T) species (Figure 2.12). The 
reasonable explanation of these phenomena is based on bromine’s heavy-atom 
effect that facilitates conversion of singlets to triplets by ISC. 
• The reaction rate exhibits progressive deceleration with the increase in 
concentration of a triplet quencher (e.g. trans-piperylene 2.85, Figure 2.13). 
• Results of time-resolved fluorescence studies on a series of photoprecursors 
reveal that replacing the unreactive acetyl substituent for the cycloaddition-
competent furanpropanoyl pendant does not affect the decay of singlet 
species. 
Table 2.3: Absolute Quantum Yields of Photocycloadditiona 
(Adapted with permission from ref. [52]; Copyright © 2014, American Chemical 
Society) 
 
QY 
2.79m, R = H 0.18 ± 0.01 
2.79n, R = Br 0.75 ± 0.06 
a Determined by comparing conversion rates of 0.01 M photoprecursor solutions  
and the benzophenone−benzhydrol actinometer system (Φ = 0.57). 
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Figure 2.12: Normalized fluorescence spectra of tetralone derivatives 2.79j and 2.79o. 
Adapted with permission from ref. [52]. Copyright © 2014, American Chemical Society. 
 
 
 
 
 
 
 
 
Figure 2.13: trans-Piperylene (2.85) quenching of 2.79n in benzene. Adapted with 
permission from ref. [52]. Copyright © 2014, American Chemical Society. 
 
It is conceivable that triplet-state cycloaddition occurs in a stepwise manner, with the 
o-azaxylylene intermediate represented as a biradicaloid (2.79p-T*, Scheme 2.25). This 
hypothesis is supported by the formation of hemiaminal side-products (e.g. 2.87) from 
certain slow-reacting cycloalkenyl derivatives, such as 2.79p, which is rationalized by 
intramolecular radical disproportionation of a common “semi-cyclized” intermediate 2.86 
followed by addition of alcohol to the enamine double bond [7]. 
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Scheme 2.25 
 
Synthetic Utility of Dearomative Photocycloadditions to Selected Arenes 
The reactions of ESIPT-generated o-azaxylylenes with heteroarene pendants perfectly 
illustrate how a photoinduced cycloaddition can serve as an effective tool for the removal 
of aromaticity. The fact that this method allows for the transformation of flat arenes into a 
diverse set of C(sp3)-enriched three-dimensional structures clearly underscores the 
synthetic power of the dearomatization approach. 
This strategy of using ubiquitous heteoaromatics to access complex molecular 
architectures through photochemical dearomatizations can also be applied in a target-
oriented setting, as demonstrated by Crimmins’ total synthesis of ginkgolide B 
(Scheme 2.26) [53]. Intramolecular [2+2] photocycloaddition of cyclopentenone to furan 
enabled quick assembly of a polycyclic system with established stereochemistries at two 
vicinal quaternary chiral centers. 
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Scheme 2.26 
In another illustrative example, Sieburth and co-workers showed that heteroarene 
photocycloadditions with [4+4] topology can be utilized for the construction of natural-
like scaffolds (Scheme 2.27) [54]. The photoinduced reaction between the 2-pyridone 
and the furan moieties furnished product 2.92 with four new stereogenic centers, which 
was then transformed into the complex triquinane model system 2.93. 
 
Scheme 2.27 
Compared to most heterocyclic arenes, benzene has a higher degree of aromaticity: its 
hydrogenation to 1,3-cyclohexadiene is endothermic, whereas furan, pyrrole and 
thiophene possess negative enthalpies of monohydrogenation (Table 2.4) [55]. However, 
the ability of light to deposit substantial amount of energy into reactants leads to the 
production of highly reactive electronically excited states; and therefore, unlocks the 
opportunities to involve benzenoid systems in the dearomative photocycloadditions. 
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Table 2.4: Enthalpies of Hydrogenations for Benzene, Furan, Pyrrole and Thiophene 
(Adapted with permission from ref. [55]; Copyright © 2007, American Chemical 
Society) 
A B ΔH(A→B), kJ · mol–1 
  
  21.65 ± 1.13 
  
–37.55 ± 0.41 
  
  –4.90 ± 1.30 
  
–24.30 ± 2.30 
 
The most widely utilized mode of benzene photodearomatization is [3+2] or meta 
cycloaddition. Since its discovery in 1966 [56, 57], this reaction found multiple 
applications in concise construction of fused cyclopentane units in natural products [58, 
59]. A classic example illustrating the power of this method is Wender’s synthetic 
campaign towards a series of sesquiterpenes: (±)-α-cedrene [60], (±)-isocomene [61] and 
(±)-silphinene [62]. For instance, irradiation of easily accessible compound 2.94 quickly 
delivered the structural core of α-cedrene (Scheme 2.28) [60]. The observed 
photochemical reactivity of 2.94 was rationalized by the formation of singlet-state 
intramolecular exo exciplex 2.94* resembling the stable conformation of 
cis-bicyclo[3.3.0] octane, where C-2 methyl assumes less sterically hindered 
β-orientation, and methoxy group stabilizes radical/cationic center [11] developing a 
radical at the adjacent carbon during the cycloaddition. Remarkably, the lack of 
selectivity in the cyclopropane ring formation was compensated by the subsequent 
convergence of both isomers 2.96' and 2.96 into a single bromination product, the more 
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stable secondary allyl bromide 2.97. Racemic α-cedrene 2.99 was obtained in just two 
additional steps, reductive debromination and Wolff–Kishner reduction of the carbonyl 
group. 
 
 
 
 
 
 
 
 
 
 
Scheme 2.28 
The more recent elegant example of employing [3+2] photocycloaddition to benzene 
as a shortcut toward a complex natural target is Mulzer’s enantioselective synthesis of 
(–)-penifulvin A (Scheme 2.29) [63]. Photoinduced cyclization of the chiral precursor 
2.100 yielded equimolar mixture of enantiopure cyclopropane-fused triquinanes 2.102 
and 2.102'. The authors proposed that the substrate 2.100 adapts essentially the same 
geometry1F2 that was previously suggested by Wender for the analogous substrate 2.94 
upon excitation (Scheme 2.28), avoiding 1,3-allylic strain between methyl and 
                                                 
2 It was implicitly specified that this conformation is achieved in ground state (as opposed to exciplex 
formation suggested by Wender). 
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hydroxymethyl groups. The angular product 2.102 was chromatographically separated 
from the linear isomer 2.102' and then converted into the desired (–)-penifulvin A 2.103 
in four straightforward steps. 
 
 
 
 
 
 
 
 
 
Scheme 2.29 
The problem of low regioselectivity at the cyclopropane construction step was 
addressed in the study by Bach and co-workers [64]. Their crucial finding is that the 
preference for linear or angular product is strongly influenced by the nature of the X 
group in the CH2X substituent located at the ortho position relative to the tethered alkene 
(Scheme 2.30). It was postulated that substrates with a three-atom methyloxymethyl 
tether between arene and olefin (2.104a–d) typically adopt a conformation where the 
internal alkenic carbon is in a close proximity to the aromatic C1. Therefore, the bond-
forming event starts occurring earlier at C1 rather than at C3; consequently, C1 acquires 
significant amount of sp3-hybridization before C3 and thus has a stronger preference for 
being a part of cyclopropane ring, which eventually leads to the linear isomer (2.105a–d). 
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In accordance with this hypothesis, the opposite situation, when arene begins to form a 
C–C bond with C3 first, favors the formation of angular product (2.105'a–d). This 
reversal in the regioselectivity is achieved in the presence of heteroatomic functions 
introducing electrostatic repulsions between lone pairs on X and alkene π density; and 
therefore, forcing the terminal olefinic carbon to occupy the position near C3. 
 
 
 
 
 
 
Scheme 2.30 
[2+2] or ortho cycloaddition to benzene aromatics, which was first reported in 1950s 
[65], found much smaller number of synthetic applications compared to [3+2] reactions. 
The rare example of an intermolecular [2+2] process is the addition of an electron-poor 
crotononitrile 2.107a to an electron-rich anisole 2.106a resulting in the cyclohexadiene-
fused cyclobutane 2.109 (Scheme 2.31) [66]. The reaction is proposed to proceed via 
singlet-state exciplex 2.108 that can also undergo electron transfer from an aromatic 
system to an olefin followed by abstraction of a proton from the solvent, leading to a 
substitution product 2.113a. This competing process becomes predominant for more 
easily oxidizable dimethoxy-functionalized benzenes (e.g. 2.106b) and alkenes with 
higher electron affinity (such as acrylonitrile 2.107b). 
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Scheme 2.31 
Intramolecular ortho photocycloaddition to benzene is also known, yet the 
preparative examples of this transformation are scarce [67-69]. These reactions are 
reminiscent of [2+2] additions of alkenes to electronically excited enones [11], since they 
occur from 3(π,π*) state of arene [67] and require the presence of electron-withdrawing 
groups, such as acetyl and cyano, that direct the addition to either α,β- or γ,δ-positions. 
For instance, photolysis of benzonitrile 2.114 yields the α,β-adduct 2.115 (Scheme 2.32, 
reaction a) [68], whereas acetophenone 2.116 regioselectively cyclizes at γ and δ centers 
(Scheme 2.32, reaction b) [70]. 
 
 
 
 
 
 
Scheme 2.32 
 46 
Asymmetric dearomatization cascade, initiated by ortho cycloaddition, was reported 
by Wagner’s group [71]. 5-Acetylsalicylic acid derivative 2.118 outfitted with chiral 
auxiliary at the amide function undergoes photoinduced stepwise [2+2] reaction, 
followed by a series of electrocyclic disrotatory transformations: thermal [6π] ring 
opening of intermediate 2.120 to cyclooctatriene 2.121 and [4π] photocyclization to 
cyclobutene 2.122 (Scheme 2.33). The authors noted that the stereocontrol is achieved at 
the formation of the biradical 2.119 but did not suggest a well-defined model explaining 
the outstanding diastereoselectivity. 
 
 
 
 
 
 
 
 
 
Scheme 2.33 
Bach has recently developed a practical synthetic method based on the same sequence 
of events occurring in “one pot” (Scheme 2.34) [69]. A number of functionalized 
salicylates with extended four-atom linkers between arene and alkene moieties were 
smoothly converted into complex tricycles possessing cyclobutachromene scaffold with 
high yields. 
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Scheme 2.34 
Besides light-driven [3+2] and [2+2] processes, [4+2] or para cycloadditions 
involving benzenoid systems are also feasible [72-75]. For instance, such reactivity was 
observed for N-benzoyl- and N-benzyl-substituted cinnamamides (2.125, Scheme 2.35) 
[72]. Upon irradiation, these precursors efficiently transform into various bicyclo[2.2.2]-
octadienes fused with succinimide (2.127a–e) and butyrolactam rings (2.127f–i). Given 
that this reaction occurs only in the presence of triplet sensitizer benzil, the stepwise 
radical addition mechanism was proposed. The complete diastereoselectivity was 
rationalized by the conformation of spiro-biradical 2.126 with an anti relationship 
between phenyl and amide carbonyl groups. Furthermore, for the substrates with 
α-substituted benzyl group the authors suggested that the reaction proceeds via the more 
favorable intermediate 2.126', where repulsions between R' and benzyl substituents in the 
pyrrolidinone ring are avoided. 
Sarlah’s group has recently developed a powerful synthetic methodology based on 
[4+2] photocycloadditions of benzene aromatics 2.128 to N-substituted 1,2,4-triazoline-
3,5-diones 2.129 (Scheme 2.36) [75]. This reaction is enabled by visible light irradiation 
producing electronically excited arenophile 2.129*, which interacts with the ground-state 
arene 2.128 and leads to the formation of charge-transfer exciplex (2.130*) collapsing  
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Scheme 2.35 
 
 
 
 
 
 
Scheme 2.36 
 
into the product 2.131; alternatively, the exciplex 2.130* can be generated by direct 
excitation of the ground-state complex 2.130 [76]. 
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Since the resulting diazabicyclo[2.2.2]octadienes undergo facile retrocycloaddition to 
the starting materials above –20 °C, these [4+2] processes are carried out at low 
temperatures and are immediately followed by post-photochemical reactions that (i) 
convert labile cycloadducts into stable compounds and (ii) highlight the synthetic utility 
of dearomatized products. Examples of such transformations include 
Upjohndihydroxylation (Scheme 2.37, reaction a) [77] and reduction of alkene with in 
situ generated diimide (Scheme 2.37, reaction b) [78]. The products 2.132 and 2.133 can 
be further transformed into functionalized cyclohexadienes 2.134 and syn-1,4-
diaminocyclohex-2-enes 2.135 [77, 78]. 
 
 
 
Scheme 2.37 
Importantly, it was also demonstrated that urazole-outfitted [4+2] adducts are useful 
synthons for C–C bond-forming processes, which can be utilized for the assembly of 
natural products. For instance, dearomatized compound 2.131a was engaged in diastereo- 
and enantioselective coupling reaction with aryl Grignard 2.136, promoted by nickel(0)-
based catalyst Ni(cod)2 in conjunction with chiral ligand (R,Rp)-
iPr-Phosferrox (Scheme 
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2.38, reaction a) [79]. This transformation delivered enantiopure anti-1,2-carboaminated 
product 2.137, a precursor for the alkaloid (+)-pancratistatin 2.138 obtained after seven 
additional steps. In another example, a different carboamination topology was achieved: 
palladium-catalyzed nucleophilic allylic substitutions with lithium enolates afforded syn-
1,4-substituted derivatives 2.140 (Scheme 2.38, reaction b) [80]. These remarkable 
dearomative transformations allowed for the conversion of benzene, a readily available 
feedstock chemical, into functionalized cyclohexadienes with two stereocenters. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.38 
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[4+2] Photocycloaddition can also be initiated by the excitation of an aromatic 
system, as demonstrated by Bochet and co-workers [73, 74]. They discovered that 
benzene rings equipped with electron-withdrawing chromophore groups are capable of 
reacting with tethered allenes in a [4+2] fashion, generating complex bicyclo[2.2.2]-
octadienes (2.142, Scheme 2.39) [74]. For benzaldehydes and ketones, significant 
amounts of benzoxepine side-products (2.144) were often obtained; it is conceivable that 
such compounds result from an alternative [4+2] pathway involving an enone-like 
fragment followed by [1,3]-sigmatropic migration of an oxymethylene bridge [73]. 
 
 
 
 
 
 
 
Scheme 2.39 
Aside from alkenes, certain dienes can play a role of a second component in para 
photocycloadditions to benzene and lead to [4+4] products; however, the systems 
reacting through this topology are extremely rare [81-83]. This process was first 
documented by Okumura for benzonitrile and 2,3-dimethyl-1,3-butadiene (2.146) [81]; 
Gilbert later extended the scope of the reaction on various methyl-, methoxy- and fluoro-
substituted benzonitriles 2.145 that afforded functionalized bicyclo[4.2.2]deca-3,7,9-
trienes 2.147 (Scheme 2.40) [82]. 
CNRRR=H,Me,MeO,F+h(254nm)dioxane149150151typicalyields55–65%(basedonreactedstartingmaterial)CN
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Scheme 2.40 
A unique case of intramolecular [4+4] was observed between benzenoid aromatics 
and 2-pyridone pendants (Scheme 2.41) [83]. The resulting cycloadducts 2.149 and 
2.149' were not isolated, because they contain an unstable 1,5-hexadiene moiety that is 
prone to thermal [3,3] Cope rearrangement (2.150 and 2.150') and a secondary 
photochemical [2+2] reaction (2.151). 
 
 
 
 
 
 
 
Scheme 2.41 
When benzene ring is a part of a polycyclic aromatic structure, its dearomatization is 
more facile. For instance, monohydrogenation of naphthalene is predicted to be 
exothermic according to the calculation from the standard molar enthalpies of formation 
[84, 85] (Scheme 2.42). 
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Scheme 2.42 
Consequently, dearomative photocycloadditions that involve polyaromatics, such as 
naphthalene [86-92], anthracene [89, 92-94] and phenanthrene [95] have been described. 
However, since these systems are not studied in the present work, their reactions are not 
covered in this review. 
Besides photoinduced dearomatizations, a number of ground-state transformations 
that convert arenes into C(sp3)-containing cycles are known: typical examples include 
Birch reduction [96], hydrogenation [97, 98], oxidation of phenols [99-102] and 
transition metal-assisted reactions [103-106]. While all these processes are interesting, 
they are not immediately relevant to this work, and therefore are also not discussed here; 
curious reader is advised to consult Porco’s review of the synthetic applications of these 
reactions [107]. 
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Chapter Three:  Results and Discussion 
Project 1: Photogenerated Diketopiperazine-Spiro-Oxiranes as Versatile Synthons 
for Accessing Diverse Polyheterocyclic Scaffolds [108] 
Thermolytic or photochemical extrusion of molecular nitrogen from substituted 
1,3,4-oxadiazolines gives access to functionalized epoxides [109-112], which are stable, 
but at the same time reactive synthons used in a multitude of useful transformations. This 
mode of reactivity, however, has not been known for oxadiazolines that are part of 
bicycles, presumably because the main route towards these systems is based on hetero-
Diels−Alder chemistry involving alkenes 3.1 and 1,3,4-oxadiazoles 3.2 (Scheme 3.1). 
These reactions afford oxadiazabicyclo[2.2.1]heptane scaffolds 3.3 that upon the loss of 
dinitrogen produce carbonyl ylides 3.4 – highly reactive zwitterionic intermediates 
utilized by Boger in the powerful tandem [4+2]/[3+2]-based methodology [113-115]. 
Intramolecular formation of a C–C bond that would lead to oxiranes (3.5) is not feasible 
in this case, because it would impose substantial strain on the bridgehead carbon atoms. 
 
 
 
Scheme 3.1 
We envisioned that the likelihood of producing bicyclic epoxides would increase if 
the bridge between two oxadiazoline carbons is extended, making the overall framework 
more flexible. Such systems could be obtained by dearomative intramolecular [4+4] 
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cycloaddition of ESIPT-generated o-azaxylylenes to oxadiazoles (Scheme 3.2), in a way 
similar to the previously described formation of O-bridged benzazocines from furan-
containing precursors [7]. Photoirradiation required to initiate this process could also 
input enough energy into the primary oxadiazoline 3.7 to trigger the extrusion of 
dinitrogen, making the entire conversion of oxadiazole 3.6 into epoxide 3.8 “one pot”. 
 
 
 
Scheme 3.2 
To test the hypothesis, an o-amino-benzaldehyde-based precursor 3.6a was assembled 
from simple building blocks by peptoid synthesis-inspired methods (Scheme 3.3, a). 
Initially, the required oxadiazole-containing fragment 3.16a was prepared by tosyl 
chloride-mediated bis-hydrazide cyclodehydration [116] followed by ester hydrolysis. 
The substrate 3.6a was then obtained by a series of high-yielding reactions: (i) acylation 
of the protected o-aminobenzaldehyde 3.9 with bromoacetyl bromide 3.10, (ii) 
subsequent coupling of the resulting primary alkyl bromide 3.11 with benzylamine, (iii) 
acylation of the secondary amine 3.12 with 5-phenyl-1,3,4-oxadiazole-2-carbonyl 
chloride 3.16a and (iv) acid-promoted aldehyde deprotection. The obtained 
photoprecursor 3.6a was subjected to photolysis with Rayonet RPR-3500 lamps 
(broadband emission centered at 350 nm) that induced the desired [4+4] 
cycloaddition/oxirane formation cascade (Scheme 3.3, b). The scope of this methodology 
was extended on a range of substrates with various aryl substituents in an oxadiazole 
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ring, which after irradiation afforded complex epoxide-fused 2,5-diketo-piperazino-
quinolinols (3.8a–g) as single diastereomers in good yields. 2F3 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.3 
Given the high reactivity of epoxides towards a wide array of nucleophiles, the 
oxirane moiety in the photoproduct represents an attractive handle for further so-called 
post-photochemical modifications that provide opportunity to increase the overall 
structure complexity and to diversify a collection of final compounds. Therefore, we 
                                                 
3 The original discovery of the photochemical process belongs to the collaborator Dr. N. N. Bhuvan 
Kumar, who also optimized conditions for the preparation and irradiation of the photoprecursors and 
investigated the reaction scope (except o-tolyl example b). 
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explored epoxide ring opening in 3.8a with azide and thiocyanate under acidic conditions 
(Scheme 3.4). Interestingly, these reactions led to different regio- and diastereochemical 
outcomes, as revealed by X-ray crystallography of the isolated products: azide in adduct 
3.17 is located at the position 3 of quinolinol and is anti to the former epoxide oxygen, 
whereas the structure of 3.18 shows the attachment of thiocyanate at C-2 and is indicative 
of syn addition of the nucleophile. 
 
 
 
 
 
 
Scheme 3.4 
To rationalize this discrepancy, we suggested the following mechanistic proposals:  
• The relatively weak acid HN3 (pKa = 4.7 [117]) is involved in general acid 
catalysis of the azide addition that proceeds via SN2 mechanism, with the 
nucleophile attacking from the face opposite to the epoxide ring and 
consequently leading to the anti product (Scheme 3.5, reaction a). 
• In the case of thiocyanate reaction, only strong acids are present in the mixture 
(pKa values for HSCN and TFA are −1.85 and 0.0, respectively [118]); 
therefore, specific acid catalysis of SN1 reaction takes place: oxirane gets fully 
protonated and then cleaves with the formation of a more stable iminium (not 
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benzylic) cation, which is trapped by thiocyanate at the “hard” N-terminus in a 
syn fashion (Scheme 3.5, reaction b). 
 
 
 
 
Scheme 3.5 
Even though eventually we managed to obtain single crystals of 3.17 and 3.18 for 
X-ray analysis, which was essential for the determination of regio- and stereochemistry, 
our initial attempts to crystallize these compounds did not seem promising. For that 
reason, we decided to convert benzylic OH in 3.8a into ketone and then run the reactions 
with the same nucleophiles, hoping that the final products would exhibit greater tendency 
for crystallization. We proceeded with oxidation of the epoxy-alcohol 3.8a with 
Dess−Martin periodinane (DMP) followed by the treatment of the resulting quinolinone 
with NaN3/TFA. To our surprise, instead of the anticipated ring opening, the epoxy-
ketone 3.21 rearranged into triazocano-indolinones 3.22 and 3.23 (Scheme 3.6; the 
structures were established by X-ray crystallography). 
 
Scheme 3.6 
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Our plausible explanation for this unusual reactivity is outlined in the Scheme 3.7. 
We proposed that the acid-catalyzed epoxide cleavage is accompanied by the shift of the 
quinolinol nitrogen, leading to the rearrangement of the 6/6 bicycle into the 5/7-fused 
system 3.24; given that no changes were observed in the absence of NaN3, it is likely that 
this step requires nucleophilic catalysis by the azide. Subsequent Schmidt reaction 
converts aliphatic ketone in 3.24 into the amide, yielding 3.23. Because the second 
product, triazocane 3.22, differs from 3.23 only by the position of one carbonyl group, we 
believe that this isomer is formed by a similar Schmidt reaction from the intermediate 
3.26. Two benzodiazepines 3.24 and 3.263F4 are presumably equilibrated via reversible 
migrations of acyl groups occurring through the spiroammonium intermediate 3.25. 
 
 
 
 
 
 
 
 
Scheme 3.7 
As we were curious to see whether elevated temperature would affect the distribution 
of the products, we tried subjecting the keto-epoxide 3.21 to the same conditions 
                                                 
4 Intermediates 3.24 and 3.26 were not detected in the mixture, most likely due to their rapid reaction 
with HN3. 
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(NaN3/TFA in DMSO) at 100 °C, and we observed the formation of two completely new 
compounds. Careful monitoring of the reaction by 1H NMR showed that these products 
start forming after the starting material 3.21 is completely converted into the triazocanes 
3.22 and 3.23. Furthermore, the same mixture of two compounds was produced from 
both pure 3.22 and 3.23 after they were separately heated with sodium azide in acidic 
DMSO. X-ray analysis of the crystalline material obtained after a large-scale experiment 
revealed that there was only one secondary product, which is the 2,3-diketopiperazino-
fused indolinol 3.27 (Scheme 3.8). The presence of two different sets of peaks in the 
NMR spectra was rationalized by the equilibrium between closed hemiaminal (3.27) and 
open keto-amide (3.27') forms that takes place in solution; evidence for the formation of 
3.27' was provided by 13C NMR spectroscopy that revealed the keto-carbonyl peak at 195 
ppm. 
 
Scheme 3.8 
The conversion of triazocanes 3.22 and 3.23 into 3.27 does not involve the addition of 
azide; however, no reaction occurred in the absence of NaN3. Therefore, the azide anion 
conceivably plays a role of a base creating buffer solution in conjunction with TFA, 
which is needed to maintain pH in a certain range that is required for the transformation. 
This hypothesis was supported by the fact that sodium acetate, which has similar basicity, 
promotes the same reaction. 
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While the mechanism of the formation of 3.27 from the triazocane 3.23 remains 
unclear, the rearrangement of 3.22 presumably starts with acid-assisted opening of the 
triazocane ring (Scheme 3.9). After tautomerization of the resulting glycine amide 
intermediate 3.28, the enol moiety recaptures the iminium cation in 3.28', furnishing the 
product 3.27' as a single diastereomer. 
 
Scheme 3.9 
To summarize, we have shown that 1,3,4-oxadiazole is dearomatized by the 
intramolecular [4+4] cycloaddition to ESIPT-generated o-azaxylylene under mild UV 
irradiation conditions; this process is immediately followed by the extrusion of dinitrogen 
leading to the oxirane-equipped 2,5-diketopiperazino-quinolinols. Importantly, we have 
demonstrated that the presence of a reactive epoxide moiety in the photoproducts makes 
them incredibly useful synthons for further post-photochemical modifications, that enable 
the increase in molecular complexity and provide the access to diverse scaffolds. 
 
Project 2: Synthesis of Complex Enantiopure Polyheterocycles by Cycloadditions of 
Amino-o-Azaxylylenes to Pyrroles [119] 
Previous studies in Kutateladze’s group showed that the hydroxy-o-azaxylylene 
intermediates produced by ESIPT in aromatic o-amidoaldehydes and o-amidoketones can 
be efficiently engaged into the intramolecular cycloadditions. These reactions generate 
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complex polyheterocyclic scaffolds containing quinolinol cores with OH group at the 
benzylic position (Scheme 3.10, X = O) [7]. 
It was envisioned that the introduction of an amino functionality into these products 
would be synthetically appealing, since it would create an additional diversity input and 
therefore would allow for the expansion of the collection of molecular architectures 
synthesized by the azaxylylene photocycloaddition methodology. This task requires 
utilizing anilides that are outfitted with ortho functionalities containing proximal C–N 
double bond, such as imines or nitrogenated heterocycles (examples of ESIPT-reactive 
systems with C=N proton acceptors can be found in the “Literature Review” chapter). 
Upon photoexcitation, these starting materials are expected to tautomerize into the 
amino-o-azaxylylenes that could react with unsaturated pendants (Scheme 3.10, X = 
NR). 
 
 
 
 
 
Scheme 3.10 
We chose to install quinoxalinone as a proton-accepting moiety into our 
photoprecursors for several reasons: 
• The resulting o-azaxylylenes would be equipped with an additional carbonyl 
group, which could accelerate the cycloaddition by making these 
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intermediates more electron-deficient; and therefore, more reactive towards 
electron-rich heterocycles; 
• Furthermore, there is an opportunity to amplify this electron-depleting effect 
by using oxophilic Lewis acids that could enhance the polarization of the 
azaxylylenes by binding to the carbonyl oxygen; 
• Quinoxalinone-containing photoprecursors can be easily synthesized in a 
modular fashion by the ring opening of isatins with o-phenylenediamine 
[120]. 
To prepare the required substrates, we first installed pyrrole rings in the chiral 
aminoacids, L-phenylalanine (3.32a) and L-ornithine (3.32b) by Paal–Knorr reaction 
(Scheme 3.11). Isatin 3.35 was then coupled with acids 3.34a and 3.34b using 
carbodiimide reagent EDC hydrochloride, followed by the ring opening with 
o-phenylenediamine 3.36, which afforded enantiopure photoprecursors 3.37a and 3.37b. 
 
 
 
 
Scheme 3.11 
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Irradiation of 3.37a and 3.37b with 365 nm UV LEDs 4F5 in the presence of 
titanium(IV) isopropoxide 5F6 induced the desired dearomative [4+2] cycloaddition of the 
Ti-bound o-azaxylylenes (3.37a-T* and 3.37b-T*) to pyrrole pendants, leading to the 
pyrrolines 3.38a and 3.38b; formation of single diastereomers was observed by 1H NMR 
in both cases (Scheme 3.12). In order to “fix” the labile enamine fragment and to 
increase the structure complexity, the primary photoproducts were further modified by 
the post-photochemical transformations: 
• 3.38a was subjected to 1,3-dipolar cycloaddition with p-toluenesulfonyl azide, 
delivering sulfonylamidine 3.39 after the extrusion of nitrogen; 
• 3.38b was treated with trichloroacetic acid that promoted intramolecular 
Friedel–Crafts alkylation of pyrrole and afforded diazocane 3.40. 
 
 
 
 
 
Scheme 3.12 
                                                 
5 According to the data obtained by the collaborator Dr. Olga Mukhina, o-quinoxalinone-
functionalized anilides have a broad UV absorption with a maximum at around 360 nm. 
 
6 Accelerating effect of Ti-based Lewis acids on the photoreaction of similar furan-containing 
precursors was also discovered by Dr. O. Mukhina. 
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The diastereochemistry of the cycloaddition was established on the basis of X-ray 
crystallography of product 3.39, which revealed syn relationship between the newly 
formed benzylic amino group and the nitrogen atom of the pyrrolidine moiety. This 
finding is consistent with the previously reported syn-selective reaction between hydroxy-
o-azaxylylenes and pyrroles [49]. 
The obtained results complement those of Drs. Olga Mukhina and Teresa Cowger, 
who studied furan-outfitted systems bearing both acyclic and cyclic imines, as well as 
quinoxalinones in the photoactive cores; the representative examples are shown in 
Scheme 3.13. 
 
 
 
 
 
 
 
 
Scheme 3.13 
In conclusion, it has been demonstrated that ESIPT-produced amino-o-azaxylylenes 
are capable of the intramolecular dearomative cycloadditions to electron-rich heterocyclic 
units, such as pyrroles. We have also shown that the reactive pyrroline moiety in the 
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photoproducts can be utilized for further modifications, affording even more complex 
structures. Even though the yields of the final compounds are modest, these sophisticated 
and enantiopure molecular architectures are accessed in a two-step one-pot reaction from 
readily available precursors. 
 
Project 3: Dearomatization of Benzenoid Arenes with o-Azaxylylenes via an 
Unprecedented [2+4] Reaction Topology [121] 
Photoinduced cycloadditions to benzene rings constitute a powerful strategy for the 
rapid access to a diverse set of C(sp3)-rich molecular scaffolds from ubiquitous arenes 
[11, 122]. Known variants of these transformations include synthetically valuable [3+2] 
and [4+2] reactions, as well as less frequently used [2+2] and [4+4] cycloadditions 
(Scheme 3.14; an overview of these processes with representative examples can be found 
in the “Literature Review” chapter). To the best of our knowledge, photochemical [2+4] 
cycloadditions, where a benzenoid arene would play a role of 2π component, have not 
been reported. 
 
 
 
Scheme 3.14 
We envisaged that the reaction with missing [2+4] topology could be achieved by the 
intramolecular cycloaddition of a phenyl group to an ESIPT-generated o-azaxylylene, 
similar to the previously described transformations involving heterocycles, such as furan, 
pyrrole and thiophene [7, 49]. It was proposed that the addition of the triplet azaxylylene 
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starts with the attack of the electrophilic N-centered radical on an unsaturated moiety, 
which explains the facile reactivity of electron-rich heteroarenes in these processes [52]. 
Consistent with this mechanistic hypothesis, we decided to test a donor-substituted 
benzenoid arene for the feasibility of the [2+4] cycloaddition. Gratifyingly, easily 
accessible substrate 3.51a outfitted with the electron-rich phenoxyacetic pendant reacted 
in the desired manner, furnishing cyclohexadieno-quinolinol syn-3.54a upon irradiation 
in DMSO with 365 nm UV LEDs (Scheme 3.15).6F7 
 
 
 
Scheme 3.15 
Inspired by this initial success, we proceeded with exploring a scope of the new 
dearomative transformation. For this purpose, we synthesized an array of substrates based 
on three different photoactive cores (o-aminobenzaldehyde 3.51, o-aminoacetophenone 
3.52, and o-aminotetralone 3.53), equipped with twelve various electron-rich aromatic 
pendants (derivatives of aryloxyacetic- (a–h) and arylpropanoic- (i–k) acids, as well as 
o-anisylbenzoic moiety l), bearing methoxy- (d, e, g–l), methyl- (b, c) and acetamido-
functionalized (f) benzene rings. The preparation of these precursors was accomplished in 
a modular fashion using the high-yielding methods (Scheme 3.16): 
• Alkylation of phenols 3.44 with methyl bromoacetate 3.45 followed by ester 
hydrolysis, affording aryloxyacetic acids 3.46; 
                                                 
7 This reaction was discovered and optimized by the collaborator Dr. O. Mukhina. 
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Scheme 3.16 
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• Amide bond formation, which was achieved either by the reaction of acyl 
chloride (3.47) with aniline (3.9, 3.48, 3.49), or by the peptide coupling 
promoted by EDC · HCl or azabenzotriazole-uronium salt HATU. 
Substrates were then photolyzed on NMR scale in various solvents. 365 nm UV 
LEDs were used as a light source, because o-amidoketones generally have broad 
absorption with λmax ≈ 350 nm [7]. These preliminary solvent screening experiments 
revealed that the majority of the precursors react cleanly in DMSO; in rare cases, other 
solvents were found to be optimal, such as DCM (3.51h) or acetone (3.53e). Subsequent 
preparative scale irradiations afforded the anticipated cyclohexadiene products in good 
yields (Scheme 3.17). In cases where aryl group is unsymmetrically substituted (3.51j,  
 
 
 
 
Scheme 3.17 
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3.53j), two regioisomers were isolated, with a notable exception of the styrene derivative 
3.51h that was converted to the sole adduct anti-3.54h. 
In most cases, diastereochemical outcomes were unambiguously established by X-ray 
of the photoproducts. For the compounds that were not obtained in a crystalline form, the 
structures were confirmed by comparing experimental spin-spin coupling constants 
(SSCCs) obtained by 1H NMR with those calculated using relativistic force field (RFF) 
DU8c method7F8 [123, 124]. Fortunately, the products, for which X-ray data are not 
available, are all derived from the aminobenzaldehyde precursors, and therefore 
diastereochemistry in these cases can be assigned based on vicinal SSCCs between 
benzylic and bridgehead protons: computed values for syn8F9 isomers are in the 5.5–6.5 Hz 
range, whereas anti compounds are predicted to have larger constants of ca. 9 Hz. The 
accuracy of NMR calculations was corroborated by the fact that the two syn photo-
products with X-ray structures, syn-3.54j and syn-3.54j', have the experimental 3J values 
of 5.9 and 5.3 Hz, respectively. Also, the prediction of greater constants for anti isomers 
is in keeping with the expectation for systems with large dihedral angles (i.e. approaching 
180°) based on Karplus equation [125]. 
With the established structures of products, it is possible to recognize several trends 
in the diastereoselectivity of the cycloaddition, for which we suggest the rationale 
outlined in Scheme 3.18.
                                                 
8 Calculations were performed by the advisor, Dr. A. Kutateladze. This method was also used to 
validate the structures of non-crystalline post-photochemical products, which will be discussed later in this 
chapter. 
 
9 Consistent with the previously described products of azaxylylene photocycloadditions, syn/anti 
nomenclature refers to a relative position of the hydroxy group and the cyclohexadiene ring. 
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Scheme 3.18 
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We propose that the addition of o-azaxylylene is stepwise, with the initial ipso-attack 
of the nitrogen-centered radical on the aromatic system [52]. In this mechanism, the 
position of hydroxymethylene radical group in the resulting spiro-intermediate (3.57–
3.59) dictates the stereochemical outcome of the reaction. In the case of 
aminobenzaldehyde derivatives, hydroxymethylene is small and rotatable; therefore, in 
these systems, DMSO produces the effect that is similar to the one previously suggested 
for HMPA [48]: due to external hydrogen bonding, the OH is forced to occupy “out” 
position (out-OH-3.57), leading to the predominant production of syn isomers (syn-3.54). 
In DCM, however, a conformation with in-OH becomes preferable, presumably because 
of an intramolecular hydrogen bonding of the hydroxy to amide carbonyl; consequently, 
anti product is obtained in this solvent (anti-3.54). Formation of anti cycloadducts (anti-
3.55, anti-3.56) also predominates for the acetophenone-based compounds, where 
hydroxymethylene is mostly rotated “in” to avoid possible steric interactions between the 
methyl substituent and the spirocyclic fragment (in-OH-3.58), and is the only option 
available for the tetralone derivatives, which have the OH group permanently locked in 
“in” position (in-OH-3.59). 
Dearomatization of electron-rich aromatics produces potentially reactive donor-
substituted cyclohexadienes. Therefore, in certain cases, instead of the primary 
cycloadducts (or in addition to them), we obtained the products of secondary post-
photochemical transformations, which are primarily acid-catalyzed. 
Vinyl ether fragment present in the compound syn-3.54g underwent spontaneous 
hydrolysis, leading to the cyclohexenone syn-3.60g (Scheme 3.19, reaction a). The same 
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process partially took place in the product anti-3.56d during chromatographic 
purification on silica gel (Scheme 3.19, reaction b). 
 
 
 
 
 
 
Scheme 3.19 
Spatial proximity of the benzylic hydroxy group to the electron-rich double bond in 
syn compounds enables formation of cyclic ketals by the nucleophilic attack on the 
protonated vinyl ether or enamide (Scheme 3.20). Such reactivity was observed for the 
syn isomers formed from precursors 3.51f, 3.51i, 3.51k and 3.51l; instructively, the anti 
photoproducts either remained unreacted (anti-3.54f, anti-3.54i), or hydrolyzed (anti-
3.60l) under the same conditions. 
A unique example of acid-catalyzed transformation was observed in the case of 
aldehyde-based precursor 3.51d (Scheme 3.21). Irradiation of this compound resulted in 
two primary photoproducts, anti-3.54d and syn-3.54d, that were subsequently treated 
with tosic acid. Under these conditions, anti-3.54d completely hydrolyzed to 
α,β-unsaturated ketone anti-3.60d, whereas the isomeric syn-3.54d transformed into two 
compounds: ketal 3.62d and enone syn-3.60d. Presumably, syn-3.60d forms as a result of 
the hydrolysis of 3.62d; therefore, with the intention to reduce the number of products by 
converting all 3.62d into syn-3.60d, we subjected the mixture to an extended reaction 
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Scheme 3.20 
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with acid. After 3 days, it was found that 3.62d was entirely consumed; however, proton 
NMR spectrum of the final product was lacking characteristic doublets in the alkenic 
region (4.5–6.5 ppm) with the SSCC ≈ 10 Hz, which would be indicative of the 
cyclohexenone moiety. X-ray analysis of the isolated pure material revealed that this new 
compound is the cyclic ether 3.63d formed from syn-3.60d by intramolecular Michael 
addition of the benzylic OH to the carbonyl-activated double bond. 
 
 
 
 
 
 
 
 
 
 
Scheme 3.21 
Cyclohexadiene fragment present in the photoproducts provides an appealing 
opportunity to diversify and grow the complexity of the core scaffolds by post-
photochemical [4+2] cycloadditions. To prove the viability of this strategy, we reacted 
syn-3.54b and anti-3.56d with benzoyl-nitroso dienophile that was generated in situ by 
the oxidation of benzhydroxamic acid [126] (Scheme 3.22). 
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Scheme 3.22 
Furthermore, we engaged the cyclohexadiene units in hetero-Diels–Alder reactions 
with singlet oxygen to access endo-peroxides (3.66 and 3.67, Scheme 3.23) – the method 
that found applications in the syntheses of numerous peroxy-containing natural products 
[127]. In addition to being an important structural element responsible for antitumor, 
antibacterial and antimalarial activities [128, 129], peroxy bridge possesses significant 
synthetic utility, which we demonstrated by subjecting 3.66 and 3.67 to further 
modifications (Scheme 3.23): 
• Base-promoted Kornblum–DeLaMare rearrangement leading to keto-alcohols 
3.68 and 3.70; interestingly, compound 3.68 underwent spontaneous 
intramolecular Michael reaction between syn-OH and enone moiety, affording 
cyclic ether 3.69 as a final product; 
• Reductive ring opening of endo-peroxide with thiourea that converted 3.67 
into the corresponding diol 3.71. 
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Scheme 3.23 
In summary, we have developed a novel method for the dearomatization of benzenoid 
arenes. Our approach is based on the intramolecular photocycloaddition proceeding via 
an unprecedented [2+4] topology, with the arene reacting as a 2π component and the 
ESIPT-produced o-azaxylylene playing a role of a 4π counterpart. The primary 
photoproducts accessed by this strategy contain reactive electron-rich cyclohexadiene 
fragments, which can be utilized as handles for the experimentally simple post-
photochemical transformations to further expand scaffold diversity and complexity. 
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Project 4: Access to Complex Polyheterocyclic Architectures by Photoinduced 
Dearomatization Cascade Reactions of Oxalyl Anilides [130] 
Both diversity-oriented and target-oriented approaches in drug discovery share the 
goal of obtaining complex molecular structures [131]. Therefore, development of new 
synthetic methodologies that enable quick growth in scaffold complexity is highly 
desirable; “step-economical” strategies, i.e. those that require minimum number of steps, 
are especially appealing [132]. 
In the previous section of this chapter, we have described an effective method for the 
assembly of various polyheterocyclic molecules, which is based on photoinduced [2+4] 
cycloadditions of ESIPT-generated o-azaxylylenes to benzenoid arenes [121]. Given that 
the resulting compounds contain diene moieties, known “sinks” for triplet energy [133-
138], we hypothesized that through the secondary excitation and subsequent ISC it would 
be possible to produce triplet dienes, which could participate in further reactions leading 
to an additional increase in molecular complexity (Scheme 3.24). Ideally, the entire 
transformation would occur in “one pot”, using a single light source for inducing both 
primary and secondary steps. 
 
 
Scheme 3.24 
365 nm irradiation of the substrates containing oxyacetic and propionic linkers leads 
only to [2+4] cycloadducts and does not promote any secondary photochemistry 
involving diene functionalities. This observation suggests that the quinolinolo-
cyclohexadiene products have reduced UV absorptivity at this wavelength in comparison 
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to the corresponding photoprecursors, presumably due to decreased π-conjugation caused 
by the lack of aromatic carbonyl. In order to solve this problem, we decided to 
incorporate a multifunctional linker between photoactive cores and benzenoid groups in 
the starting materials. The ideal tether would not only enhance light-harvesting properties 
of the molecule, but also act as a triplet sensitizer for the diene and thus enable further 
photoinduced transformations. In addition, the new linker would preferably bring other 
benefits, such as (i) straightforward and high-yielding assembly of photoprecursor and 
(ii) formation of an additional pharmacophore in the final product. 
We envisioned that oxalyl unit is the most suitable candidate for the role of 
multifunctional linker in our photoprecursors, for the following reasons: 
• The presence of two carbonyl groups adjacent to each other would 
presumably improve UV absorption of the resulting primary photoproduct by 
extending π-conjugation; 
• α-Dicarbonyl compounds, such as benzil [139] and biacetyl [140], are known 
triplet sensitizers due to efficient ISC; 
• Photoprecursors can be readily assembled by using oxalyl chloride to “zip” 
two aniline fragments, one of which is the photoactive core and the second is 
the unsaturated moiety that is dearomatized during [2+4] photoreaction; 
• Upon cycloaddition, oxalyl amide would fold into imidazolidine-4,5-dione, a 
potential pharmacophore group [141-145]. 
In order to test the feasibility of secondary photoreactions in oxalyl-equipped 
systems, we prepared the substrate 3.83ag through the straightforward synthetic route: 
first, we reacted N-methylanisidine 3.79ag with the excess of oxalyl chloride 3.80 and 
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then coupled the resulting acyl chloride 3.81ag with 1,3-dioxolane-protected o-amino-
benzaldehyde 3.9; finally, acid-catalyzed deprotection of the aldehyde yielded the 
precursor 3.83ag (Scheme 3.25). 
 
 
 
 
Scheme 3.25 
The oxalyl amide substrate 3.83ag was then irradiated under the conditions 
previously optimized for the aryloxyacetic and arylpropionic precursors, i.e. with 365 nm 
LEDs and in DMSO as a solvent. To our delight, monitoring the reaction progress by 
proton NMR revealed that the initially formed cyclohexadiene 3.85ag was depleted upon 
extended photolysis and converted into the 2-azabicyclo[2.2.2]octene product 3.87ag, 
whose structure was established by X-ray crystallography (Scheme 3.26). 
 
 
 
Scheme 3.26 
This result clearly demonstrates that the introduction of the oxalyl tether allows the 
achievement of a cascade transformation, where both photochemical steps (3.83ag → 
3.85ag and 3.85ag → 3.87ag) occur consecutively in a single pot, producing polycyclic 
scaffolds that are more complex than the primary cyclohexadiene-outfitted structures. 
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To probe the scope of the new photocascade, we synthesized a diverse set of 
benzaldehyde- (3.83) and acetophenone-derived substrates (3.84) based on 
N-alkylanilines having various substituents in benzene ring, such as methoxy (a, b, d), 
methoxycarbonyl (b), γ-lactam (c) and hydroxy (e) groups, as well as different 
functionalities in the α-position to the tertiary nitrogen atom: phenyl (h), 2-thienyl (i), 
cyclopropyl (j), 3-pyridyl (k), tert-butyl (l), 3-cyclopentenyl (m) and 3-indolinyl (n; 
Scheme 3.27). Initially, we prepared an array of N-alkylanilines (3.79) either by 
reductive amination (reaction a), or by monoalkylation of aromatic amine with RBr 
(reactions b, c); in one case, p-anisidine derivative 3.79an was accessed through ring-
opening of aziridine 3.78 followed by intramolecular Buchwald–Hartwig reaction [146] 
(reaction d). The majority of photoprecursors were then assembled by coupling 
N-alkylanilines 3.79 with the excess of oxalyl chloride 3.80 to get 2-anilino-2-oxoacetyl 
chlorides 3.81, which were then used to acylate protected o-aminobenzaldehyde 3.9 or 
o-aminoacetonphenone 3.48. For the substrate 3.84ck, however, we inverted the order of 
amide couplings, because aniline 3.79ck underwent decomposition upon treatment with 
10 equivalents of oxalyl chloride. Additionally, phenol derivative 3.83eh was accessed by 
demethylation of the anisole precursor 3.83ah with boron tribromide [147]. 
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Scheme 3.27 
 83 
The photochemical cascade observed for compound 3.83ag was consistently 
reproduced on all other substrates, providing the corresponding 2-azabicyclo[2.2.2]-
octenes (3.87, 3.88) in 35–75% yields (Scheme 3.28). Structures of the four products 
(3.87ah, 3.88ah, 3.87aj', 3.87bh') were unambiguously determined by X-ray; other 
compounds were characterized by 1H and 13C NMR, and their structures were verified 
with the help of DU8+ NMR computations [123, 124, 148, 149].9F10 
 
 
 
Scheme 3.28 
                                                 
10 NMR calculations were performed by the advisor, Dr. A. Kutateladze. This method was also used to 
validate the structures of non-crystalline post-photochemical products, which will be discussed later in this 
chapter. 
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Diastereomers 3.87aj and 3.87aj' were distinguished by analyzing the multiplicity of 
the low-field alkenic signal in proton NMR. In compound 3.87aj, the cyclopropyl 
substituent is oriented in such a way that the proton HA has two small SSCCs (≈ 1 Hz) 
with methine proton HB and methylene proton HC (Figure 3.1, a); these long-range 
constants are present due to the W-arrangement of the bonds between the nuclei [150]. 
The isomer 3.87aj', on the other hand, lacks the W-type coupling interaction between HA 
and HB; therefore, its low-field olefin signal has only one small SSCC (Figure 3.1, b). 
This rationale is consistent with DU8+ NMR calculations that confirmed the existence of 
two small W-constants in 3.87aj and one in 3.87aj'; furthermore, the structure of 3.87aj' 
was additionally validated by X-ray crystallography. The same criterion (absence or 
presence of the W-type SSCC between the alkene and methine protons) was also used to 
differentiate the epimers 3.87al and 3.87al' (Figure 3.2). 
Structures of the obtained photoproducts indicate that the cycloaddition step occurs 
with the exclusive anti-diastereoselectivity, as opposed to our previous dearomatization 
of benzenoid arenes [121]. Consistent with the mechanistic rationale for [2+4] photo-
cycloaddition depicted in Scheme 3.18, we suggest that the observed stereochemical 
outcome originates from the predominant formation of in-OH rotamer (in-OH-3.89, 
in-OH-3.90), which could be explained by the propensity of oxalyl amide to create 
exceptionally tight intramolecular hydrogen bonds with the hydroxy group (Scheme 
3.29).
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Figure 3.1: Alkenic region of 1H NMR spectra of 3.87aj and 3.87aj'. 
(a) 
(b) 
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Figure 3.2: Alkenic region of 1H NMR spectrum of 3.87al and 3.87al'. 
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Scheme 3.29 
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 For the secondary photochemical reaction, i.e. the formation of azabicyclo[2.2.2]-
octenes from the primary photoproducts, we propose the mechanism, which is based on 
our hypothesis about the role of oxalyl tether and involves the following steps 
(Scheme 3.30): 
• Excitation of the oxalyl anilide chromophore followed by ISC into the triplet 
manifold (3.85, 3.86 → 3.85-T2, 3.86-T2); 
• Triplet energy transfer from the dicarbonyl fragment to the cyclohexadiene 
moiety (3.85-T2, 3.86-T2 → 3.85-T1, 3.86-T1); 
• 1,5-hydrogen atom transfer (HAT) from the N–CHn–R,R′ carbon to the 
terminal dienic carbon, resulting in the intermediate with two conjugated 
radicals (3.85-T1, 3.86-T1 → 3.91-T1, 3.92-T1); 
• ISC with subsequent recombination of two radical centers (3.91-T1, 3.92-T1 
→ 3.87, 3.88). 
For the simplest N-methyl derivative 3.87ag (R = R' = R'' = H, Xn = p-OMe), all 
intermediates and HAT transition state were calculated by DFT method at the 
B3LYP/6-311+G(d,p) level of theory10F11, which supported the proposed reaction pathway. 
Computational results revealed that the triplets in T2 and T1 states of the primary product 
are indeed localized on α-dicarbonyl and diene, respectively (as indicated by changes in 
bond lengths in these moieties). Importantly, the energy of 3.85ag-T1 is ca. 20 kcal/mol 
lower than that of 3.85ag-T2, which corroborates earlier suggested hypothesis that the 
dienic unit serves as a “triplet sink”. The next step, 1,5-HAT, is predicted to be fast 
                                                 
11 Calculations were performed by the advisor, Dr. A. Kutateladze. 
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Scheme 3.30 
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(calculated activation barrier is 15.9 kcal/mol) and exergonic on the triplet hypersurface 
(diradical 3.91ag-T1 is ca. 8 kcal/mol “downhill” compared to 3.85ag-T1). 
Additional evidence for the biradical mechanism was provided by the discovery of 
diaza-benzofenestrane 3.88ah' (Scheme 3.30), which was isolated in trace quantities 
after the irradiation of acetophenone-based precursor 3.84ah and was characterized by 
X-ray. Formation of this minor product is rationalized by recombination of 3.92ah-T1 at 
the alternative terminus of the allylic radical. 
In order to gain more mechanistic information about the 1,5-HAT step, we compared 
relative quantum yields of the azabicyclo[2.2.2]octene production for the protic substrate 
3.83ag and its trideuteromethyl analogue 3.83ag-d3, which was prepared by alkylation of 
the protected p-anisidine with iodomethane-d3, followed by deprotection and the same 
steps previously used to access 3.83ag (Scheme 3.31). 
 
 
 
 
 
 
 
 
 
Scheme 3.31 
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By comparing the reactivity of 3.83ag and 3.83ag-d3, we expected to get evidence for 
a primary kinetic isotope effect (KIE), because the proposed HAT step involves breaking 
C–H/C–D bond. The experiment was carried out by running NMR scale irradiations of 
these compounds on a “carousel” photoreactor to average out the influence of LED-to-
sample distance on the reaction rate. From the obtained NMR data, we derived an 
extremely large ΦH/ΦD value of 72 ± 12 11F12 that implies quantum tunneling [151]. 
Since the secondary photoreaction is a multi-step process, we recognized that this 
number might reflect not only the difference in HAT rates between protic and deuterated 
compounds, but also the isotope effects on lifetimes of the excited state species along the 
reaction coordinate. Therefore, with the intention to get a more accurate KIE value for 
HAT by minimizing the possible influence of isotopic composition on lifetimes of the 
intermediates, we synthesized the monodeuterated photoprecursor 3.83ag-d; the required 
isotopically labeled aniline 3.79ag-d was prepared by sodium borodeuteride reduction of 
the imine intermediate formed from p-anisidine 3.74a and formaldehyde (Scheme 3.32). 
 
 
 
 
 
Scheme 3.32 
                                                 
12 Calculation details can be found in the “Experimental Section” chapter. 
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3.83ag-d was then irradiated under standard conditions, and the resulting product 
mixture was analyzed by proton NMR. Based on acquired data, we determined the 
percentages of azabicyclo[2.2.2]octenes deuterated at different positions (3.83ag-d and 
3.83ag-d ', Scheme 3.33); using these numbers and applying statistical correction for two 
hydrogens vs. one deuterium atom, we obtained the ratio ΦH/ΦD = 34 ± 14.12 F13 Given that 
this number is lower than the one calculated in the previous experiment, we rationalize 
that D substitution has an effect on lifetimes of excited species. At the same time, this 
value exceeds the maximum possible room temperature primary KIE by a factor of 4, and 
thereby indicates that 1,5-HAT occurs through quantum tunneling [151]. This 
phenomenon is not unprecedented: for instance, KIEs of 5−55 were reported for the 
proton-transfer step in the enzyme methylamine dehydrogenase [152]; also, significant 
contributions of hydrogen atom tunneling were found for 1,5-HAT from the methyl 
group to the excited-state carbonyl oxygen [153-157]. 
 
 
Scheme 3.33 
The processes that follow HAT in the mechanism of the azabicyclo[2.2.2]octene 
formation, i.e. ISC and radical recombination (3.91-T1, 3.92-T1 → 3.87, 3.88; 
Scheme 3.30), also proceeded with remarkably fast rates, as demonstrated by the 
                                                 
13 Calculation details can be found in the “Experimental Section” chapter. 
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photolysis of precursor with cyclopropylmethyl radical clock (3.83aj, Scheme 3.34) that 
did not generate any ring-opened side products, such as 3.93, 3.94 or 3.95. This result 
suggests that the collapse of the diradical 3.91aj-T1 is so rapid that it outcompetes strain-
relieving rearrangement of the cyclopropane.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.34 
The overall efficiency of the secondary photoreaction is illustrated by the fact that all 
cyclohexadiene intermediates (except methyl-substituted 3.85ag) are barely detectable in 
the irradiation mixtures by NMR. It is conceivable that alkyl or aryl R' groups (which are 
                                                 
14 It is important to note that faster radical clocks [158], such as 2,2-diphenylcyclobutylmethyl [159] 
and bicyclo[2.1.0]pent-2-yl [160], might undergo rearrangements at rates comparable to that of HAT.  
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absent in the N-methylated system) provide additional stabilization to the radical center in 
3.91-T1/3.92-T1 and thus facilitate the transformation of primary compounds 3.85/3.86 
into cyclized photoproducts 3.87/3.88. 
The fast rate of the second photocascade step is further supported by the exclusive 
formation of tertiary alcohol 3.87eh from the phenolic substrate 3.83eh (Scheme 3.35). 
The initially produced dienol 3.85eh undergoes rapid and complete conversion into the 
corresponding secondary photoproduct 3.87eh and does not tautomerize into the enone 
3.87eh', which was not observed by NMR at any point during the reaction. 
 
 
 
 
 
 
Scheme 3.35 
After identifying several important mechanistic aspects of the new photoinduced 
cascade, we turned our attention to the additional synthetic potential offered by this 
reaction. We recognized that X and Y groups originally located at the opposite ends in 
p-substituted N-alkylaniline (3.79, Scheme 3.36) are brought into a vicinal relationship as 
a result of the photochemical dearomatization (3.88). These moieties can be easily varied, 
due to the wide selection of p-functionalized anilines 3.74 and aldehydes 3.75 that are 
used as starting materials for the modular assembly of the photoprecursors 3.84. We 
decided to take advantage of this feature and synthesize azabicyclo[2.2.2]octenes bearing 
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specific X and Y substituents (3.88), with the intention to demonstrate the utility of these 
groups as “handles” for post-photochemical ring formations enabling further increase in 
the molecular complexity. 
 
 
 
 
 
Scheme 3.36 
We prepared photoprecursor 3.84fo in two straightforward steps, by (i) reductive 
amination of 2-fluoro-nicotinaldehyde 3.75o with mono-Boc-protected p-phenylene-
diamine 3.74f, followed by (ii) coupling the resulting aniline 3.79fo with acyl chloride 
3.82 readily obtained from o-aminoacetophenone 3.48 and oxalyl chloride 3.80 (Scheme 
3.37, a). Irradiation of 3.84fo provided the secondary photoproduct 3.88fo outfitted with 
nucleophilic (NHBoc) and electrophilic (fluoropyridyl) functionalities that are 
strategically prearranged for further cyclization. We were pleased to discover that simple 
heating of 3.88fo in trifluoroacetic acid (TFA) deprotects the amino group and 
simultaneously activates the electrophilic moiety, enabling the desired formation of the 
azaindoline 3.96. This approach was also extended on 2-(methoxycarbonyl)phenyl 
derivative 3.88fp that underwent acid-induced lactamization, leading to the dihydro-
isoquinolone 3.97 (Scheme 3.37, b). 
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Scheme 3.37 
Furthermore, we found that the same conditions are capable of promoting Pictet–
Spengler reaction, where the iminium intermediate 3.98/3.99, generated in situ from the 
amine and the external aldehyde (3.75h/3.75k), diastereoselectively alkylates the 
electron-rich 3,5-dimethoxyphenyl moiety (Scheme 3.38). This transformation assembles 
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the tetrahydroisoquinoline unit decorated with additional functionality, such as phenyl 
(3.100) or 3-pyridyl (3.101). 
 
 
 
 
 
 
 
 
 
Scheme 3.38 
In addition to various cyclizations, treatment with TFA induces dehydration of 
benzylic alcohol that forms a styrenic double bond. As a result, modified photoproducts 
contain two alkene fragments that can also be subjected to further transformations 
enhancing the complexity of the final products. 
We discovered that the styrenic olefin can be selectively oxidized with m-chloro-
peroxybenzoic acid (mCPBA): oxirane 3.103 was obtained in 27% after three steps 
(photocascade, dehydration and epoxidation; Scheme 3.39, reaction a). Importantly, the 
double bond in the azabicyclo[2.2.2]octene core remained intact, presumably due to the 
effect of the neighboring aminal fragment responsible for π(C=C) → σ*(C–N) 
interactions that deplete the alkene of the π density. Furthermore, superior reactivity of 
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the styrene double bond in the electrophilic epoxidation could be attributable to its 
enhanced nucleophilic character imparted by the electron donation from o-nitrogen. Even 
though amide nitrogens usually exhibit relatively weak electron-donating properties, this 
system might be an exception, because structural constraints could lead to misalignment 
of the lone pair on N atom with the carbonyl group, reducing the n(N) → π*(C=O) 
interaction [161]. 
In contrast to the reaction with mCPBA, 1,3-dipolar cycloaddition with the in situ 
generated benzonitrile oxide exclusively affected the azabicyclo[2.2.2]octene moiety, 
furnishing isoxazoline 3.105, as well as the product of double addition 3.106 (Scheme 
3.39, reaction b). 
 
 
 
 
 
 
 
 
Scheme 3.39 
An even more direct route towards isoxazoline-outfitted structures was implemented 
by running the photochemical cascade in DMF with the subsequent addition of dibromo-
formaldoxime 3.107 and base (Scheme 3.40). This “one-pot” procedure, carried out with 
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a single purification, afforded diastereochemically pure bromoisoxazoline 3.108 
containing seven contiguous stereocenters and a fully saturated benzene ring. 
 
 
 
Scheme 3.40 
To summarize, we have developed a new methodology based on the photoinduced 
two-step cascade reaction that yields complex polyheterocyclic architectures with 
azabicyclo-[2.2.2]octene core. In the primary photoprocess, ESIPT-generated 
o-azaxylylene undergoes intramolecular dearomative [4+2] cycloaddition to an aniline 
pendant. The second step of the photocascade involves triplet sensitization of 1,3-
cyclohexadiene by the oxalyl amide moiety, 1,5-HAT from the N–CHn–R,R′ carbon to 
the triplet diene, and the collapse of the diradical intermediate to form [2.2.2]-bicyclic 
structure; remarkably, KIE studies provide evidence for quantum tunneling in the 1,5-
HAT process. The central role in this chemistry belongs to the oxalyl linker, which 
(i) enables quick modular assembly of the substrates from feedstock chemicals and 
(ii) initiates a secondary photochemical step. The novel cascade reaction can be used to 
access photoproducts containing specific functional groups, in order to exploit them in 
further complexity-building modifications. 
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Chapter Four:  Experimental Section 
General Methods 
Common solvents were purchased from Fisher Scientific and used as is, except for 
THF, which was refluxed over and distilled from sodium benzophenone ketyl prior to 
use. Common reagents were purchased from Sigma-Aldrich, TCI America, AK 
Scientific, Oakwood Chemical or AstaTech and used without additional purification. 
NMR spectra were recorded at 25 °C on a Bruker Avance III 500 MHz instrument; 
spectra are referenced to TMS (δ = 0 ppm, 1H; 0 ppm, 13C) or the residual protic solvents: 
chloroform (δ = 7.26 ppm, 1H; 77.16 ppm, 13C), DMSO (δ = 2.50 ppm, 1H; 39.52 ppm, 
13C), methanol (δ = 3.31 ppm, 1H; 49.00 ppm, 13C), DMF (δ = 2.75 ppm, 1H; 34.89 ppm, 
13C), DCM (δ = 54.00 ppm, 13C), acetone (δ = 2.05 ppm, 1H). High resolution mass 
spectra were obtained on a Waters Synapt G2 HDMS Quadrupole/ToF mass spectrometer 
with electrospray ionization (Central Analytical Laboratory, University of Colorado 
Boulder). Flash column chromatography was performed using Teledyne Isco RediSep® 
Rf Normal Phase Silica Gel (230–400 mesh or 400–632 mesh) on a Teledyne Isco 
CombiFlash® Rf 200 instrument. X-ray structures were obtained with a Bruker SMART 
APEX II diffractometer (see Appendix A). 
 
 101 
Experimental Section for Project 1 
Synthesis of Photoprecursors 
 
General Procedure A for the Synthesis of Ethyl 5-Aryl-1,3,4-oxadiazole-2-
carboxylates. Used a modified literature protocol [116]. Under nitrogen, aryl-2-
carbohydrazide (3.13; 7.00 mmol) and TEA (21.0 mmol) were dissolved in DCM (50 
mL), the solution was cooled to 0 °C, and then ethyl oxalyl chloride (3.14; 7.70 mmol) 
was added dropwise. The reaction mixture was slowly warmed to room temperature, 
stirred for 8 h, and treated with TsCl (7.00 mmol). After stirring overnight, the mixture 
was diluted with DCM (40 mL) and washed 3 times with sat. aq. NaHCO3 (2 mL) diluted 
with water (10 mL), and then with water (20 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered, and the solvent was removed in vacuo to yield the desired 
oxadiazole ester (3.15; if necessary, the product was additionally purified by flash 
chromatography on silica gel). 
Ethyl 5-Phenyl-1,3,4-oxadiazole-2-carboxylate (3.15a). General 
procedure A was followed on a 36.5 mmol scale of benzhydrazide 
(3.13a), which after flash chromatography on silica gel (gradient elution: hexane → 
hexane–ethyl acetate 80:20) afforded 6.32 g (79%) of the title compound. 1H NMR (500 
MHz, CDCl3) δ 8.09 – 8.03 (m, 2H), 7.54 – 7.49 (m, 1H), 7.48 – 7.42 (m, 2H), 4.48 (q, J 
= 7.2 Hz, 2H), 1.40 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.3, 156.4, 
154.3, 132.7, 129.2, 127.5, 122.7, 63.4, 14.0. 
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Ethyl 5-(2-Methylphenyl)-1,3,4-oxadiazole-2-carboxylate 
(3.15b). General procedure A was followed in a 6.73 mmol scale 
of o-toluic hydrazide (3.13b), which afforded 1.53 g (98%) of the title compound. 1H 
NMR (500 MHz, CDCl3) δ 8.05 (dd, J = 7.8, 1.4 Hz, 1H), 7.48 (td, J = 7.6, 1.5 Hz, 1H), 
7.41 – 7.33 (m, 2H), 4.56 (q, J = 7.1 Hz, 2H), 2.75 (s, 3H), 1.48 (t, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 166.9, 156.2, 154.6, 139.3, 132.3, 132.0, 129.7, 126.4, 122.0, 
63.5, 22.1, 14.2. 
 
 
 
General Procedure B for the Synthesis of Potassium 5-Aryl-1,3,4-oxadiazole-2-
carboxylates. 5-Aryl-1,3,4-oxadiazole-2-carboxylic acid ethyl ester (3.15; 4.00 mmol) 
was dissolved in THF (14 mL) and EtOH (3 mL). The solution was cooled to 0 °C and 
treated with KOH (4.20 mmol) in H2O (1 mL). The resulting mixture was stirred at 
ambient temperature for 1 h. The product (4.2) precipitated out of the solution and was 
separated by filtration. 
Potassium 5-Phenyl-1,3,4-oxadiazole-2-carboxylate (4.2a). General 
procedure B was followed on a 14.2 mmol scale of 3.15a, which 
afforded 2.66 g (82%) of the title compound. 1H NMR (500 MHz, MeOD) δ 8.15 – 8.11 
(m, 2H), 7.65 – 7.55 (m, 3H). 13C NMR (126 MHz, MeOD) δ 166.4, 163.1, 159.5, 133.4, 
130.4, 128.2, 125.0. 
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Potassium 5-(4-Methylphenyl)-1,3,4-oxadiazole-2-carboxylate 
(4.2b). General procedure B was followed on a 6.59 mmol scale of 
3.15b with 8.24 mmol of KOH, which afforded 1.46 g (92%) of the title compound. 1H 
NMR (500 MHz, MeOD) δ 8.01 (dd, J = 7.8, 1.4 Hz, 1H), 7.48 (td, J = 7.5, 1.5 Hz, 1H), 
7.43 – 7.40 (m, 1H), 7.40 – 7.36 (m, 1H), 2.69 (s, 3H). 13C NMR (126 MHz, MeOD) δ 
166.7, 162.7, 159.6, 139.8, 132.8, 132.8, 130.4, 127.4, 124.1, 21.9. 
 
 
 
General Procedure C for the Synthesis of Acyl Chlorides. Under nitrogen, to a 
stirred suspension of potassium 5-aryl-1,3,4-oxadiazole-2-carboxylate (4.2; 2.50 mmol) 
in acetonitrile (10 mL) cooled to 0 °C, oxalyl chloride (2.62 mmol) was added dropwise 
over 10 min. DMF (3 drops, ca. 0.03 mL) was added to the reaction mixture, and 
vigorous gas evolution was observed. The resulting reaction mixture was stirred for 2 h 
and used for the next step without purification. 
 
 
 
General Procedure D for Amide Coupling Followed by Dioxolane Deprotection. 
Under nitrogen, N-(2-(1,3-dioxolan-2-yl)phenyl)-2-(benzylamino)acetamide [7] (3.12; 
2.00 mmol) was dissolved in DCM (10 mL), the solution was treated with DIPEA 
(6.00 mmol) and cooled to 0 °C, and then suspension of acyl chloride (3.16; 1.4 mmol) in 
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acetonitrile (prepared according to general procedure C) was added dropwise. The 
reaction mixture was stirred at 0 °C for 30 min, and then at ambient temperature 
overnight. The reaction was quenched with water (5 mL), and aqueous layer was 
extracted with DCM (2×25 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and the solvent was removed in vacuo to yield crude dioxolane-
protected photoprecursor, which was then purified by flash chromatography on silica gel 
(gradient elution: hexane → hexane–ethyl acetate 70:30) and subsequently deprotected 
by stirring with TsOH·H2O (0.400 mmol) in acetone (15 mL) at ambient temperature for 
1 day. Solvent was removed in vacuo, and the residue was dissolved in DCM (25 mL). 
The solution was washed with sat. aq. NaHCO3 (2×5 mL) and then with water (5 mL). 
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
Further purification by flash chromatography on silica gel yielded the desired 
photoprecursor (3.6). 
N-Benzyl-N-(2-(2-formylphenylamino)-2-oxoethyl)-5-
phenyl-1,3,4-oxadiazole-2-carboxamide (3.6a). General 
procedure C was followed on an 11.7 mmol scale of 4.2a, 
and the resulting acyl chloride 3.16a was coupled with 9.75 mmol of 3.12 according to 
general procedure D, which after flash chromatography on silica gel (gradient elution: 
hexane → hexane–ethyl acetate 70:30) afforded 2.37 g (55% after two steps) of the title 
compound in a form of two equilibrating rotamers (A and B). 1H NMR (500 MHz, 
CDCl3) δ 11.51 (s, 1H, A), 11.49 (s, 1H, B), 9.87 (d, J = 0.7 Hz, 1H, B), 9.86 (d, J = 0.7 
Hz, 1H, A), 8.71 (d, J = 8.4 Hz, 1H, A), 8.66 (d, J = 8.4 Hz, 1H, B), 8.19 – 8.16 (m, 2H, 
A), 8.16 – 8.14 (m, 2H, B), 7.70 – 7.47 (m, 11H, A+B), 7.44 – 7.29 (m, 11H, A+B), 7.27 
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(dd, J = 7.4, 1.0 Hz, 1H, B), 7.24 (dd, J = 7.4, 1.0 Hz, 1H, A), 5.46 (s, 2H, A), 4.96 (s, 2H, 
B), 4.86 (s, 2H, B), 4.33 (s, 2H, A). 13C NMR (126 MHz, CDCl3) δ 195.7, 195.7, 167.1, 
166.5, 165.9, 165.8, 158.4, 158.1, 155.8, 155.6, 140.3, 140.3, 136.4, 136.3, 136.1, 136.0, 
135.3, 135.1, 132.7, 129.3, 129.3, 129.1, 129.1, 128.9, 128.4, 128.4, 128.3, 127.8, 127.7, 
123.6, 123.1, 123.0, 122.0, 122.0, 120.1, 120.1, 53.9, 52.5, 51.5, 50.4. HRMS (ESI) calcd 
for C25H21N4O4
+ (MH+) 441.1563, found 441.1557. 
N-Benzyl-N-(2-(2-formylphenylamino)-2-oxoethyl)-5-
(2-methyphenyl)-1,3,4-oxadiazole-2-carboxamide 
(3.6b). General procedure C was followed on an 5.87 
mmol scale of 4.2b, and the resulting acyl chloride 3.16b was coupled with 4.19 mmol of 
3.12 according to general procedure D, which after flash chromatography on silica gel 
(gradient elution: hexane → hexane–ethyl acetate 70:30) afforded 0.368 g (19% after two 
steps) of the title compound in a form of two equilibrating rotamers (A and B). 1H NMR 
(500 MHz, CDCl3) δ 11.50 (s, 1H, A), 11.49 (s, 1H, B), 9.84 (s, 1H, A + 1H, B), 8.70 (d, J 
= 8.5 Hz, 1H, A), 8.65 (d, J = 8.5 Hz, 1H, B), 8.06 (t, J = 6.4 Hz, 1H, A + 1H, B), 7.68 – 
7.62 (m, 1H, A + 1H, B), 7.59 (q, J = 8.9 Hz, 1H, A + 1H, B), 7.49 – 7.19 (m, 9H, A + 9H, 
B), 5.45 (s, 2H, B), 4.94 (s, 2H, A), 4.87 (s, 2H, A), 4.32 (s, 2H, B), 2.75 (s, 3H, A), 2.70 
(s, 3H, B). 13C NMR (126 MHz, CDCl3) δ 195.6, 195.6, 167.1, 166.4, 166.2, 166.0, 
157.9, 157.6, 155.9, 155.6, 140.2, 140.2, 139.2, 139.2, 136.3, 136.2, 136.0, 136.0, 135.3, 
135.1, 132.1, 132.0, 131.9, 129.8, 129.7, 129.0, 129.0, 128.9, 128.4, 128.3, 128.2, 126.4, 
126.4, 123.5, 122.1, 122.0, 121.9, 120.0, 120.0, 53.8, 52.4, 51.4, 50.4, 22.3, 22.2. HRMS 
(ESI) calcd for C26H23N4O4
+ (MH+) 455.1714, found 455.1701. 
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Photochemical Reactions 
 
 
 
 
General Procedure E for the Photoassisted Synthesis of Epoxides. Photoprecursor 
(3.6; 1.00 mmol) was dissolved in MeCN (16 mL). MeOH (64 mL) and water (4.5 mL) 
were added, and the solution was degassed by bubbling nitrogen or argon for 30 min. The 
mixture was irradiated in a Pyrex reaction vessel using Rayonet photoreactor equipped 
with RPR-3500 UV lamps (broadband 300-400 nm UV source with peak emission at 
350 nm), with the reaction progress monitored by 1H NMR. After completion, solvents 
were removed in vacuo, and the solid residue was washed with methanol (10 mL), 
filtered and air-dried to yield the desired epoxide photoproduct (3.8). 
anti-9-Hydroxy-3-benzyl-10-phenyl-7,8-benzo-11-oxa-3,6-
diazatricyclo[8.1.0.01,6]undeca-7-ene-2,5-dione (3.8a). General 
procedure E was followed on a 0.953 mmol scale of 3.6a, which 
afforded 0.230 g (59%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 7.68 – 7.62 
(m, 2H), 7.56 (dt, J = 8.0, 0.7 Hz, 1H), 7.49 – 7.39 (m, 4H), 7.40 – 7.34 (m, 3H), 7.32 (td, 
J = 7.4, 1.2 Hz, 1H), 7.27 (dd, J = 7.5, 1.6 Hz, 1H), 7.21 – 7.10 (m, 2H), 5.24 (d, J = 4.2 
Hz, 1H), 4.79 (d, J = 14.4 Hz, 1H), 4.35 (d, J = 14.4 Hz, 1H), 4.06 (s, 2H), 2.72 (d, J = 
4.2 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 164.2, 158.3, 134.9, 133.3, 131.9, 130.5, 
129.6, 129.1, 129.0, 129.0, 128.7, 128.5, 128.3, 127.8, 127.7, 126.7, 74.2, 70.7, 69.4, 
50.2, 49.4. HRMS (ESI) calcd for C25H20N2NaO4
+ (MNa+) 435.1321, found 435.1345. 
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anti-9-Hydroxy-3-benzyl-10-(2-methylphenyl)-7,8-benzo-11-oxa-
3,6-diazatricyclo[8.1.0.01,6]undeca-7-ene-2,5-dione (3.8b). General 
procedure E was followed on a 0.722 mmol scale of 3.6b, which 
afforded 0.160 g (52%) of the title compound in a form of two 
equilibrating rotamers (A and B). 1H NMR (500 MHz, DMSO) δ 7.64 – 7.17 (m, 12H, A 
+ 11H, B), 7.15 – 6.99 (m, 1H, A + 2H, B), 6.08 (s, 1H, B), 5.96 (d, J = 7.6 Hz, 1H, A), 
5.04 (d, J = 7.5 Hz, 1H, A + 1H, B), 4.91 (d, J = 14.5 Hz, 1H, A), 4.61 (d, J = 14.3 Hz, 
1H, B), 4.51 (d, J = 14.4 Hz, 1H, B), 4.44 – 4.28 (m, 2H, A + 2H, B), 4.25 (d, J = 14.5 
Hz, 1H, A), 2.34 (s, 3H, A), 2.08 (s, 3H, B). 13C NMR (126 MHz, DMSO) δ 163.6, 157.9, 
136.1, 135.7, 131.8, 131.7, 131.5, 130.3, 130.2, 129.2, 128.8, 128.6, 128.4, 128.0, 127.8, 
126.7, 125.9, 124.2, 71.3, 70.7, 68.7, 49.6, 49.1, 18.6. HRMS (ESI) calcd for 
C26H23N2O4
+ (MH+) 427.1653, found 427.1671. 
Post-Photochemical Modifications 
 
 
 
 
(±)-(4aS,5S,6S)-5-Azido-3-benzyl-4a,6-dihydroxy-5-phenyl-2,3,5,6-tetrahydro-
1H-pyrazino[1,2-a]quinoline-1,4(4aH)-dione (3.17). Safety note: sodium azide and 
trifluoroacetic acid can produce highly toxic hydrazoic acid [162]; furthermore, care 
should be taken when inorganic azides are used in the presence of DCM, due to potential 
formation of explosive diazidomethane [163, 164]. Epoxide 3.8a (0.116 g, 0.281 mmol) 
was dissolved in DMSO (2.81 mL) under nitrogen. Trifluoroacetic acid (108 µL, 1.41 
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mmol) and sodium azide (0.274 g, 4.22 mmol) were added, and the mixture was stirred at 
70 °C for 43 h. The reaction mixture was allowed to cool down to ambient temperature 
and was concentrated under high vacuum (60 °C/0.15 Torr). The residue was taken in 
DCM (40 mL) and washed with water (4x10 mL). The product was extracted from 
aqueous layer with DCM (2×20 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and the solvent was removed in vacuo. Further purification 
by flash chromatography on silica gel pretreated with pyridine (gradient elution: hexane 
→ hexane–ethyl acetate + 1% TEA 50:50) afforded 0.067 g (52%) of the title compound. 
1H NMR (500 MHz, CDCl3) δ 7.77 – 7.72 (m, 1H), 7.56 – 7.46 (m, 6H), 7.45 – 7.34 (m, 
5H), 7.29 (dd, J = 7.6, 1.9 Hz, 2H), 6.14 (d, J = 6.3 Hz, 1H), 4.84 (s, 1H), 4.66 (d, J = 
14.2 Hz, 1H), 4.48 (d, J = 17.8 Hz, 1H), 4.47 (d, J = 14.2 Hz, 1H), 4.08 (d, J = 17.8 Hz, 
1H), 2.24 (d, J = 6.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 164.1, 163.0, 134.4, 134.3, 
132.8, 130.0, 129.3, 129.2, 129.2, 129.1, 128.8, 127.9, 127.8, 127.5, 127.0, 126.7, 86.9, 
72.7, 72.7, 51.2, 50.9. HRMS (ESI) calcd for C25H21N5NaO4
+ (MNa+) 478.1486, found 
478.1514. 
 
 
 
 
(±)-(41R,7aS,8S)-3-Benzyl-8-hydroxy-7a-phenyl-6-thioxo-2,3,5,6,7a,8-
hexahydrooxazolo[4,5-b]pyrazino[1,2-a]quinoline-1,4-dione (3.18). Epoxide 3.8a 
(0.197 g, 0.478 mmol) was dissolved in DMSO (16.0 mL) under nitrogen. Trifluoroacetic 
acid (73.2 µL, 0.955 mmol) and potassium thiocyanate (0.465 g, 4.78 mmol) were added, 
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and the mixture was stirred at 70 °C for 35 h. The reaction mixture was allowed to cool to 
ambient temperature and concentrated under high vacuum (60 °C/0.15 Torr). The residue 
was taken in DCM (70 mL) and washed with water (3×20 mL). The product was 
extracted from aqueous layer with DCM (50 mL). The combined organic layers were 
dried over anhydrous Na2SO4, filtered, and the solvent was removed in vacuo. Further 
purification by flash chromatography on silica gel pretreated with pyridine (gradient 
elution: hexane → hexane–ethyl acetate + 1% TEA 50:50) afforded 0.134 g (60%) of the 
title compound. 1H NMR (500 MHz, MeOD) δ 7.63 – 7.56 (m, 2H), 7.49 (ddd, J = 7.8, 
6.9, 2.0 Hz, 1H), 7.45 – 7.30 (m, 9H), 7.27 (dd, J = 7.5, 2.0 Hz, 2H), 4.62 (s, 1H), 4.56 
(d, J = 14.3 Hz, 1H), 4.43 (d, J = 18.7 Hz, 1H), 4.35 (d, J = 14.3 Hz, 1H), 4.23 (d, J = 
18.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 188.3, 164.8, 162.4, 137.2, 136.6, 135.8, 
135.6, 130.4, 130.2, 130.2, 130.0, 129.6, 129.4, 129.4, 129.2, 128.9, 127.5, 98.1, 85.1, 
74.3, 51.2, 49.8. HRMS (ESI) calcd for C26H22N3O4S
+ (MH+) 472.1326, found 472.1320. 
 
 
 
 
(±)-(41S,5aS)-3-Benzyl-5a-phenyl-2,3-dihydrooxireno[2,3-b]pyrazino[1,2-
a]quinoline-1,4,6(5aH)-trione (3.21). Hydroxy-epoxide 3.8a (0.688 g, 1.67 mmol) was 
dissolved in DMSO (16.7 mL) under nitrogen. Dess–Martin periodinane (0.849 g, 
2.00 mmol) was added, and the mixture was stirred at room temperature for 17 h. The 
reaction mixture was concentrated under high vacuum (60 °C/0.15 Torr), then the residue 
was taken in chloroform (90 mL) and washed with saturated aq. NaHCO3 (10 mL) and 
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water (3×20 mL). The product was extracted from aqueous layer with chloroform (50 
mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and the 
solvent was removed in vacuo. Further purification by flash chromatography on silica gel 
pretreated with pyridine (gradient elution: hexane → hexane–ethyl acetate + 1% TEA 
80:20) afforded 0.465 g (68%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 7.85 
(dd, J = 7.7, 1.6 Hz, 1H), 7.71 (dd, J = 8.2, 1.1 Hz, 1H), 7.64 (ddd, J = 8.4, 7.4, 1.6 Hz, 
1H), 7.51 – 7.36 (m, 6H), 7.32 (qd, J = 3.9, 1.8 Hz, 3H), 7.14 – 7.07 (m, 2H), 4.70 (d, J = 
14.4 Hz, 1H), 4.33 (d, J = 14.4 Hz, 1H), 4.16 (d, J = 18.6 Hz, 1H), 4.07 (d, J = 18.6 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 189.5, 163.1, 156.0, 134.6, 134.4, 133.8, 129.3, 
129.1, 128.7, 128.6, 128.3, 128.0, 127.7, 127.6, 127.4, 126.6, 125.8, 72.7, 70.7, 50.4, 
49.4. HRMS (ESI) calcd for C25H18N2NaO4
+ (MNa+) 433.1159, found 433.1173. 
 
 
 
 
4-Benzyl-12a-phenyl-1,3,4,12a-tetrahydro-[1,3,6]triazocino[1,2-a]indole-2,5,6,12-
tetraone (3.22) and 4-Benzyl-12a-phenyl-1,4,5,12a-tetrahydro-[1,3,6]triazocino[1,2-
a]indole-2,3,6,12-tetraone (3.23). Keto-epoxide 3.21 (0.137 g, 0.333 mmol) was 
dissolved in DMSO (11.1 mL) under nitrogen. Trifluoroacetic acid (25.5 µL, 0.333 
mmol) and sodium azide (65 mg, 0.999 mmol) were added, and the mixture was stirred at 
room temperature for 13 h. The reaction mixture was concentrated under high vacuum 
(60 °C/0.15 Torr), and further purification by flash chromatography on silica gel 
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pretreated with pyridine (gradient elution: hexane → hexane–ethyl acetate + 1% TEA 
70:30) afforded 0.052 g (37%) of 3.22 and 0.039 g (27%) of 3.23. 
3.22: 1H NMR (500 MHz, CDCl3) δ 8.75 (dd, J = 9.1, 0.9 Hz, 1H), 
7.95 – 7.87 (m, 2H), 7.49 (td, J = 7.5, 0.9 Hz, 1H), 7.48 – 7.42 (m, 
3H), 7.36 – 7.29 (m, 3H), 7.29 – 7.20 (m, 4H), 6.63 (s, 1H), 4.66 
(dd, J = 14.4, 1.5 Hz, 1H), 4.30 (dd, J = 17.1, 1.6 Hz, 1H), 3.83 (d, J 
= 17.2 Hz, 1H), 3.56 (d, J = 14.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 192.2, 168.0, 
162.7, 161.5, 152.4, 139.2, 134.1, 133.9, 130.6, 129.7, 129.1, 129.0, 128.4, 127.2, 126.5, 
125.0, 119.7, 119.7, 78.2, 50.1, 48.9. HRMS (ESI) calcd for C25H19N3NaO4
+ (MNa+) 
448.1268, found 448.1284. 
3.23: 1H NMR (500 MHz, CDCl3) δ 8.68 (d, J = 8.5 Hz, 1H), 7.81 
(ddd, J = 8.6, 7.3, 1.4 Hz, 1H), 7.73 (d, J = 7.4 Hz, 1H), 7.71 (dd, J 
= 7.8, 1.5 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.37 (tt, J = 7.4, 1.2 Hz, 
1H), 7.36 – 7.23 (m, 6H), 7.21 (dd, J = 7.5, 2.0 Hz, 2H, ), 7.11 (d, J = 8.0 Hz, 1H), 4.52 
(dd, J = 17.1, 1.6 Hz, 1H), 4.45 (dd, J = 14.6, 1.6 Hz, 1H), 3.97 (d, J = 17.1 Hz, 1H), 3.36 
(d, J = 14.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 192.0, 165.7, 165.3, 161.7, 151.4, 
138.7, 134.0, 133.6, 130.4, 129.1, 129.0, 128.4, 128.4, 128.3, 126.4, 126.1, 123.5, 119.2, 
119.2, 80.2, 51.4, 49.0. HRMS (ESI) calcd for C25H19N3NaO4
+ (MNa+) 448.1268, found 
448.1286. 
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(±)-(2aS,2a1S,9bR)-3-Benzyl-9b-hydroxy-2a1-phenyl-1,3,5a-triaza-2a,3-dihydro-
1H-cyclopenta[jk]fluorene-2,4,5(2a1H,5aH,9bH)-trione (3.27) and (±)-(1R,10aS)-2-
Benzyl-3,4,10-trioxo-10a-phenyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole-1-
carboxamide (3.27'). Keto-epoxide 3.21 (0.200 g, 0.487 mmol) was dissolved in DMSO 
(16.2 mL) under nitrogen. Trifluoroacetic acid (37.3 µL, 0.487 mmol) and sodium azide 
(0.475 g, 7.31 mmol) were added, and the mixture was stirred at room temperature for 
2 h, and then at 100 °C for 2 h. The reaction mixture was concentrated under high 
vacuum (60 °C/0.15 Torr), and further purification by flash chromatography on silica gel 
pretreated with pyridine (gradient elution: hexane → hexane–ethyl acetate + 1% TEA 
50:50) afforded 0.095 g (46%) of the product in a form of two equilibrating isomers, 3.27 
and 3.27'. 1H NMR (500 MHz, MeOD) δ 8.53 (d, J = 8.4 Hz, 1H, 3.27'), 8.18 (d, J = 8.0 
Hz, 1H, 3.27), 7.87 (ddd, J = 8.5, 7.4, 1.4 Hz, 1H, 3.27'), 7.71 (d, J = 7.7 Hz, 1H, 3.27'), 
7.53 (td, J = 7.8, 1.4 Hz, 1H, 3.27), 7.45 (dd, J = 7.6, 1.2 Hz, 1H, 3.27), 7.39 (td, J = 7.6, 
0.9 Hz, 1H, 3.27'), 7.37 – 7.27 (m, 1H, 3.27, 3H, 3.27'), 7.26 (td, J = 7.4, 1.2 Hz, 2H, 
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3.27), 7.25 – 7.18 (m, 3H, 3.27'), 7.15 (td, J = 7.8, 1.4 Hz, 4H, 3.27), 7.11 (t, J = 7.7 Hz, 
2H, 3.27'), 6.97 (d, J = 8.1 Hz, 4H, 3.27), 6.88 (d, J = 7.5 Hz, 2H, 3.27'), 5.55 (d, J = 
14.7 Hz, 1H, 3.27), 5.06 (s, 1H, 3.27'), 5.03 (s, 1H, 3.27), 4.91 (d, J = 14.8 Hz, 1H, 
3.27'), 4.28 (d, J = 14.7 Hz, 1H, 3.27), 4.02 (d, J = 14.7 Hz, 1H, 3.27'). 13C NMR 
(126 MHz, MeOD) δ 194.7, 171.8, 169.5, 159.8, 157.5, 155.9, 155.2, 152.0, 141.3, 139.3, 
135.9, 135.6, 135.5, 133.8, 133.5, 131.9, 130.4, 130.4, 130.0, 129.9, 129.7, 129.7, 129.6, 
129.6, 129.2, 129.0, 128.2, 128.0, 127.6, 126.1, 126.0, 124.8, 124.1, 119.5, 118.8, 93.3, 
74.6, 73.2, 63.5, 61.3, 51.7, 51.6, 49.6. HRMS (ESI) calcd for C25H20N3O4
+ (MH+) 
426.1449, found 426.1469. 
 
Experimental Section for Project 2 
Synthesis of Photoprecursors 
 
 
 
 
 
 
 
General Procedure A for the Synthesis of 2-(1H-Pyrrol-1-yl)alkanoic acids. Used 
a modified literature protocol [49]. Amino acid (3.32; 60.6 mmol) and anhydrous sodium 
acetate (5.02 g, 61.2 mmol) were dissolved in water (81 mL), glacial AcOH (27 mL) and 
DCE (81 mL). The mixture was stirred at 80 °C for 10 min, treated with 
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2,5-dimethoxytetrahydrofuran (3.33; 7.92 mL, 8.08 g, 60.6 mmol), and stirred at 80 °C 
for 7–14 h. After cooling to ambient temperature, the product was extracted with DCM 
(3×100 mL), the combined organic layers were subsequently washed with sat. aq. NaCl 
(50 mL) and water (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The residue was filtered through silica gel. Two fractions were collected: first 
fraction was obtained by eluting with 500 mL of hexanes–ethyl acetate 98:2, second 
fraction was obtained by eluting with 1000 mL of hexanes–ethyl acetate 50:50. The 
second fraction was concentrated in vacuo to afford the desired pyrrole derivative (3.34). 
(S)-3-Phenyl-2-(1H-pyrrol-1-yl)propanoic acid (3.34a). General 
procedure A was followed on a 60.6 mmol scale of L-phenylalanine 
(3.32a), which afforded 5.36 g (41%) of the title compound. 1H NMR 
(500 MHz, CDCl3) δ 7.24 (m, 3H), 7.02 (dd, J = 7.6, 1.9, 2H), 6.71 (t, J = 2.2, 2H), 6.17 
(t, J = 2.1, 2H), 4.80 (dd, J = 9.2, 5.9, 1H), 3.46 (dd, J = 14.0, 5.9, 1H), 3.30 (dd, J = 
14.0, 9.2, 1H). 
(S)-2,5-Di(1H-pyrrol-1-yl)pentanoic acid (3.34b). General 
procedure A was followed on a 11.9 mmol scale of L-ornithine 
monohydrochloride (3.32b) with 23.7 mmol of sodium acetate and 
23.7 mmol of 3.33, which afforded 1.38 g (50%) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 6.68 (t, J = 2.2, 2H), 6.60 (t, J = 2.1, 2H), 6.20 
(t, J = 2.2, 2H), 6.15 (t, J = 2.1, 2H), 4.44 (dd, J = 10.3, 5.4, 1H), 3.86 (t, J = 6.8, 2H), 
2.12 (m, 1H), 2.02 (m, 1H), 1.75 (m, 1H), 1.65 (m, 1H). 
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General Procedure B for One-Pot Coupling and Isatin Opening. Under nitrogen, 
acid (3.34; 2.40 mmol) was dissolved in DCM (12 mL), the solution was cooled to 0 °C 
and treated with isatin (3.35; 2.00 mmol), EDC·HCl (2.40 mmol) and DMAP 
(0.20 mmol). The reaction mixture was stirred at ambient temperature for 3 h, treated 
with solution of 1,2-phenylenediamine (3.36; 2.40 mmol) in DCM (3 mL), and stirred 
overnight. Solvent was removed in vacuo, and further purification by flash 
chromatography on silica gel yielded the desired photoprecursor (3.37). 
(S)-N-(2-(3-Oxo-3,4-dihydroquinoxalin-2-yl)phenyl)-3-phenyl-2-
(1H-pyrrol-1-yl)propanamide (3.37a). General procedure B was 
followed on a 4.92 mmol scale of 3.34a, which after flash 
chromatography on silica gel (gradient elution: hexane → hexane–
ethyl acetate 50:50) afforded 1.54 g (72%) of the title compound. 1H 
NMR (500 MHz, CDCl3) δ 10.87 (s, 1H), 9.68 (s, 1H), 8.17 (d, J = 8.3, 1H), 7.91 (dd, J = 
7.8, 1.6, 1H), 7.76 (dd, J = 8.1, 1.3, 1H), 7.59 (ddd, J = 8.4, 7.3, 1.4, 1H), 7.52 (td, J = 
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8.4, 7.9, 1.6, 1H), 7.40 (ddd, J = 8.3, 7.3, 1.3, 1H), 7.28 (m, 2H), 7.03 (m, 3H), 6.89 (m, 
2H), 6.55 (t, J = 2.1, 2H), 5.89 (t, J = 2.1, 2H), 4.67 (dd, J = 9.4, 5.6, 1H), 3.63 (dd, J = 
14.1, 5.6, 1H), 3.13 (dd, J = 14.1, 9.4, 1H). 13C NMR (126 MHz, CDCl3) δ 168.5, 156.1, 
154.7, 137.2, 136.1, 132.6, 131.4, 131.2, 131.0, 130.9, 129.6, 128.8, 128.4, 126.7, 126.7, 
124.8, 124.7, 124.1, 120.1, 115.8, 109.5, 66.2, 38.9. HRMS (ESI) calcd for 
C27H22N4NaO2
+ (MNa+) 457.1635, found 457.1647. 
(S)-N-(2-(3-Oxo-3,4-dihydroquinoxalin-2-yl)phenyl)-2,5-
di(1H-pyrrol-1-yl)pentanamide (3.37b). General procedure B 
was followed on a 5.34 mmol scale of 3.34b, which after flash 
chromatography on silica gel (gradient elution: hexane → 
hexane–ethyl acetate 30:70) afforded 1.54 g (64%) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 11.34 (br, 1H), 9.29 (s, 1H), 8.12 (d, J = 8.3, 
1H), 7.86 (d, J = 7.8, 1H), 7.78 (d, J = 8.1, 1H), 7.59 (t, J = 7.7, 1H), 7.51 (t, J = 7.9, 1H), 
7.42 (t, J = 7.7, 1H), 7.28 (m, 2H), 6.54 (s, 2H), 6.51 (s, 2H), 6.06 (s, 2H), 5.88 (s, 2H), 
4.36 (dd, J = 10.4, 4.9, 1H), 3.78 (m, 2H), 2.30 (m, 1H), 1.90 (m, 1H), 1.59 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 168.9, 155.5, 155.2, 136.0, 132.6, 131.4, 131.2, 131.2, 130.9, 
130.0, 127.0, 124.8, 124.8, 124.1, 120.6, 120.0, 115.5, 109.9, 108.3, 63.9, 49.2, 29.7, 
28.1. HRMS (ESI) calcd for C27H25N5NaO2
+ (MNa+) 474.1900, found 474.1913. 
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Photochemical Reactions Followed by Post-Photochemical Modifications 
 
 
 
 
(2S,2bR,4aR,5R)-2-Benzyl-3-(4-methylbenzenesulfonylimino)-2a1,3,4,4a-
tetrahydro-1'H-spiro[2a,9b-diazapentaleno[1,6-ab]naphthalene-5,2'-quinoxaline]-
1,3'(2H,4'H)-dione (3.39). Photoprecursor 3.37a (0.177 g, 0.407 mmol) was dissolved in 
anhydrous DCM (17 mL) under nitrogen, and the solution was degassed by bubbling 
nitrogen for 30 min. Titanium (IV) isopropoxide (0.18 mL, 0.632 mmol) was added, and 
the mixture was irradiated with UV LED-based illuminator (five 250 mW @ 365 nm 
Nichia chips) at –20 °C for 21 h. Then the solution was washed with water (5 mL), and 
the product was extracted from aqueous layer with DCM (4 mL). The combined organic 
layers were dried over anhydrous Na2SO4 and filtered. DMSO (2.0 mL) and tosyl azide 
(0.31 mL, 0.40 g, 2.04 mmol) were added, and DCM was removed in vacuo. The 
resulting mixture was stirred at ambient temperature for 2 days, and then concentrated 
under high vacuum (60 °C/0.15 Torr). Further purification by flash chromatography on 
silica gel pretreated with pyridine (gradient elution: hexane → hexane–ethyl acetate + 1% 
TEA 50:50) afforded 0.092 g (40% after two steps) of the title compound. 1H NMR (500 
MHz, CDCl3) δ 8.85 (s, 1H), 7.68 (d, J = 8.0, 2H), 7.59 (d, J = 7.9, 1H), 7.28 (m, 6H), 
7.01 (m, 4H), 6.78 (d, J = 7.7, 1H), 6.71 (t, J = 7.6, 1H), 6.62 (t, J = 7.6, 1H), 6.12 (d, J = 
7.9, 1H), 4.87 (t, J = 4.7, 1H), 4.49 (d, J = 8.0, 1H), 4.04 (ddd, J = 9.9, 8.0, 2.3 Hz, 1H), 
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3.92 (dd, J = 18.8, 2.3, 1H), 3.88 (s, 1H), 3.47 (dd, J = 18.7, 9.6, 1H), 3.38 (dd, J = 14.1, 
4.8, 1H), 3.29 (dd, J = 14.1, 4.9, 1H), 2.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 172.4, 
169.0, 165.0, 143.1, 138.8, 135.3, 131.5, 131.1, 130.8, 129.7, 129.6, 129.5, 128.9, 127.8, 
126.9, 126.7, 126.0, 124.4, 123.4, 120.8, 116.1, 115.4, 74.8, 63.0, 62.6, 42.6, 36.1, 33.5, 
21.6. HRMS (ESI) calcd for C34H29N5NaO4S
+ (MNa+) 626.1832, found 626.1851. 
 
 
 
 
 
 
(13aS)-2,3,7,7a,7a1,13a-Hexahydro-1H,1'H-spiro[3a,6b1,12b-triazacyclopenta 
[4',5']cycloocta[1',2',3':3,4]pentaleno[1,6-ab]naphthalene-8,2'-quinoxaline]-
3',13(4'H,6bH)-dione (3.40). Photoprecursor 3.37b (0.420 g, 0.930 mmol) was dissolved 
in anhydrous DCM (46.5 mL) under nitrogen, and the solution was degassed by bubbling 
nitrogen for 30 min. Titanium (IV) isopropoxide (0.41 mL, 1.40 mmol) was added, and 
the mixture was irradiated with UV LED-based illuminator (five 250 mW @ 365 nm 
Nichia chips) at –20 °C for 37 h. Then the solution was stirred with sat. aq. NH4Cl (17 
mL) for 30 min. Organic layer was separated, and the product was extracted from 
aqueous layer with DCM (4×5 mL). The combined organic layers were washed with 
water (17 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
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residue was redissolved in nitromethane (19 mL), and the resulting solution was filtered 
through cotton and cooled to 0 °C. Under nitrogen, solution of trichloroacetic acid (0.190 
g, 1.16 mmol) in nitromethane (0.5 mL) was added, and the reaction mixture was left at 0 
°C for 2 days. Then it was concentrated in vacuo, and further purification by flash 
chromatography on silica gel pretreated with pyridine (gradient elution: hexane → 
hexane–ethyl acetate + 1% TEA 50:50) afforded 0.040 g (10% after two steps) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 8.61 (dd, J = 8.4, 1.3, 1H), 8.05 (s, 1H), 7.78 
(dd, J = 7.9, 1.6, 1H), 7.40 (ddd, J = 8.5, 7.3, 1.6, 1H), 7.14 (td, J = 7.6, 1.3, 1H), 6.97 
(td, J = 7.7, 1.4, 1H), 6.84 (td, J = 7.7, 1.3, 1H), 6.78 (dd, J = 7.9, 1.4, 1H), 6.73 (dd, J = 
7.8, 1.3, 1H), 6.46 (t, J = 2.3, 1H), 5.98 (dd, J = 3.6, 2.7, 1H), 5.71 (br, 1H), 5.28 (d, J = 
4.3, 1H), 4.79 (br, 1H), 4.41 (dd, J = 10.3, 4.3, 1H), 4.20 (s, 1H), 3.85 (m, 2H), 3.25 (ddd, 
J = 10.5, 9.2, 4.3, 1H), 2.33 (m, 3H), 2.17 (m, 1H), 1.84 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 173.6, 169.2, 135.7, 133.2, 132.0, 130.1, 127.9, 124.9, 124.7, 124.6, 124.2, 
123.4, 120.4, 118.4, 115.2, 114.6, 106.5, 105.9, 79.2, 66.0, 61.3, 55.1, 48.8, 41.3, 31.8, 
28.4. HRMS (ESI) calcd for C27H26N5O2
+ (MH+) 452.2081, found 452.2100. 
 
Experimental Section for Project 3 
Synthesis of Photoprecursors 
The following compounds were synthesized according to previously described 
procedures (or similarly): 2-(p-tolyloxy)acetic acid (3.46b) [165], 2-(3,5-dimethyl-
phenoxy)acetic acid (3.46c) [166], 2-(4-methoxyphenoxy)acetic acid (3.46d) [165], 
2-(4-acetamidophenoxy)acetic acid (3.46f) [167], 2-(3,5-dimethoxyphenoxy)acetic acid 
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(3.46g) [165], 2-(1,3-dioxolan-2-yl)aniline (3.9) [7] and 8-amino-3,4-dihydronaphthalen-
1(2H)-one (3.49) [168]. 
The following compounds are commercially available: 3-(4-methoxyphenyl) 
propionic acid (3.46i), 3-(3,4-dimethoxyphenyl)propionic acid (3.46j), 3-(2,4,6-
trimethoxyphenyl)propanoic acid (3.46k) and bis(4'-methoxy)phenylcarboxylic acid 
(3.46l). 
 
 
 
 
2-(2-Methoxy-4-vinylphenoxy)acetic Acid (3.46h). 2-Methoxy-4-vinylphenol 
(3.44h; 4.00 mL, 4.44 g, 29.6 mmol) was dissolved in anhydrous acetone (30 mL). 
Methyl bromoacetate (3.45; 3.36 mL, 5.43 g, 35.5 mmol) and potassium carbonate (16.3 
g, 118 mmol) were added, and the mixture was refluxed for 12 h. Solids were filtered off, 
and the solvent was removed in vacuo. The residue was dissolved in methanol and water 
(80 mL, 1:1). LiOH (5.68 g, 237 mmol) was added at 0 °C, and the mixture was stirred at 
ambient temperature overnight. After that, methanol was removed in vacuo, 10% aq. HCl 
was added till pH 1–2, and the product was extracted from the aqueous layer with ethyl 
acetate (3×150 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered, and the solvent was removed in vacuo to yield 6.14 g (99%) of the title 
compound. 1H NMR (500 MHz, MeOD) δ 7.12 (d, J = 1.4 Hz, 1H), 6.98 (dd, J = 8.3, 1.5 
Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 6.68 (dd, J = 17.6, 10.9 Hz, 1H), 5.68 (d, J = 17.6 Hz, 
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1H), 5.15 (d, J = 10.9 Hz, 1H), 4.43 (s, 2H), 3.93 (d, J = 1.5 Hz, 3H). HRMS (ESI) calcd 
for C11H12O4Li
+ (MLi+) 215.0890, found 215.0889. 
 
 
 
 
General Procedure A for the Synthesis of Acyl Chlorides. Under nitrogen, acid 
(3.46; 6.59 mmol) was dissolved in anhydrous DCM (10 mL), the solution was cooled to 
0 °C and threated with DMF (10 drops), and then oxalyl chloride (0.61 mL, 0.92 g, 7.3 
mmol) was added dropwise. The mixture was stirred at ambient temperature for 4 h and 
after that, it was used directly for the next step. 
 
 
 
 
 
 
 
 
General Procedure B for the Reaction of Anilines with Acyl Chlorides. Under 
nitrogen, aniline (3.9, 3.49; 4.94 mmol) was dissolved in anhydrous DCM (17 mL), the 
mixture was treated with DIPEA (1.87 mL, 1.38 g, 10.7 mmol) and cooled to 0 °C, and 
then solution of acyl chloride (3.47; 6.59 mmol) in anhydrous DCM (10 mL) was added 
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dropwise. The mixture was stirred at ambient temperature overnight, and then diluted 
with DCM (80 mL). The solution was washed with water (3×15 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to yield the desired amide. Crude 
dioxolane-protected photoprecursors (4.4) were then deprotected according to general 
procedure D, whereas all other photoprecursors (3.53) were purified by flash 
chromatography on silica gel. 
 
 
 
 
 
 
 
 
General Procedure C for HATU-Promoted Coupling of Acids with Anilines. 
Under nitrogen, acid (3.46; 5.49 mmol) was dissolved in anhydrous DMF (9 mL), the 
solution was treated with HOAt (0.896 g, 6.59 mmol), HATU (2.51 g, 6.59 mmol) and 
DIPEA (2.39 mL, 1.77 g, 13.7 mmol) and then stirred at ambient temperature for 30 min. 
Subsequently, aniline (3.9, 3.48; 6.60 mmol) was added, and the mixture was stirred at 
ambient temperature for 1 day. DMF was removed under high vacuum (50 °C/0.15 Torr), 
the residue was dissolved in DCM (50 mL) and washed two times with sat. aq. NaHCO3 
(3 mL) diluted with water (30 mL). The organic layer was washed with water (30 mL), 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo to yield the desired 
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amide. Crude dioxolane-protected photoprecursors (4.4) were then deprotected according 
to general procedure D, whereas photoprecursor 3.52d was purified by flash 
chromatography on silica gel. 
 
 
 
 
General Procedure D for Dioxolane Deprotection. Dioxolane-protected 
photoprecursor (4.4; 4.94 mmol) was dissolved in acetone (38 mL), TsOH·H2O 
(0.988 mmol) was added, and the mixture was stirred at ambient temperature for 1 day. 
Solvent was removed in vacuo, and the residue was dissolved in DCM (90 mL). The 
solution was washed with sat. aq. NaHCO3 (2×15 mL) and then with water (25 mL). The 
organic layer was dried over anhydrous Na2SO4, filtered, and the solvent was removed in 
vacuo. Further purification by flash chromatography on silica gel yielded the desired 
photoprecursor (3.51). 
N-(2-Formylphenyl)-2-(p-tolyloxy)acetamide (3.51b). 
2-(p-Tolyloxy)acetic acid chloride (3.47b), which was prepared 
from 8.47 mmol of 2-(p-tolyloxy)acetic acid (3.46b) according 
to general procedure A, was coupled to 2-(1,3-dioxolan-2-yl)aniline (3.9; 1.04 g, 6.27 
mmol) following general procedure B. Dioxolane protection was then removed according 
to general procedure D, which after flash chromatography on silica gel (gradient elution: 
hexane → hexane–DCM 50:50) afforded 1.10 g (65% after two steps) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 12.16 (s, 1H), 9.97 (s, 1H), 8.83 (d, J = 8.4 Hz, 
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1H), 7.71 (dd, J = 7.6, 1.7 Hz, 1H), 7.64 (ddd, J = 8.9, 7.3, 1.7 Hz, 1H), 7.28 (td, J = 7.5, 
1.1 Hz, 1H), 7.14 (m, 2H), 7.02 (m, 2H), 4.63 (s, 2H), 2.31 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 195.1, 168.5, 155.4, 139.8, 136.1, 136.1, 131.6, 130.3, 123.7, 122.5, 120.2, 
114.8, 67.9, 20.7. HRMS (ESI) calcd for C16H16NO3
+ (MH+) 270.1125, found 270.1131. 
2-(3,5-Dimethylphenoxy)-N-(2-formylphenyl)acetamide 
(3.51c). 2-(3,5-Dimethylphenoxy)acetic acid chloride (3.47c), 
which was prepared from 5.18 mmol of 2-(3,5-dimethyl-
phenoxy)acetic acid (3.46c) according to general procedure A, 
was coupled to 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.637 g, 3.86 mmol) following general 
procedure B. Dioxolane protection was then removed according to general procedure D, 
which after flash chromatography on silica gel (gradient elution: hexane → hexane–DCM 
50:50) afforded 0.931 g (85% after two steps) of the title compound. 1H NMR (500 MHz, 
CDCl3) δ 12.16 (s, 1H), 9.98 (s, 1H), 8.84 (d, J = 8.4 Hz, 1H), 7.72 (dd, J = 7.6, 1.7 Hz, 
1H), 7.64 (ddd, J = 8.8, 7.3, 1.6 Hz, 1H), 7.28 (td, J = 7.5, 1.1 Hz, 1H), 6.75 (m, 2H), 
6.69 (m, 1H), 4.62 (s, 2H), 2.33 (br s, 6H). 13C NMR (126 MHz, CDCl3) δ 195.0, 168.5, 
157.5, 139.9, 139.7, 136.1, 136.1, 124.0, 123.6, 122.5, 120.2, 112.7, 67.6, 21.6. HRMS 
(ESI) calcd for C17H18NO3
+ (MH+) 284.1281, found 284.1288. 
N-(2-Formylphenyl)-2-(4-methoxyphenoxy)acetamide 
(3.51d). 2-(4-Methoxyphenoxy)acetic acid chloride (3.47d), 
which was prepared from 6.59 mmol of 2-(4-methoxy-
phenoxy)acetic acid (3.46d) according to general procedure A, was then coupled to 2-
(1,3-dioxolan-2-yl)aniline (3.9; 0.815 g, 4.94 mmol) according to general procedure B. 
Dioxolane protection was then removed according to general procedure D, which after 
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flash chromatography on silica gel (gradient elution: hexane → ethyl acetate) afforded 
0.843 g (60% after two steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.16 
(s, 1H), 9.97 (d, J = 0.7 Hz, 1H), 8.83 (d, J = 8.4 Hz, 1H), 7.71 (dd, J = 7.6, 1.7 Hz, 1H), 
7.64 (ddd, J = 8.7, 7.3, 1.7 Hz, 1H), 7.28 (td, J = 7.5, 1.1 Hz, 1H), 7.06 (m, 2H), 6.89 (m, 
2H), 4.61 (s, 2H), 3.78 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 195.1, 168.5, 154.9, 
151.7, 139.8, 136.2, 136.1, 123.7, 122.5, 120.2, 115.9, 115.0, 68.5, 55.9. HRMS (ESI) 
calcd for C16H16NO4
+ (MH+) 286.1074, found 286.1080. 
2-(4-Acetamidophenoxy)-N-(2-formylphenyl)acetamide 
(3.51f). General procedure A was followed on a 3.46 
mmol scale of 2-(4-acetamido-phenoxy)acetic acid (3.46f). 
Corresponding acyl chloride (3.47f) was redissolved in anhydrous acetonitrile (10 mL) 
and coupled to 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.439 g, 2.66 mmol) according to 
general procedure B. Dioxolane protection was then removed according to general 
procedure D, which after flash chromatography on silica gel (gradient elution: DCM → 
DCM–methanol 98:2) afforded 0.571 g (69% after two steps) of the title compound. 1H 
NMR (500 MHz, CDCl3) δ 12.16 (s, 1H), 9.96 (d, J = 0.8 Hz, 1H), 8.82 (d, J = 8.4 Hz, 
1H), 7.71 (dd, J = 7.7, 1.7 Hz, 1H), 7.64 (ddd, J = 8.8, 7.4, 1.7 Hz, 1H), 7.46 (m, 2H), 
7.28 (td, J = 7.5, 1.1 Hz, 1H), 7.16 (s, 1H), 7.08 (m, 2H), 4.63 (s, 2H), 2.16 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 195.1, 168.3, 168.2, 154.2, 139.8, 136.2, 136.1, 132.4, 123.7, 
122.5, 122.0, 120.2, 115.4, 68.0, 24.6. HRMS (ESI) calcd for C17H17N2O4
+ (MH+) 
313.1183, found 313.1183. 
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2-(3,5-Dimethoxyphenoxy)-N-(2-formylphenyl) 
acetamide (3.51g). 2-(3,5-dimethoxyphenoxy)acetic acid 
chloride (3.47g), which was prepared from 1.21 mmol of 2-
(3,5-dimethoxyphenoxy)acetic acid (3.46g) according to 
general procedure A, was then coupled to 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.154 g, 
0.931 mmol) according to general procedure B. Dioxolane protection was then removed 
according to general procedure D, which after flash chromatography on silica gel 
(gradient elution: DCM → DCM–methanol 99:1) afforded 0.143 g (49% after two steps) 
of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.14 (s, 1H), 9.96 (d, J = 0.7 Hz, 
1H), 8.82 (d, J = 8.4 Hz, 1H), 7.71 (dd, J = 7.6, 1.7 Hz, 1H), 7.63 (ddd, J = 8.9, 7.2, 1.7 
Hz, 1H), 7.28 (td, J = 7.5, 1.1 Hz, 1H), 6.32 (d, J = 2.2 Hz, 2H), 6.16 (t, J = 2.2 Hz, 1H), 
4.61 (s, 2H), 3.80 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 195.0, 168.1, 161.8, 159.3, 
139.8, 136.1, 136.1, 123.7, 122.5, 120.2, 94.4, 94.0, 67.8, 55.6. HRMS (ESI) calcd for 
C17H18NO5
+ (MH+) 316.1179, found 316.1187. 
 
 
 
 
N-(2-Formylphenyl)-2-(2-methoxy-4-vinylphenoxy)acetamide (3.51h). Under 
nitrogen, 2-(2-methoxy-4-vinylphenoxy)acetic acid (3.46h; 0.576 g, 2.77 mmol) was 
dissolved in anhydrous DMF (5 mL), the solution was treated with EDC·HCl (0.530 g, 
2.77 mmol), DMAP (68 mg, 0.55 mmol), and 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.549 g, 
3.32 mmol) and then was stirred at ambient temperature for 1 day. DMF was removed 
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under high vacuum (50 °C/0.15 Torr). The residue was dissolved in DCM (50 mL), and 
the solution was washed with water (3×20mL) and sat. aq. NaHCO3 (10mL). The organic 
layer was dried over anhydrous Na2SO4, filtered, and the solvent was removed in vacuo. 
Dioxolane protection was then removed according to general procedure D with 
2.79 mmol of TsOH·H2O, which after flash chromatography on silica gel (gradient 
elution: DCM → DCM–methanol 99:1) afforded 0.090 g (10% after two steps) of the 
title compound. 1H NMR (500 MHz, CDCl3) δ 12.03 (s, 1H), 9.95 (s, 1H), 8.83 (d, J = 
8.4 Hz, 1H), 7.70 (dd, J = 7.7, 1.7 Hz, 1H), 7.63 (ddd, J = 8.8, 7.3, 1.7 Hz, 1H), 7.28 (td, 
J = 7.5, 1.1 Hz, 1H), 7.03 (d, J = 1.9 Hz, 1H), 6.96 (d, J = 8.2 Hz, 1H), 6.93 (dd, J = 8.2, 
1.9 Hz, 1H), 6.66 (dd, J = 17.6, 10.8 Hz, 1H), 5.65 (dd, J = 17.5, 0.8 Hz, 1H), 5.19 (dd, J 
= 10.9, 0.8 Hz, 1H), 4.70 (s, 2H), 3.98 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.8, 
168.7, 150.3, 147.1, 139.8, 136.5, 136.0, 136.0, 133.1, 123.7, 122.7, 120.4, 119.4, 115.2, 
112.9, 109.9, 69.7, 56.2. HRMS (ESI) calcd for C18H18NO4
+ (MH+) 312.1230, found 
312.1234. 
 
 
 
N-(2-Formylphenyl)-3-(4-methoxyphenyl)propanamide (3.51i). 3-(4-Methoxy-
phenyl)propionic acid (3.46i; 0.958 g, 5.32 mmol) was converted into the corresponding 
acid chloride (3.47i) by refluxing in thionyl chloride (5.00 mL, 8.16 g, 68.5 mmol) under 
nitrogen for 1 day [169]. After removal of volatiles in vacuo, the resulting acyl chloride 
was coupled to 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.684 g, 4.15 mmol) according to 
general procedure B. Dioxolane protection was then removed according to general 
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procedure D, which after flash chromatography on silica gel (gradient elution: hexane → 
hexane–ethyl acetate 90:10) afforded 0.924 g (78% after two steps) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 11.13 (s, 1H), 9.90 (s, 1H), 8.75 (d, J = 8.4 Hz, 
1H), 7.66 (dd, J = 7.6, 1.6 Hz, 1H), 7.61 (ddd, J = 8.6, 7.4, 1.6 Hz, 1H), 7.22 (t, J = 7.5 
Hz, 1H), 7.18 (d, J = 8.3 Hz, 2H), 6.83 (d, J = 8.3 Hz, 2H), 3.77 (s, 3H), 3.03 (m, 2H), 
2.75 (dd, J = 8.7, 6.9 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 195.6, 171.9, 158.2, 141.1, 
136.3, 136.2, 132.6, 129.4, 123.0, 121.7, 120.0, 114.1, 55.4, 40.5, 30.6. HRMS (ESI) 
calcd for C17H18NO3
+ (MH+) 284.1281, found 284.1293.  
3-(3,4-Dimethoxyphenyl)-N-(2-formylphenyl) 
propanamide (3.51j). General procedure C was followed 
on a 2.38 mmol scale of 3-(3,4-dimethoxyphenoxy) 
propanoic acid (3.46j) with 3.33 mmol of 2-(1,3-dioxolan-2-yl)aniline (3.9). Dioxolane 
protection was then removed according to general procedure D, which after flash 
chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 85:15) 
afforded 0.552 g (74% after two steps) of the title compound. 1H NMR (500 MHz, 
CDCl3) δ 11.11 (s, 1H), 9.88 (s, 1H), 8.75 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 7.7, 1.7 Hz, 
1H), 7.60 (ddd, J = 8.7, 7.3, 1.7 Hz, 1H), 7.21 (td, J = 7.5, 1.1 Hz, 1H), 6.78 (m, 3H), 
3.84 (s, 3H), 3.83 (s, 3H), 3.02 (dd, J = 8.4, 7.1, 2H), 2.75 (dd, J = 8.4, 7.1 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 195.6, 171.8, 149.0, 147.6, 141.0, 136.3, 136.1, 133.1, 
123.0, 121.6, 120.3, 119.9, 111.7, 111.4, 56.0, 55.9, 40.4, 31.1. HRMS (ESI) calcd for 
C18H20NO4
+ (MH+) 314.1387, found 314.1395. 
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N-(2-Formylphenyl)-3-(2,4,6-trimethoxyphenyl) 
propanamide (3.51k). General procedure C was followed 
on a 1.33 mmol scale of 3-(2,4,6-trimethoxyphenoxy) 
propanoic acid (3.46k) with 1.87 mmol of 2-(1,3-dioxolan-
2-yl)aniline (3.9). Dioxolane protection was then removed according to general procedure 
D, which after flash chromatography on silica gel pretreated with pyridine (gradient 
elution: hexane → hexane–ethyl acetate 85:15) afforded 0.337 g (74% after two steps) of 
the title compound. 1H NMR (500 MHz, CDCl3) δ 11.08 (s, 1H), 9.90 (s, 1H), 8.80 (d, J 
= 8.4 Hz, 1H), 7.65 (dd, J = 7.7, 1.7 Hz, 1H), 7.60 (ddd, J = 8.7, 7.4, 1.7 Hz, 1H), 7.20 
(td, J = 7.5, 1.0 Hz, 1H), 6.11 (s, 2H), 3.80 (s, 3H), 3.78 (s, 6H), 3.03 (m, 2H), 2.59 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 195.3, 173.2, 159.8, 158.9, 141.4, 136.2, 136.0, 
122.6, 121.6, 119.9, 109.3, 90.5, 55.7, 55.5, 38.5, 19.3. HRMS (ESI) calcd for 
C19H22NO5
+ (MH+) 344.1492, found 344.1500. 
N-(2-Formylphenyl)-4'-methoxybiphenyl-2-carboxamide 
(3.51l). 4'-Methoxybiphenyl-2-carbonyl chloride (3.47l), which 
was prepared from 1.39 mmol of 4'-methoxy-biphenyl-2-
carboxylic acid (3.46l) according to general procedure A, was 
coupled to 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.174 g, 1.05 mmol) following general 
procedure B. Dioxolane protection was then removed according to general procedure D, 
which after flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl 
acetate 90:10) afforded 0.269 g (77% after two steps) of the title compound. 1H NMR 
(500 MHz, C6D6) δ 11.44 (s, 1H), 9.25 (d, J = 8.5 Hz, 1H), 9.09 (d, J = 0.7 Hz, 1H), 7.79 
(dd, J = 7.7, 1.4 Hz, 1H), 7.48 (m, 2H), 7.27 (dd, J = 7.7, 1.3 Hz, 1H), 7.13 (td, J = 7.6, 
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1.5 Hz, 1H), 7.07 (ddd, J = 8.8, 7.3, 1.7 Hz, 1H), 7.05 (td, J = 7.5, 1.3 Hz, 1H), 6.68 (m, 
2H), 6.65 (dd, J = 7.7, 1.7 Hz, 1H), 6.54 (td, J = 7.5, 1.1 Hz, 1H), 3.12 (s, 3H). 13C NMR 
(126 MHz, C6D6) δ 194.4, 169.3, 159.7, 141.4, 140.3, 137.0, 135.8, 135.8, 132.9, 131.0, 
130.7, 130.6, 129.3, 127.4, 122.5, 121.8, 119.9, 114.2, 54.6. HRMS (ESI) calcd for 
C21H18NO3
+ (MH+) 332.1281, found 332.1276. 
N-(2-Acetylphenyl)-2-(4-methoxyphenoxy)acetamide 
(3.52d). General procedure C was followed on a 5.49 mmol 
scale of 2-(4-methoxy-phenoxy)acetic acid (3.46d) with 
6.60 mmol of 2'-aminoacetophenone (3.48) in 5 mL of 
anhydrous DMF, which after flash chromatography on silica gel (gradient elution: hexane 
→ hexane–ethyl acetate 85:15) afforded 1.04 g (64%) of the title compound. 1H NMR 
(500 MHz, CDCl3) δ 12.63 (s, 1H), 8.83 (dd, J = 8.5, 1.3 Hz, 1H), 7.92 (dd, J = 8.0, 1.6 
Hz, 1H), 7.57 (ddd, J = 8.7, 7.2, 1.6 Hz, 1H), 7.16 (ddd, J = 8.0, 7.3, 1.2 Hz, 1H), 7.06 
(m, 2H), 6.88 (m, 2H), 4.58 (s, 2H), 3.77 (s, 3H), 2.67 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 202.2, 168.3, 154.8, 151.8, 139.9, 135.0, 131.7, 123.1, 122.7, 121.0, 116.0, 
114.9, 68.7, 55.8, 28.6. HRMS (ESI) calcd for C17H18NO4
+ (MH+) 300.1230, found 
300.1233.  
2-(4-Methoxyphenoxy)-N-(8-oxo-5,6,7,8-tetrahydro-
naphthalen-1-yl)acetamide (3.53d). 2-(4-Methoxy-
phenoxy)acetic acid chloride (3.47d), which was prepared 
from 11.5 mmol of 2-(4-methoxyphenoxy)acetic acid 
(3.46d) according to general procedure A, was coupled to 8-amino-3,4-dihydro-
naphthalen-1(2H)-one (3.49; 1.38 g, 8.55 mmol) following general procedure B. Further 
 131 
purification by flash chromatography on silica gel (gradient elution: hexane → DCM) 
afforded 2.03 g (73%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 13.04 (s, 
1H), 8.70 (dd, J = 8.2, 0.9 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.07 (m, 2H), 6.98 (dd, J = 
7.6, 1.1 Hz, 1H), 6.88 (m, 2H), 4.59 (s, 2H), 3.78 (s, 3H), 2.98 (t, J = 6.1 Hz, 2H), 2.72 
(dd, J = 7.2, 5.9 Hz, 2H), 2.09 (p, J = 6.4 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 202.8, 
168.5, 154.8, 151.9, 146.2, 140.9, 135.0, 123.9, 119.2, 118.6, 116.1, 115.0, 68.8, 55.9, 
40.9, 31.1, 22.9. HRMS (ESI) calcd for C19H20NO4
+ (MH+) 326.1387, found 326.1382. 
 
 
 
 
2-(2,6-Dimethoxyphenoxy)-N-(8-oxo-5,6,7,8-tetrahydro-naphthalen-1-yl) 
acetamide (3.53e). Under nitrogen, 8-amino-3,4-dihydronaphthalen-1(2H)-one (3.49; 
0.985 g, 6.12 mmol) was dissolved in anhydrous DCM (22 mL), the solution was treated 
with pyridine (0.74 mL, 0.73 g, 9.2 mmol) and cooled to 0 °C, and then solution of 
bromoacetyl bromide (3.10; 0.60 mL, 1.4 g, 6.7 mmol) in anhydrous DCM (6 mL) was 
added dropwise. The mixture was stirred at ambient temperature overnight and then 
quenched with water (10 mL). After 1 h of stirring, the organic layer was separated, and 
the product was extracted with DCM (3×15 mL). The combined organic layers were 
washed with water (3x10 mL), dried over anhydrous Na2SO4, filtered, and the solvent 
was removed in vacuo. The residue (crude 3.50) was dissolved in acetone (8 mL), and 
then 2,6-dimethoxyphenol (3.44e; 1.02 g, 6.62 mmol) and cesium carbonate (2.16 g, 6.62 
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mmol) were added. The mixture was stirred under reflux for 2 h. The solvent was 
removed in vacuo, water (10 mL) and DCM (40 mL) were added, organic layer was 
separated, and the product was extracted from aqueous layer with DCM (3×20 mL). The 
combined organic layers were washed with water (10 mL), dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. Further purification by flash chromatography on silica 
gel (gradient elution: hexane → hexane–ethyl acetate 50:50) afforded 1.47 g (68% after 
two steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 13.00 (s, 1H), 8.73 (dd, J 
= 8.4, 1.1 Hz, 1H), 7.47 (dd, J = 8.5, 7.5 Hz, 1H), 7.02 (t, J = 8.4 Hz, 1H), 6.97 (dd, J = 
7.5, 1.1 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.57 (s, 2H), 3.82 (s, 6H), 2.98 (t, J = 6.1 Hz, 
2H), 2.68 (dd, J = 7.2, 5.9 Hz, 2H), 2.08 (p, J = 6.2 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 201.9, 169.6, 153.4, 145.9, 141.1, 136.8, 134.7, 124.4, 123.6, 119.5, 118.9, 
105.5, 72.8, 56.3, 40.7, 31.2, 22.9. HRMS (ESI) calcd for C20H22NO5
+ (MH+) 356.1492, 
found 356.1484. 
3-(3,4-Dimethoxyphenyl)-N-(8-oxo-5,6,7,8-tetrahydro-
naphthalen-1-yl)propanamide (3.53j). 3-(3,5-
Dimethoxyphenyl)propionic acid chloride (3.47j), which 
was prepared from 4.76 mmol of 3-(3,5-
dimethoxyphenyl)propionic acid (3.46j) with 23.8 mmol of oxalyl chloride in anhydrous 
benzene (10 mL) according to general procedure A, was coupled to 8-amino-3,4-
dihydronaphthalen-1(2H)-one (3.49; 0.639 g, 3.97 mmol) following general procedure B. 
Further purification by flash chromatography on silica gel (gradient elution: hexane → 
hexane–ethyl acetate 80:20) afforded 0.576 g (41%) of the title compound. 1H NMR (500 
MHz, C6D6) δ 12.45 (s, 1H), 9.20 (dd, J = 8.5, 1.1 Hz, 1H), 7.10 (dd, J = 8.5, 7.5 Hz, 
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1H), 6.71 (dd, J = 8.1, 2.1 Hz, 1H), 6.66 (d, J = 2.1 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 
6.43 (dt, J = 7.5, 1.0 Hz, 1H), 3.42 (s, 3H), 3.38 (s, 3H), 3.05 (t, J = 7.6 Hz, 2H), 2.61 (t, 
J = 7.6 Hz, 2H), 2.26 (t, J = 6.1 Hz, 2H), 2.18 (dd, J = 7.2, 5.9 Hz, 2H), 1.36 (p, J = 6.4 
Hz, 2H). 13C NMR (126 MHz, C6D6) δ 202.7, 171.4, 150.2, 148.7, 145.9, 143.0, 135.1, 
133.9, 122.6, 120.7, 118.5, 118.4, 113.0, 112.8, 55.7, 55.5, 41.0, 40.6, 31.5, 30.9, 22.7. 
HRMS (ESI) calcd for C21H24NO4
+ (MH+) 354.1700, found 354.1706. 
Photochemical Reactions and Acid-Catalyzed Post-Photochemical Modifications 
 
 
 
 
 
 
 
 
 
 
General Procedure E for the Photochemical Reaction. Photoprecursor (3.51–3.53; 
1.50 mmol) was dissolved in DMSO (500 mL), and the solution was degassed by 
bubbling nitrogen for 1 h. The mixture was irradiated with UV LED-based illuminator 
(five 250 mW @ 365 nm Nichia chips) with the reaction progress monitored by 1H NMR. 
After completion, the mixture was poured onto ice, and the product was extracted with 
DCM (4×350 mL). The combined organic layers were washed with water (3×100 mL), 
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dried over anhydrous Na2SO4, filtered, and the solvent was removed in vacuo. Crude 
photoproduct mixtures obtained from the precursors 3.51d, 3.51f and 3.51l were directly 
subjected to the acid-catalyzed modifications according to general procedure F; in all 
other cases, further purification by flash chromatography on silica gel yielded the desired 
photoproducts or the hydrolyzed/cyclized derivatives (formed spontaneously during the 
irradiation or on the column). 
Table 4.1: Irradiation Times 
Photoprecursor Photoproduct(s) Reaction Time (h) 
  
 4.5 
  
10 
  
 3 
  
 3.5 
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Photoprecursor Photoproduct(s) Reaction Time (h) 
  
60 
  
 2.5 
  
 4 
  
 4.5 
  
 4 
  
 4 
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Photoprecursor Photoproduct(s) Reaction Time (h) 
 
 
 3.5 
 
 
 2.5 
 
 
40 
 
 
 7.5 
 
General Procedure F for the Acid-Catalyzed Modification. The mixture of 
photoproducts (0.413 mmol) was dissolved in THF (24 mL), treated with TsOH·H2O 
(0.016 g, 0.083 mmol) and stirred at ambient temperature overnight. Solvent was 
removed in vacuo, and the residue was dissolved in DCM (35 mL). The solution was 
washed with sat. aq. NaHCO3 (2×5 mL) and then with water (5 mL). The organic layer 
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was dried over anhydrous Na2SO4 and concentrated in vacuo, and the crude products 
were purified by flash chromatography on silica gel. 
syn-12-Hydroxy-15-methyl-2-oxa-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-
6,8,10,14,16-pentaen-4-one (syn-3.54b). General procedure E was followed on a 0.346 g 
(1.28 mmol) scale of 3.51b, which after flash chromatography on silica gel (gradient 
elution: DCM → DCM–methanol 98:2) afforded 0.239 g (69%) of syn-3.54b. 
syn-3.54b: 1H NMR (500 MHz, MeOD) δ 7.47 (m, 1H), 7.41 (m, 
1H), 7.29 (m, 2H), 5.83 (m, 2H), 5.64 (tq, J = 3.4, 1.7 Hz, 1H), 4.96 
(dd, J = 6.3, 1.0 Hz, 1H), 4.63 (d, J = 14.3 Hz, 1H), 4.31 (d, J = 14.4 
Hz, 1H), 3.53 (ddq, J = 6.2, 3.7, 2.6 Hz, 1H), 1.61 (dd, J = 2.6, 1.6 Hz, 3H). 13C NMR 
(126 MHz, MeOD) δ 170.1, 137.5, 132.3, 130.7, 130.5, 128.1, 127.6, 125.5, 124.2, 123.9, 
120.5, 94.5, 68.0, 66.8, 51.9, 21.3. HRMS (ESI) calcd for C16H16NO3
+ (MH+) 270.1125, 
found 270.1133. 
syn-12-Hydroxy-14,16-dimethyl-2-oxa-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-
6,8,10,14,16-pentaen-4-one (syn-3.54c). General procedure E was followed on a 0.332 g 
(1.17 mmol) scale of 3.51c, which after flash chromatography on silica gel (gradient 
elution: hexane → hexane–ethyl acetate 70:30) afforded 0.245 g (74%) of syn-3.54c. 
syn-3.54c: 1H NMR (500 MHz, MeOD) δ 8.31 (dd, J = 8.3, 1.2 Hz, 
1H), 7.53 (dd, J = 7.7, 1.5 Hz, 1H), 7.35 (td, J = 8.3, 7.9, 1.6 Hz, 
1H), 7.20 (td, J = 7.5, 1.2 Hz, 1H), 5.87 (s, 1H), 5.46 (s, 1H), 4.85 
(d, J = 6.1 Hz, 1H), 4.42 (d, J = 14.1 Hz, 1H), 4.16 (d, J = 14.1 Hz, 1H), 2.78 (d, J = 6.1 
Hz, 1H), 2.00 (d, J = 1.6 Hz, 3H), 1.75 (d, J = 1.6 Hz, 3H). 13C NMR (126 MHz, MeOD) 
δ 171.5, 142.5, 136.3, 133.9, 131.5, 131.0, 129.6, 126.2, 125.8, 120.7, 119.5, 94.8, 66.5, 
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65.0, 51.6, 22.3, 21.5. HRMS (ESI) calcd for C17H18NO3
+ (MH+) 284.1281, found 
284.1284. 
anti-12-Hydroxy-2-oxa-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-6,8,10,16-
tetraene-4,15-dione (anti-3.60d) and N-[9-Oxo-11,18-dioxa-8-azapentacyclo 
[13.2.1.02,7.08,12.012,17]octadeca-2,4,6,13-tetraen-15-yl]acetamide (3.63d). General 
procedure E was followed on a 0.296 g (1.04 mmol) scale of 3.51d. The crude 
photoproducts were then subjected to general procedure F with 1.05 mmol of TsOH·H2O, 
with one modification: the mixture was refluxed for 3 days. Further purification by flash 
chromatography on silica gel (gradient elution: DCM → DCM–methanol 98:2) afforded 
0.066 g (23% after two steps) of anti-3.60d and 0.145 g (51% after two steps) of 3.63d. 
anti-3.60d: 1H NMR (500 MHz, CDCl3) δ 8.22 (dd, J = 8.3, 1.2 Hz, 
1H), 7.56 (dt, J = 7.8, 1.2 Hz, 1H), 7.38 (dddd, J = 8.3, 7.3, 1.6, 0.7 
Hz, 1H), 7.26 (ddd, J = 7.8, 7.3, 1.2 Hz, 1H), 6.73 (dd, J = 10.1, 2.3 
Hz, 1H), 6.11 (dd, J = 10.1, 1.2 Hz, 1H), 4.52 (d, J = 14.3 Hz, 1H), 4.49 (dd, J = 9.4, 9.2 
Hz, 1H), 4.25 (d, J = 14.3 Hz, 1H), 3.09 (dd, J = 17.5, 4.35 Hz, 1H), 3.01 (ddd, J = 17.5, 
2.3, 1.2 Hz, 1H), 2.72 (d, J = 9.2 Hz, 1H), 2.63 (ddt, J = 9.4, 4.35, 2.3 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ 196.2, 167.8, 146.0, 134.0, 132.0, 129.5, 128.5, 128.3, 126.1, 120.1, 
91.1, 70.3, 67.5, 46.7, 36.6. HRMS (ESI) calcd for C15H14NO4
+ (MH+) 272.0917, found 
272.0926. 
3.63d: 1H NMR (500 MHz, CDCl3) δ 8.56 (ddt, J = 8.2, 1.1, 0.6 Hz, 
1H), 7.37 (ddd, J = 8.3, 7.4, 1.6 Hz, 1H), 7.16 (dd, J = 7.5, 1.6 Hz, 
1H), 7.10 (ddd, J = 7.5, 7.4, 1.1 Hz, 1H), 4.84 (s, 1H), 4.60 (d, J = 
14.2 Hz, 1H), 4.55 (d, J = 14.2 Hz, 1H), 4.51 (ddd, J = 4.3, 1.3, 1.2 Hz, 1H), 3.00 (ddt, J 
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= 18.3, 5.0, 0.9 Hz, 1H), 2.89 (ddt, J = 17.4, 1.3, 0.8 Hz, 1H), 2.74 (ddd, J = 18.3, 2.6, 1.9 
Hz, 1H), 2.69 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 205.7, 166.6, 134.5, 130.3, 128.7, 
126.7, 124.9, 117.9, 99.3, 81.4, 79.6, 68.7, 46.2, 40.8, 40.7. HRMS (ESI) calcd for 
C15H14NO4
+ (MH+) 272.0917, found 272.0909. 
anti-N-12-Hydroxy-4-oxo-2-oxa-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-
6,8,10,14,16-pentaen-15-yl]acetamide (anti-3.54f) and N-[9-Oxo-11,18-dioxa-8-
azapentacyclo[13.2.1.02,7.08,12.012,17]octadeca-2,4,6,13-tetraen-15-yl]acetamide (3.62f). 
General procedure E was followed on a from 0.286 g (0.848 mmol) scale of 3.51f. Under 
nitrogen, the crude photoproducts were redissolved in anhydrous DCM (30 mL) and 
treated with 0.2 M HCl in ether (260 µL, 0.052 mmol). The mixture was refluxed for 
5 days, volatiles were removed in vacuo, and further purification by flash 
chromatography on silica gel (gradient elution: DCM → DCM–methanol 95:5) afforded 
0.014 g (5%) of anti-3.54f and 0.119 g (45% after two steps) of 3.62f. 
anti-3.54f: 1H NMR (500 MHz, DMSO) δ 9.39 (s, 1H), 8.14 
(dd, J = 8.25, 1.2 Hz, 1H), 7.46 (d, J = 7.3 Hz, 1H), 7.32 (dddd, 
J = 8.25, 7.3, 1.6, 0.6 Hz, 1H), 7.17 (ddd, J = 8.25, 7.3, 1.2 Hz, 
1H), 6.64 (dd, J = 6.2, 2.2 Hz, 1H), 6.25 (dd, J = 9.85, 2.2 Hz, 1H), 6.04 (d, J = 9.85 Hz, 
1H), 5.82 (d, J = 7.7 Hz, 1H), 4.44 (d, J = 14.1 Hz, 1H), 4.32 (dd, J = 8.6, 7.8 Hz, 1H), 
4.27 (d, J = 14.1 Hz, 1H), 2.78 (ddd, J = 8.6, 6.2, 1.3 Hz, 1H), 1.94 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 168.5, 132.2, 132.1, 130.9, 128.9, 128.8, 127.9, 127.2, 124.4, 
119.1, 110.6, 99.5, 92.1, 71.6, 65.8, 45.0, 23.8. HRMS (ESI) calcd for C17H17N2O4
+ 
(MH+) 313.1183, found 313.1182. 
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3.62f: 1H NMR (500 MHz, DMSO) δ 8.68 (s, 1H), 8.07 (dd, J = 
8.2, 1.3 Hz, 1H), 7.38 (m, 2H), 7.20 (ddd, J = 7.7,7.3, 1.3 Hz, 
1H), 6.50 (dd, J = 9.6, 1.4 Hz, 1H), 5.56 (dd, J = 9.6, 2.2 Hz, 
1H), 5.19 (d, J = 5.3 Hz, 1H), 4.57 (d, J = 14.0 Hz, 1H), 4.38 (d, J = 14.0 Hz, 1H), 3.07 
(ddd, J = 5.3, 5.0, 2.2 Hz, 1H), 2.50 (m, 1H), 2.27 (d, J = 11.3 Hz, 1H), 1.86 (s, 3H). 13C 
NMR (126 MHz, DMSO) δ 169.8, 167.6, 140.1, 132.0, 130.8, 128.6, 126.5, 125.0, 124.8, 
119.2, 92.2, 86.7, 71.7, 66.5, 43.1, 37.7, 23.3. HRMS (ESI) calcd for C17H17N2O4
+ (MH+) 
313.1183, found 313.1187. 
syn-12-Hydroxy-14-methoxy-2-oxa-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-
6,8,10,14-tetraene-4,16-dione (syn-3.60g). General procedure E was followed on a 
0.241 g (0.764 mmol) scale of 3.51g, which after flash chromatography on silica gel 
(gradient elution: hexane → ethyl acetate) afforded 0.079 g (34%) of syn-3.60g. 
syn-3.60g: 1H NMR (500 MHz, DMSO) δ 8.26 (dd, J = 8.3, 1.2 Hz, 
1H), 7.50 (dd, J = 7.7, 1.6 Hz, 1H), 7.40 (ddd, J = 8.3, 7.3, 1.6 Hz, 
1H), 7.23 (ddd, J = 7.7, 7.3, 1.2 Hz, 1H), 5.94 (d, J = 5.7 Hz, 1H), 
5.56 (s, 1H), 4.90 (dd, J = 5.7, 5.3 Hz, 1H), 4.52 (d, J = 14.2 Hz, 1H), 4.25 (d, J = 14.2 
Hz, 1H), 3.77 (s, 3H), 3.19 (dd, J = 5.3, 1.9 Hz, 1H), 2.88 (d, J = 16.2 Hz, 1H), 2.64 (dd, 
J = 16.2, 1.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 195.0, 173.2, 168.5, 132.0, 131.0, 
128.7, 128.1, 124.6, 118.8, 103.9, 92.9, 65.2, 63.5, 56.4, 49.5, 43.2. HRMS (ESI) calcd 
for C16H15NO5Li
+ (MLi+) 308.1105, found 308.1108. 
anti-15-Ethenyl-12-hydroxy-17-methoxy-2-oxa-5-azatetracyclo[11.4.0.01,5.06,11] 
heptadeca-6,8,10,14,16-pentaen-4-one (anti-3.54h). General procedure E was followed 
on a 0.090 g (0.290 mmol) scale of 3.51h, with the following modifications: DCM 
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(96 mL) was used as a solvent, no aqueous workup was performed. Further purification 
by flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 
60:40) afforded 0.064 g (71%) of anti-3.54h. 
anti-3.54h: 1H NMR (500 MHz, DMSO) δ 8.33 (d, J = 8.3 Hz, 1H), 
7.45 (d, J = 7.8 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.17 (t, J = 7.5 Hz, 
1H), 6.41 (dd, J = 17.6, 10.9 Hz, 1H), 6.04 (d, J = 6.0 Hz, 1H), 5.96 
(d, J = 7.9 Hz, 1H), 5.63 (s, 1H), 5.48 (d, J = 17.5 Hz, 1H), 5.11 (d, J = 10.9 Hz, 1H), 
4.35 (t, J = 8.6 Hz, 1H), 4.31 (s, 2H), 3.59 (s, 3H), 2.84 (dd, J = 9.3, 6.0 Hz, 1H). 13C 
NMR (126 MHz, DMSO) δ 169.1, 155.8, 136.5, 132.2, 132.0, 130.2, 128.0, 127.1, 124.4, 
122.6, 117.8, 112.7, 93.9, 93.1, 70.5, 66.6, 55.9, 46.8. HRMS (ESI) calcd for C18H18NO4
+ 
(MH+) 312.1230, found 312.1239. 
anti-12-Hydroxy-15-methoxy-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-
6,8,10,14,16-pentaen-4-one (anti-3.54i) and 15-Methoxy-18-oxa-8-azapentacyclo 
[13.2.1.02,7.08,12.012,17]octadeca-2,4,6,13-tetraen-9-one (3.62i). General procedure E was 
followed on a 0.308 g (1.09 mmol) scale of 3.51i with the following modifications: 
methanol (45 mL) was used as a solvent, no aqueous workup was performed. Further 
purification by flash chromatography on silica gel (gradient elution: hexane → hexane–
ethyl acetate 40:60) afforded 0.027 g (9%) of anti-3.54i and 0.153 g (50%) of 3.62i. 
anti-3.54i: 1H NMR (500 MHz, CDCl3) δ 8.61 (dd, J = 8.4, 1.2 
Hz, 1H), 7.55 (d, J = 7.7 Hz, 1H), 7.28 (dddd, J = 8.4, 7.3, 1.6, 
0.7 Hz, 1H), 7.12 (ddd, J = 7.7, 7.3, 1.2 Hz, 1H), 5.92 (dd, J = 
9.95, 1.7 Hz, 1H), 5.79 (dd, J = 9.95, 2.5 Hz, 1H), 5.21 (dd, J = 6.6, 2.5 Hz, 1H), 4.67 (d, 
J = 9.15 Hz, 1H), 3.63 (s, 3H), 2.56 (ddd, J = 17.0, 12.1, 8.8, 1H), 2.56 (s, 1H), 2.35 
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(ddd, J = 9.15, 6.6, 1.7 Hz, 1H), 2.23 (m, 2H), 2.02 (td, J = 12.3, 9.2 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ 174.2, 153.8, 136.9, 134.8, 130.8, 128.3, 126.9, 126.3, 124.0, 119.8, 
94.5, 71.7, 65.7, 54.7, 45.8, 34.4, 31.4. HRMS (ESI) calcd for C17H18NO3
+ (MH+) 
284.1281, found 284.1288. 
3.62i: 1H NMR (500 MHz, CDCl3) δ 8.18 (dd, J = 8.3, 1.2 Hz, 
1H), 7.47 (dd, J = 7.7, 1.6 Hz, 1H), 7.32 (ddd, J = 8.7, 7.4, 1.6 
Hz, 1H), 7.16 (ddd, J = 7.7, 7.3, 1.2 Hz, 1H), 6.07 (dd, J = 9.6, 
1.8 Hz, 1H), 5.34 (dd, J = 9.6, 2.2 Hz, 1H), 5.13 (d, J = 5.4 Hz, 1H), 3.49 (s, 3H), 2.78 
(ddd, J = 5.5,5.4, 2.2 Hz, 1H), 2.73 (dd, J = 18.0, 8.5 Hz, 1H), 2.58 (ddd, J = 17.5, 8.4, 
7.2 Hz, 1H), 2.47 (ddd, J = 11.0, 5.5, 1.8 Hz, 1H), 2.21 (m, 2H), 2.01 (d, J = 11.0 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 172.9, 136.3, 133.3, 130.6, 129.7, 128.8, 127.6, 
125.0, 121.2, 104.2, 72.3, 64.7, 50.6, 45.4, 35.3, 30.5, 30.1. HRMS (ESI) calcd for 
C17H18NO3
+ (MH+) 284.1281, found 284.1287. 
syn-12-Hydroxy-14,15-dimethoxy-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-
6,8,10,14,16-pentaen-4-one (syn-3.54j), anti-12-hydroxy-15,16-dimethoxy-5-
azatetracyclo[11.4.0.01,5.06,11]heptadeca-6,8,10,14,16-pentaen-4-one (anti-3.54j'), syn-
12-hydroxy-15,16-dimethoxy-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-6,8,10,14,16-
pentaen-4-one (syn-3.54j'). General procedure E was followed on a 0.338 g (1.08 mmol) 
scale of 3.51j, which after flash chromatography on silica gel pretreated with pyridine 
(gradient elution: hexane → hexane–ethyl acetate + 1% TEA 40:60) afforded 0.151 g 
(45%) of syn-3.54j, 0.025 g (7%) of anti-3.54j' and 0.085 g (25%) of syn-3.54j'. 
 143 
syn-3.54j: 1H NMR (500 MHz, CDCl3) δ 8.43 (dd, J = 8.35, 1.2 
Hz, 1H), 7.55 (dd, J = 7.8, 1.6 Hz, 1H), 7.33 (ddd, J = 8.35, 7.3, 
1.7 Hz, 1H), 7.16 (ddd, J = 7.8, 7.3 1.2 Hz, 1H), 5.94 (d, J = 9.9 
Hz, 1H), 5.65 (dd, J = 9.9, 1.2 Hz, 1H), 4.71 (dd, J = 9.3, 5.9 Hz, 1H), 3.91 (s, 3H), 3.61 
(s, 3H), 2.82 (dd, J = 5.85, 1.2 Hz, 1H), 2.68 (ddd, J = 17.0, 11.8, 8.8 Hz, 1H), 2.50 (d, J 
= 9.4 Hz, 1H), 2.46 (ddd, J = 17.0, 9.05, 1.8 Hz, 1H), 2.38 (ddd, J = 12.4, 8.8, 1.8 Hz, 
1H), 2.27 (ddd, J = 12.4, 11.8, 9.05 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 173.7, 
139.1, 137.6, 134.1, 130.3, 129.6, 129.4, 128.9, 126.7, 124.5, 120.7, 65.4, 63.2, 59.3, 
59.0, 50.7, 36.6, 30.9. HRMS (ESI) calcd for C18H20NO4
+ (MH+) 314.1387, found 
314.1386. 
anti-3.54j': 1H NMR (500 MHz, CDCl3) δ 8.69 (dd, J = 8.4, 1.7 
Hz, 1H), 7.56 (dt, J = 7.6, 1.2 Hz, 1H), 7.30 (ddd, J = 8.4, 7.3, 
1.2 Hz, 1H), 7.13 (ddd, J = 7.6, 7.3, 1.7 Hz, 1H), 5.34 (d, J = 6.8 
Hz, 1H), 4.82 (d, J = 1.7 Hz, 1H), 4.73 (dd, J = 9.2, 8.5 Hz, 1H), 3.71 (s, 3H), 3.53 (s, 
3H), 2.64 (ddd, J = 16.9, 12.4, 8.6 Hz, 1H), 2.35 (ddd, J = 9.2, 6.8, 1.7 Hz, 1H), 2.32 
(ddd, J = 16.9, 9.0, 1.4 Hz, 1H), 2.31 (d, J = 8.5 Hz, 1H), 2.26 (ddd, J = 12.2, 8.6, 1.4 Hz, 
1H), 2.05 (ddd, J = 12.4, 12.2, 9.0 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 174.2, 150.9, 
150.4, 134.8, 130.2, 128.4, 126.7, 123.9, 119.6, 102.4, 97.2, 71.8, 65.7, 55.4, 55.3, 46.2, 
35.4, 31.3. HRMS (ESI) calcd for C18H20NO4
+ (MH+) 314.1387, found 314.1388. 
syn-3.54j': 1H NMR (500 MHz, CDCl3) δ 8.18 (dd, J = 8.2, 1.2 
Hz, 1H), 7.43 (dd, J = 7.7, 1.6 Hz, 1H), 7.32 (ddd, J = 8.2, 7.3, 
1.6 Hz, 1H), 7.17 (ddd, J = 7.7, 7.3, 1.2 Hz, 1H), 4.88 (d, J = 5.5 
Hz, 1H), 4.73 (s, 1H), 4.48 (dd, J = 6.1, 5.3 Hz, 1H), 3.61 (s, 3H), 3.55 (s, 3H), 3.07 (dd, 
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J = 5.3, 5.5 Hz, 1H), 2.74 (ddd, J = 16.95, 12.2, 8.25 Hz, 1H), 2.52 (d, J = 6.1 Hz, 1H), 
2.44 (ddd, J = 16.95, 8.8, 1.2 Hz, 1H), 2.33 (ddd, J = 12.4, 8.25, 1.2 Hz, 1H), 2.17 (ddd, J 
= 12.4, 12.2, 8.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 173.2, 151.3, 150.8, 134.0, 
131.7, 128.4, 127.7, 124.8, 121.6, 99.9, 92.9, 66.8, 63.1, 55.4, 55.3, 47.0, 37.9, 30.6. 
HRMS (ESI) calcd for C18H20NO4
+ (MH+) 314.1387, found 314.1385. 
13,15,17-Trimethoxy-18-oxa-8-azapentacyclo[13.2.1.02,7.08,12.012,17]octadeca-
2,4,6,13-tetraen-9-one (3.62k). General procedure E was followed on a 0.232 g 
(0.675 mmol) scale of 3.51k, which after flash chromatography on silica gel (gradient 
elution: hexane → hexane–ethyl acetate 80:20) afforded 0.178 g (77%) of 3.62k. 
3.62k: 1H NMR (500 MHz, MeOD) δ 7.90 (dd, J = 8.2, 1.2 Hz, 
1H), 7.42 (dd, J = 7.8, 1.5 Hz, 1H), 7.30 (ddd, J = 8.6, 7.4, 1.6 
Hz, 1H), 7.18 (td, J = 7.5, 1.3 Hz, 1H), 5.05 (m, 2H), 3.52 (s, 
3H), 3.42 (s, 3H), 3.34 (s, 3H), 2.96 (dd, J = 10.5, 1.5 Hz, 1H), 2.60 (m, 3H), 2.17 (m, 
1H), 1.86 (d, J = 10.5 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 176.8, 157.2, 133.5, 
131.7, 129.2, 129.1, 126.1, 122.4, 106.2, 105.7, 84.0, 72.2, 71.2, 56.0, 51.7, 50.7, 36.1, 
32.2, 24.2. HRMS (ESI) calcd for C19H22NO5
+ (MH+) 344.1492, found 344.1497. 
19-Methoxy-22-oxa-8-azahexacyclo[17.2.1.02,7.08,16.010,15.016,21]docosa-
2,4,6,10(15),11,13,17-heptaen-9-one (3.62l) and anti-7-Hydroxy-14-azapentacyclo 
[12.7.0.01,6.08,13.016,21]henicosa-2,8,10,12,16(21),17,19-heptaene-4,15-dione (anti-
3.60l). General procedure E was followed on a 0.137 g (0.413 mmol) scale of 3.51l. The 
crude photoproducts were then subjected to general procedure F, which after flash 
chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 80:20) 
afforded 0.033 g (24%) of 3.62l and 0.040 g (31%) of anti-3.60l. 
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3.62l: 1H NMR (500 MHz, CDCl3) δ 8.21 (dd, J = 8.2, 1.2 Hz, 
1H), 7.98 (dt, J = 7.4, 1.1 Hz, 1H), 7.63 (m, 2H), 7.57 (m, 1H), 
7.54 (dd, J = 7.7, 1.4 Hz, 1H), 7.44 (ddd, J = 8.2, 7.4, 1.7 1H), 
7.22 (ddd, J = 7.7, 7.4, 1.2 Hz, 1H), 6.34 (dd, J = 9.6, 1.1 Hz, 1H), 5.27 (d, J = 5.2 Hz, 
1H), 5.16 (dd, J = 9.6, 2.1 Hz, 1H), 3.57 (s, 3H), 2.80 (dddd, J = 5.2, 4.1, 2.1, 2.0 Hz, 
1H), 2.59 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 165.6, 146.3, 139.1, 132.8, 131.5, 
130.4, 129.6, 129.0, 127.6, 127.6, 127.5, 125.1, 124.8, 123.2, 121.8, 104.2, 73.0, 66.2, 
50.7, 44.3, 35.8. HRMS (ESI) calcd for C21H18NO3
+ (MH+) 332.1281, found 332.1288. 
anti-3.60l: 1H NMR (500 MHz, CDCl3) δ 8.22 (dd, J = 8.3, 1.2 Hz, 
1H), 8.00 (ddd, J = 7.4, 1.3, 0.8 Hz, 1H), 7.66 (td, J = 7.5, 1.3 Hz, 
1H), 7.62 (dd, J = 7.4, 1.1 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.47 
(dddd, J = 8.3, 7.3, 1.6, 0.7, 0.9 Hz, 1H), 7.38 (dddd, J = 8.2, 7.3, 
1.7, 0.7 Hz, 1H), 7.23 (ddd, J = 7.6, 7.3,1.2 Hz, 1H), 6.65 (dd, J = 10.1, 2.3 Hz, 1H), 6.20 
(dd, J = 10.1, 0.8 Hz, 1H), 4.77 (dd, J = 9.2, 9.0 Hz, 1H), 3.28 (dd, J = 18.6, 4.5 Hz, 1H), 
3.22 (ddd, J = 18.6, 2.1, 0.8 Hz, 1H), 2.37 (dddd, J = 9.0, 4.5, 2.3, 2.1 Hz, 1H), 2.07 (d, J 
= 9.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 196.2, 165.7, 150.0, 143.5, 133.6, 133.0, 
132.3, 131.7, 130.1, 129.1, 128.9, 128.3, 125.6, 125.4, 123.8, 122.2, 69.9, 66.4, 46.9, 
38.5. HRMS (ESI) calcd for C20H15NO3Li
+ (MLi+) 324.1206, found 324.1209. 
syn-12-Hydroxy-15-methoxy-12-methyl-2-oxa-5-azatetracyclo[11.4.0.01,5.06,11] 
heptadeca-6,8,10,14,16-pentaen-4-one (syn-3.55d) and anti-12-hydroxy-15-methoxy-
12-methyl-2-oxa-5-azatetracyclo[11.4.0.01,5.06,11]heptadeca-6,8,10,14,16-pentaen-4-
one (anti-3.55d). General procedure E was followed on a 0.449 g (1.50 mmol) scale of 
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3.52d, which after flash chromatography on silica gel (gradient elution: hexane → ethyl 
acetate) afforded 0.043 g (10%) of syn-3.55d and 0.340 g (76%) of anti-3.55d. 
syn-3.55d: 1H NMR (500 MHz, MeOD) δ 7.59 (dd, J = 7.3, 1.9 
Hz, 1H), 7.56 (dd, J = 7.8, 1.4 Hz, 1H), 7.31 (td, J = 7.6, 1.8 Hz, 
1H), 7.27 (td, J = 7.5, 1.6 Hz, 1H), 5.86 (dd, J = 9.9, 0.7 Hz, 
1H), 5.81 (dd, J = 9.9, 2.4 Hz, 1H), 5.00 (dd, J = 4.3, 2.5 Hz, 1H), 4.63 (d, J = 14.5 Hz, 
1H), 4.31 (d, J = 14.5 Hz, 1H), 3.47 (s, 3H), 3.39 (d, J = 4.3 Hz, 1H), 1.51 (s, 3H). 
13C NMR (126 MHz, MeOD) δ 170.3, 152.6, 139.9, 131.8, 128.5, 127.7, 127.5, 127.1, 
126.2, 124.0, 94.3, 92.5, 72.8, 66.6, 55.3, 54.7, 30.8. HRMS (ESI) calcd for C17H18NO4
+ 
(MH+) 300.1230, found 300.1235. 
anti-3.55d: 1H NMR (500 MHz, MeOD) δ 7.73 (dd, J = 7.9, 1.3 
Hz, 1H), 7.52 (dd, J = 7.7, 1.5 Hz, 1H), 7.34 (td, J = 7.7, 1.5 Hz, 
1H), 7.25 (td, J = 7.6, 1.3 Hz, 1H), 5.89 (dd, J = 10.0, 0.8 Hz, 
1H), 5.86 (dd, J = 9.9, 2.2 Hz, 1H), 4.78 (dd, J = 4.9, 2.2 Hz, 1H), 4.55 (d, J = 14.1 Hz, 
1H), 4.29 (d, J = 14.1 Hz, 1H), 3.51 (s, 3H), 3.38 (d, J = 4.8 Hz, 1H), 1.68 (s, 3H). 
13C NMR (126 MHz, MeOD) δ 171.6, 153.4, 137.9, 133.9, 129.8, 129.3, 128.2, 127.1, 
126.9, 124.2, 94.6, 92.4, 73.6, 67.0, 54.9, 54.4, 26.3. HRMS (ESI) calcd for C17H18NO4
+ 
(MH+) 300.1230, found 300.1228. 
anti-12-Hydroxy-9-methoxy-5-oxa-2-azapentacyclo[10.7.1.02,6.06,11.016,20]icosa-
1(19),7,9,16(20),17-pentaen-3-one (anti-3.56d) and anti-12-Hydroxy-5-oxa-2-
azapentacyclo[10.7.1.02,6.06,11.016,20]icosa-1(19),7,16(20),17-tetraene-3,9-dione (anti-
3.61d). General procedure E was followed on a 0.187 g (0.575 mmol) scale of 3.53d, 
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which after flash chromatography on silica gel (gradient elution: hexane → ethyl acetate) 
afforded 0.098 g (52%) of anti-3.56d and 0.072 g (38%) of anti-3.61d. 
anti-3.56d: 1H NMR (500 MHz, CDCl3) δ 7.35 (d, J = 7.8 Hz, 
1H), 7.25 (dd, J = 7.8, 7.7 Hz, 1H), 6.99 (dd, J = 7.7, 1.1 Hz, 
1H), 5.82 (dd, J = 9.9, 2.4 Hz, 1H), 5.61 (d, J = 9.9 Hz, 1H), 4.65 
(dd, J = 4.8, 2.4 Hz, 1H), 4.55 (d, J = 14.1 Hz, 1H), 4.45 (d, J = 
14.1 Hz, 1H), 3.63 (d, J = 4.8 Hz, 1H), 3.50 (s, 3H), 2.75 (dt, J = 16.5, 4.5 Hz, 1H), 2.68 
(ddd, J = 16.4, 10.5, 5.4 Hz, 1H), 2.24 (ddd, J = 13.6, 11.6, 3.8 Hz, 1H), 2.18 (s, 1H), 
2.04 (dddd, J = 13.6, 5.1, 3.0, 1.2 Hz 1H), 1.90 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
169.3, 150.6, 138.5, 133.4, 132.1, 128.6, 127.9, 127.3, 126.5, 122.7, 93.4, 91.0, 71.8, 
66.2, 55.0, 54.5, 35.7, 29.7, 19.8. HRMS (ESI) calcd for C19H19LiNO4
+ (MLi+) 332.1469, 
found 332.1481. 
anti-3.61d: 1H NMR (500 MHz, CDCl3) δ 7.35 (dd, J = 7.8, 1.5 Hz, 
1H), 7.32 (dd, J = 7.8, 7.3 Hz, 1H), 7.09 (d, J = 7.3 Hz, 1H), 6.62 
(d, J = 10.1 Hz, 1H), 6.03 (dd, J = 10.1, 0.8 Hz, 1H), 4.57 (d, J = 
14.4 Hz, 1H), 4.42 (d, J = 14.4 Hz, 1H), 3.20 (dd, J = 11.8, 6.6 Hz, 
1H), 2.81 (d, J = 16.5 Hz, 1H), 2.68 (dd, J = 16.5, 6.6 Hz), 2.67 (m, 1H), 2.26 (s, 1H), 
1.91 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 196.3, 171.2, 144.9, 139.1, 132.7, 130.0, 
129.0, 128.9, 128.0, 123.7, 90.7, 71.1, 65.6, 50.6, 38.3, 34.2, 29.4, 18.8. HRMS (ESI) 
calcd for C18H17NO4Li
+ (MLi+) 318.1312, found 318.1320. 
anti-12-Hydroxy-7,11-dimethoxy-5-oxa-2-azapentacyclo[10.7.1.02,6.06,11.016,20] 
icosa-1(19),7,9,16(20),17-pentaen-3-one (anti-3.56e). General procedure E was 
followed on a 0.480 g (1.35 mmol) scale of 3.53e with the following modifications: 
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acetone (120 mL) was used as a solvent, no aqueous workup was performed. Further 
purification by flash chromatography on silica gel (gradient elution: hexane → hexane–
ethyl acetate 80:20) afforded 0.232 g (48%) of anti-3.56e. 
anti-3.56e: 1H NMR (500 MHz, CDCl3) δ 7.27 (m, 2H), 7.04 (m, 1H), 
5.98 (dd, J = 10.3, 6.6 Hz, 1H), 5.13 (dd, J = 10.3, 0.8 Hz, 1H), 4.91 
(dd, J = 6.7, 0.8 Hz, 1H), 4.78 (d, J = 13.3 Hz, 1H), 4.41 (d, J = 13.3 
Hz, 1H), 3.68 (s, 3H), 3.50 (s, 3H), 3.07 (s, 1H), 2.77 (dt, J = 16.2, 3.8 Hz, 1H), 2.63 
(ddd, J = 16.5, 11.4, 5.2 Hz, 1H), 2.11 (m, 2H), 1.91 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 171.4, 158.4, 138.9, 133.5, 130.2, 128.3, 128.2, 127.3, 123.2, 117.3, 93.2, 92.3, 
84.1, 74.0, 68.9, 55.8, 53.2, 32.6, 29.6, 19.5. HRMS (ESI) calcd for C20H22NO5
+ (MH+) 
356.1492, found 356.1498. 
anti-12-Hydroxy-9,10-dimethoxy-2-azapentacyclo[10.7.1.02,6.06,11.016,20]icosa-
1(19),7,9,16(20),17-pentaen-3-one (anti-3.56j) and anti-12-Hydroxy-8,9-dimethoxy-2-
azapentacyclo[10.7.1.02,6.06,11.016,20]icosa-1(19),7,9,16(20),17-pentaen-3-one (anti-
3.56j'). General procedure E was followed on a 0.500 g (1.41 mmol) scale of 3.53j, 
which after flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl 
acetate 50:50) afforded 0.080 g (16%) of anti-3.56j and 0.268 g (54%) of anti-3.56j'. 
anti-3.56j: 1H NMR (500 MHz, MeOD) δ 7.44 (d, J = 7.9 Hz, 
1H), 7.19 (t, J = 7.8 Hz, 1H), 6.93 (dd, J = 7.7, 1.1 Hz, 1H), 5.71 
(d, J = 9.9 Hz, 1H), 5.14 (dd, J = 9.9, 1.2 Hz, 1H), 3.83 (s, 3H), 
3.57 (s, 3H), 3.21 (d, J = 1.3 Hz, 1H), 2.82 (m, 1H), 2.72 (m, 
2H), 2.64 (ddd, J = 17.3, 9.8, 5.2 Hz, 1H), 2.56 (ddd, J = 13.1, 9.8, 5.2 Hz, 1H), 2.15 (m, 
2H), 2.03 (m, 1H), 1.88 (td, J = 13.2, 3.9 Hz, 1H), 1.80 (ddq, J = 13.0, 6.5, 3.6 Hz, 1H). 
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13C NMR (126 MHz, MeOD) δ 175.6, 139.8, 139.1, 137.3, 136.8, 136.0, 131.7, 128.5, 
127.3, 125.2, 122.2, 70.4, 68.9, 61.6, 58.8, 58.6, 35.0, 32.7, 30.9, 29.9, 19.4. HRMS 
(ESI) calcd for C21H24NO4
+ (MH+) 354.1700, found 354.1704. 
anti-3.56j': 1H NMR (500 MHz, MeOD) δ 7.29 (d, J = 7.8 Hz, 
1H), 7.20 (t, J = 7.8 Hz, 1H), 6.97 (dd, J = 7.7, 1.2 Hz, 1H), 4.78 
(d, J = 5.0 Hz, 1H), 4.60 (s, 1H), 3.51 (s, 3H), 3.43 (s, 3H), 3.36 
(d, J = 5.0 Hz, 1H), 2.79 (m, 2H), 2.69 (ddd, J = 16.2, 10.4, 5.1), 
2.54 (ddd, J = 8.1, 5.4, 2.8), 2.52 (dd, J = 9.3, 5.8), 2.30 (m, 1H), 2.20 (ddd, J = 13.4, 
12.0, 3.4 Hz, 1H), 1.96 (m, 2H), 1.84 (m, 1H). 13C NMR (126 MHz, MeOD) δ 175.3, 
150.1, 148.9, 139.6, 137.0, 134.0, 128.4, 127.3, 123.4, 101.7, 95.4, 72.0, 66.4, 56.1, 55.3, 
55.1, 39.6, 36.9, 30.8, 30.6, 20.6. HRMS (ESI) calcd for C21H24NO4
+ (MH+) 354.1700, 
found 354.1693. 
Post-Photochemical Hetero-Diels–Alder Reactions and Further Transformations 
 
 
 
 
General Procedure G for the Reaction with (Nitrosocarbonyl)benzene. Under 
nitrogen, the crude photoproduct (1.08 mmol) was dissolved in anhydrous DCM (2 mL), 
and the solution was treated with tetrabutylammonium periodate (1.23 g, 2.84 mmol). 
Benzhydroxamic acid (0.411 g, 3.00 mmol) was added portionwise over 1 h, and the 
mixture was stirred at ambient temperature overnight. After that, the mixture was poured 
into water (10 mL), and the product was extracted with DCM (2×20 mL). The combined 
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organic layers were washed with water (3×5 mL), dried over anhydrous Na2SO4 and 
concentrated in vacuo. Further purification by flash chromatography on silica gel yielded 
the desired cycloadduct. 
16-Benzoyl-13-hydroxy-19-methyl-3,17-dioxa-6,16-
diazapentacyclo[13.2.2.02,6.02,14.07,12]nonadeca-7,9,11,18-tetraen-
5-one (3.64). General procedure E was followed on a 0.203 g (0.751 
mmol) scale of 3.51b, which afforded crude syn-3.54b. The 
obtained photoproduct was then subjected to general procedure G, which after flash 
chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 30:70) 
afforded 0.140 g (46% after two steps) of the title compound. 1H NMR (500 MHz, 
DMSO) δ 7.57 (d, J = 7.6 Hz, 2H), 7.48 (m, 4H), 7.30 (m, 2H), 7.18 (br s, 1H), 6.31 (br 
d, J = 3.4 Hz, 1H), 5.47 (br s, 1H), 5.05 (br s, 1H), 4.89 (t, J = 5.2 Hz, 1H), 4.62 (d, J = 
14.2 Hz, 1H), 4.35 (d, J = 14.2 Hz, 1H), 3.21 (br s, 1H), 1.27 (br s, 3H). 13C NMR (126 
MHz, DMSO) δ 168.1, 132.4, 132.4, 131.4, 128.5, 128.2, 128.1, 127.3, 125.1, 124.4, 
121.2, 120.3, 93.4, 74.7, 65.1, 63.2, 50.4, 19.3. HRMS (ESI) calcd for C23H21N2O5
+ 
(MH+) 405.1445, found 405.1452. 
18-Benzoyl-15-hydroxy-21-methoxy-3,19-dioxa-6,18-
diazahexacyclo[15.2.2.17,11.02,6.02,16.015,22]docosa-
7,9,11(22),20-tetraen-5-one (3.65). General procedure E was 
followed on a 0.351 mg (1.08 mmol) scale of 3.53d, which 
afforded crude anti-3.56d. The obtained photoproduct was then subjected to general 
procedure G, which after flash chromatography on silica gel (gradient elution: hexane → 
hexane–ethyl acetate 60:40) afforded 0.208 g (42% after two steps) of the title 
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compound. 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.3 Hz, 2H), 7.47 (t, J = 7.4 Hz, 
1H), 7.40 (m, 2H), 7.29 (dd, J = 7.8, 1.2 Hz, 1H), 7.25 (dd, J = 7.8, 7.6 Hz, 1H), 6.99 (dd, 
J = 7.6, 1.2 Hz, 1H), 5.25 (br s, 1H), 4.63 (d, J = 6.7 Hz, 1H), 4.52 (d, J = 14.5 Hz, 1H), 
4.46 (dd, J = 6.7, 3.0 Hz, 1H), 4.44 (d, J = 14.5 Hz, 1H), 3.23 (d, J = 2.8 Hz, 1H), 2.81 (s, 
3H), 2.75 (dt, J = 17.2, 3.1 Hz, 1H), 2.65 (ddd, J = 16.6, 12.2, 4.9, 1H), 2.22 (s, 1H), 2.06 
(m, 2H), 1.95 (m, 1H), 1.83 (qdd, J = 12.9, 4.3, 2.9 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ 171.9, 169.7, 160.2, 138.7, 135.0, 133.3, 131.7, 129.4, 128.9, 128.6, 128.1, 
126.7, 121.9, 95.3, 90.6, 77.7, 69.0, 66.1, 55.2, 54.7, 53.6, 34.7, 29.7, 18.9. HRMS (ESI) 
calcd for C26H25N2O6
+ (MH+) 461.1707, found 461.1710. 
 
 
 
 
 
General Procedure H for the Reaction with Singlet Oxygen. The crude 
photoproduct (1.39 mmol) was dissolved in anhydrous DCM (139 mL), and sensitizer 
(tetraphenylporphyrin or methylene blue; 6.9 µmol) was added. The mixture was placed 
into water bath and irradiated with fluorescent lamp (visible light) at ambient temperature 
with constant oxygen bubbling. The reaction progress was monitored by 1H NMR. After 
completion, the resulting crude endo-peroxide solution was either used directly for the 
next step, or concentrated in vacuo with subsequent purification by flash chromatography 
on silica gel, which yielded the pure cycloadduct. 
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General Procedure I for Kornblum–DeLaMare Rearrangement. Solution of 
crude endo-peroxide (0.59 mmol) in anhydrous DCM (36 mL) was treated with TEA 
(103 µL, 75 mg, 0.74 mmol). The mixture was stirred at ambient temperature overnight, 
and then washed with water (2×20 mL). The organic layer was dried over anhydrous 
Na2SO4 and concentrated in vacuo. Further purification by flash chromatography on 
silica gel yielded the desired rearrangement product. 
12,14-Dihydroxy-15-methoxy-2-oxa-5-azatetracyclo 
[11.4.0.01,5.06,11]heptadeca-6,8,10,15-tetraene-4,17-dione (3.69). 
General procedure E was followed on a 0.203 g (0.751 mmol) scale 
of 3.51b, which afforded crude syn-3.54b. The obtained photoproduct was then subjected 
to general procedure H (irradiation time = 3 h), yielding the solution of crude endo-
peroxide 3.66. After that, general procedure I was followed, with several modifications: 
30 mL of DCM was used as a solvent, aqueous work-up was not performed. Further 
purification by flash chromatography on silica gel (gradient elution: DCM → DCM–
methanol 95:5) afforded 0.080 g (35% after three steps) of the title compound. 1H NMR 
(500 MHz, DMSO) δ 8.42 (d, J = 8.2 Hz, 1H), 7.39 (m, 2H), 7.16 (td, J = 7.5, 1.2 Hz, 
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1H), 6.11 (d, J = 3.9 Hz, 1H), 5.06 (d, J = 4.3 Hz, 1H), 4.46 (d, J = 14.0 Hz, 1H), 4.44 
(dd, J = 4.5, 3.7 Hz, 1H), 4.32 (d, J = 14.0 Hz, 1H), 3.04 (dd, J = 4.5, 4.3 Hz, 1H), 2.99 
(d, J = 17.8 Hz, 1H), 2.27 (d, J = 17.8 Hz, 1H), 1.29 (s, 3H). 13C NMR (126 MHz, 
DMSO) δ 204.9, 168.6, 132.8, 130.7, 129.6, 124.6, 124.4, 117.1, 90.7, 80.3, 74.9, 70.7, 
67.2, 47.6, 45.2, 22.9. HRMS (ESI) calcd for C16H16NO5
+ (MH+) 302.1023, found 
302.1026. 
15-Hydroxy-21-methoxy-3,18,19-trioxa-6-azahexacyclo 
[15.2.2.17,11.02,6.02,16.015,22]docosa-7,9,11(22),20-tetraen-5-one 
(3.67). General procedure E was followed on a 0.151 g 
(0.463 mmol) scale of 3.53d, which afforded crude anti-3.56d. The obtained 
photoproduct was then subjected to general procedure H (irradiation time = 4 h), which 
after flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl 
acetate 65:35) afforded 0.093 g (56% after two steps) of the title compound. 1H NMR 
(500 MHz, CDCl3) δ 7.32 (dt, J = 7.7, 1.1 Hz, 1H), 7.27 (dd, J = 7.7, 7.6 Hz, 1H), 6.99 
(d, J = 7.6 Hz, 1H), 4.69 (dd, J = 7.2, 2.7 Hz, 1H), 4.66 (dd, J = 7.2, 1.0 Hz, 1H), 4.63 
(ddd, J = 3.5, 2.7, 1.0 Hz, 1H), 4.53 (d, J = 14.6 Hz, 1H), 4.48 (d, J = 14.6 Hz, 1H), 3.29 
(d, J = 3.5 Hz, 1H), 2.87 (s, 3H), 2.75 (ddt, J = 16.2, 3.7, 2.0 Hz, 1H), 2.61 (ddd, J = 
16.4, 11.7, 4.9 Hz, 1H), 2.07 (s, 1H), 2.02 (m, 1H), 1.87 (m, 3H). 13C NMR (126 MHz, 
CDCl3) δ 169.6, 158.6, 138.5, 134.9, 129.0, 128.5, 126.7, 122.0, 93.7, 91.7, 77.1, 75.0, 
68.6, 66.0, 55.2, 55.0, 34.5, 29.6, 18.8. HRMS (ESI) calcd for C19H20NO6
+ (MH+) 
358.1285, found 358.1288. 
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10,12-Dihydroxy-9-methoxy-5-oxa-2-azapentacyclo 
[10.7.1.02,6.06,11.016,20]icosa-1(19),8,16(20),17-tetraene-3,7-
dione (3.70). General procedure E was followed on a 0.192 g 
(0.588 mmol) scale of 3.53d, which afforded crude anti-3.56d. The obtained 
photoproduct was then subjected to general procedure H (irradiation time = 4 h), yielding 
the solution of crude endo-peroxide 3.67. After that, general procedure I was followed, 
which after flash chromatography on silica gel (gradient elution: DCM → DCM–
methanol 97:3) afforded 0.061 g (29% after three steps) of the title compound. 1H NMR 
(500 MHz, MeOD) δ 7.58 (dd, J = 8.0, 1.1 Hz, 1H), 7.26 (t, J = 7.8 Hz, 1H), 7.03 (dd, J = 
7.7, 1.1 Hz, 1H), 5.44 (s, 1H), 4.62 (d, J = 13.6 Hz, 1H), 4.39 (d, J = 13.5 Hz, 1H), 4.17 
(d, J = 4.1 Hz, 1H), 3.74 (s, 3H), 3.13 (d, J = 4.1 Hz, 1H), 2.89 (dt, J = 16.4, 5.0 Hz, 1H), 
2.66 (ddd, J = 15.9, 9.1, 6.1 Hz, 1H), 2.00 (m, 3H), 1.79 (m, 1H). 13C NMR (126 MHz, 
MeOD) δ 193.3, 178.8, 172.3, 140.7, 134.2, 131.1, 129.5, 127.8, 121.3, 101.6, 93.7, 71.2, 
69.1, 67.3, 60.0, 57.5, 35.4, 29.8, 19.4. HRMS (ESI) calcd for C19H19NO6Li
+ (MLi+) 
364.1367, found 364.1371. 
7,10,12-Trihydroxy-9-methoxy-5-oxa-2-azapentacyclo 
[10.7.1.02,6.06,11.016,20]icosa-1(19),8,16(20),17-tetraen-3-one 
(3.71). General procedure E was followed on a 0.151 g 
(0.463 mmol) scale of 3.53d, which afforded crude anti-3.56d. The obtained 
photoproduct was then subjected to general procedure H (irradiation time = 4 h), yielding 
the solution of crude endo-peroxide 3.67. Solvent was removed in vacuo, and the residue 
was redissolved in methanol (4.6 mL). Thiourea (0.041 g, 0.543 mmol) was added, and 
the mixture was stirred at ambient temperature overnight. The solvent was removed in 
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vacuo, and further purification by flash chromatography on silica gel (gradient elution: 
hexane → ethyl acetate) afforded 0.033 g (20% after three steps) of the title compound 
(combined fractions were washed with water to remove thiourea). 1H NMR (500 MHz, 
MeOD) δ 7.84 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 8.1,7.5 Hz, 1H), 7.03 (dd, J = 7.5, 1.0 
Hz, 1H), 4.70 (d, J = 3.2 Hz, 1H), 4.64 (d, J = 13.8 Hz, 1H), 4.40 (d, J = 13.8 Hz, 1H), 
4.21 (d, J = 1.4 Hz, 1H), 4.15 (d, J = 3.2 Hz, 1H), 3.53 (s, 3H), 3.08 (dq, J = 13.4, 6.9, 5.8 
Hz, 1H), 2.99 (d, J = 1.4 Hz, 1H), 2.63 (ddd, J = 15.2, 6.5, 4.5 Hz, 1H), 2.02 (m, 1H), 
1.93 (ddd, J = 13.8, 7.9, 4.1 Hz, 1H), 1.71 (ddd, J = 13.7, 8.7, 7.3 Hz, 1H), 1.60 (dtdd, J = 
12.9, 8.7, 6.6, 4.1 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 170.9, 159.8, 142.3, 133.5, 
130.4, 129.5, 126.8, 120.1, 98.1, 98.0, 71.0, 69.3, 69.0, 67.8, 60.3, 55.5, 32.1, 28.6, 19.2. 
HRMS (ESI) calcd for C19H21NO6Li
+ (MLi+) 366.1523, found 366.1514. 
 
Experimental Section for Project 4 
Synthesis of Photoprecursors 
 
 
 
 
General Procedure A for Reductive Amination. Aniline (3.74; 8.29 mmol) was 
dissolved in anhydrous DCM (25 mL). Aldehyde (3.75; 8.7 mmol) and molecular sieves 
4Å were added, and the mixture was stirred at ambient temperature till completion 
(monitored by 1H NMR). Solids were filtered off and washed with DCM. The filtrate was 
concentrated in vacuo. The residue was dissolved in absolute methanol (30 mL), the 
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resulting solution was cooled to 0 °C, treated (slowly) with sodium borohydride or 
sodium cyanoborohydride (9.12 mmol), and stirred overnight. Methanol was removed in 
vacuo, the residue was partitioned between ethyl acetate (100 mL) and water (15 mL). 
Organic layer was separated, washed with water (2×10 mL) and sat. aq. NaCl (10 mL), 
dried over anhydrous Na2SO4, and the solvent was removed in vacuo to afford the desired 
N-alkylaniline (3.79; if necessary, the product was additionally purified by flash 
chromatography on silica gel). 
 
 
 
General Procedure B for Reductive Amination. Used a modified literature protocol 
[170]. Under argon, aldehyde (3.75; 1.90 mmol) was dissolved in 1,2-dichloroethane 
(15 mL), the solution was treated with aniline (3.74; 2.09 mmol), glacial acetic acid 
(1.90 mmol) and sodium triacetoxyborohydride (5.70 mmol) and stirred overnight. Then, 
the reaction was quenched with sat. aq. NaHCO3 (10 mL) and stirred for 1 h. Insoluble 
solids were filtered off and washed with DCM (20 mL). Organic layer was separated. 
Aqueous layer was mixed with sat. aq. NaHCO3 (10 mL) and extracted with DCM 
(3×20 mL; solids formed during extraction were filtered off and washed with the same 
DCM used for extraction). The combined organic layers were washed with sat. aq. 
NaHCO3 (2×10 mL), water (2×10 mL) and sat. aq. NaCl (10 mL), dried over anhydrous 
Na2SO4, and the solvent was removed in vacuo to afford the desired N-alkylaniline (3.79; 
the products were used for the next steps without chromatographical purification). 
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General Procedure C for the Coupling of N-Alkylanilines with Photoactive 
Cores via Oxalyl Linker. Solution of N-alkylaniline (3.79; 2.00 mmol) in anhydrous 
DCM (10 mL) was quickly poured into solution of oxalyl chloride (3.80; 20 mmol) in 
anhydrous DCM (10 mL) with vigorous stirring (note: slow addition may lead to 
formation of bis-oxalyl amide), and the mixture was stirred at ambient temperature for 
1 h. Volatiles were removed in vacuo, and the residue (acyl chloride 3.81) was 
redissolved in anhydrous DCM (10 mL) under nitrogen. Solution of primary aniline (3.9, 
3.48; 1.89 mmol) and triethylamine (3.0 mmol) in anhydrous DCM (10 mL) was added 
dropwise at 0 °C under nitrogen. The mixture was stirred at ambient temperature 
overnight, and then it was diluted with DCM (40 mL) and washed with water (3×10 mL). 
The organic layer was dried over anhydrous Na2SO4, and the solvent was removed in 
vacuo. Crude dioxolane-protected photoprecursors (4.5) were then deprotected according 
to general procedure E, whereas photoprecursor 3.84ah was purified by flash 
chromatography on silica gel. 
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General Procedure D for the Coupling of Acid-Sensitive N-Alkylanilines with 
2'-Aminoacetophenone via Oxalyl Linker. Solution of 2'-aminoacetophenone (3.48; 
3.05 mmol) in anhydrous DCM (15 mL) was quickly poured into solution of oxalyl 
chloride (3.80; 30 mmol) in anhydrous DCM (15 mL) with vigorous stirring (note: slow 
addition may lead to formation of bis-oxalyl amide), and the mixture was stirred at 
ambient temperature for 1 h. Volatiles were removed in vacuo, and the residue (acyl 
chloride 3.82) was redissolved in anhydrous DCM (15 mL) under nitrogen. Solution of 
N-alkylaniline (3.79; 1.53 mmol) and triethylamine (0.32 mL, 0.23 g, 2.3 mmol) in 
anhydrous DCM (15 mL) was added dropwise at 0 °C under nitrogen. The mixture was 
stirred at ambient temperature overnight, after that it was diluted with DCM (40 mL) and 
washed 3 times with sat. aq. NaHCO3 (10 mL) diluted with water (10 mL), and then with 
water (20 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was 
removed in vacuo. Further purification by flash chromatography on silica gel yielded the 
desired photoprecursors (3.84). 
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General Procedure E for Dioxolane Deprotection. Dioxolane-protected 
photoprecursor (4.5; 1.89 mmol) was dissolved in acetone (15 mL), TsOH·H2O 
(0.567 mmol) was added, and the mixture was stirred at ambient temperature for 1 day. 
Solvent was removed in vacuo, and the residue was dissolved in DCM (50 mL). The 
solution was washed with sat. aq. NaHCO3 (2×10 mL) and then with water (10 mL). The 
organic layer was dried over anhydrous Na2SO4, filtered, and the solvent was removed in 
vacuo. Further purification by flash chromatography on silica gel yielded the desired 
photoprecursor (3.83). 
N'-(2-Formylphenyl)-N-(4-methoxyphenyl)-N-
methylethanediamide (3.83ag). 4-Methoxy-N-methylaniline 
(3.74ag; 1.43 mmol) was coupled with oxalyl chloride (3.80; 
11 mmol), and the resulting acyl chloride 3.79ag was coupled with 
2-(1,3-dioxolan-2-yl)aniline (3.9; 0.873 mmol) according to general procedure C, with 
the following modifications: solid 4-methoxy-N-methylaniline was added to a solution of 
oxalyl chloride in anhydrous DCM (15 mL) at 0 °C; second coupling step was carried out 
in 6 mL of anhydrous DCM with DIPEA (1.9 mmol) as a base. Dioxolane protection was 
then removed according to general procedure E with 0.18 mmol of TsOH·H2O, which 
 160 
after flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl 
acetate 80:20) afforded 0.178 g (65%) of the title compound. 1H NMR (500 MHz, 
CDCl3) δ 12.30 (s, 1H), 9.97 (d, J = 0.7 Hz, 1H), 8.49 (d, J = 8.4 Hz, 1H), 7.69 (dd, J = 
7.7, 1.7 Hz, 1H), 7.51 (ddd, J = 8.7, 7.4, 1.7 Hz, 1H), 7.24 (dd, J = 7.5, 1.1 Hz, 1H), 7.15 
(m, 2H), 6.89 (m, 2H), 3.80 (s, 3H), 3.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.9, 
162.1, 159.7, 159.0, 139.4, 136.4, 136.1, 135.9, 127.2, 124.0, 122.7, 120.2, 114.7, 55.5, 
39.5. HRMS (ESI) calcd for C17H16N2O4Na
+ (MNa+) 335.1002, found 335.1010. 
 
 
 
 
N'-(2-Formylphenyl)-N-(4-methoxyphenyl)-N-(2H1)methylethanediamide 
(3.83ag-d). 
Step 1. 4-Methoxy-N-(2H1)methylaniline (3.79ag-d). Prepared according to a modified 
literature protocol [171]. Under nitrogen, sodium methoxide (1.10 g, 20.4 mmol) was 
dissolved in absolute methanol (5 mL), and the solution was cooled to 0 °C. Solution of 
p-anisidine (3.74a; 0.502 g, 4.08 mmol) in absolute methanol (5 mL) was added. The 
mixture was stirred for 10 minutes, and then it was added to a solution of 
paraformaldehyde (0.178 g, 5.93 mmol) in absolute methanol (10 mL) under nitrogen. 
After 24 h stirring at ambient temperature, sodium borodeuteride (0.171 g, 4.08 mmol) 
was added portionwise at 0 °C. The reaction mixture was allowed to warm up to room 
temperature, and then refluxed for 3 h. The product was purified according to general 
procedure A, which afforded 0.534 g of the title compound. The crude product was used 
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for the next step without chromatographical purification. 1H NMR (500 MHz, CDCl3) δ 
6.80 (m, 2H), 6.59 (m, 2H), 3.75 (s, 3H), 2.79 (t, J = 1.8 Hz, 2H). HRMS (ESI) calcd for 
C8H11DNO
+ (MH+) 139.0976, found 139.0983. 
Step 2. N'-(2-Formylphenyl)-N-(4-methoxyphenyl)-N-(2H1)methylethanediamide 
(3.83ag-d). 0.276 g of N-alkylaniline 3.79ag-d was coupled with oxalyl chloride (3.80; 
20 mmol), and the resulting acyl chloride 3.81ag-d was coupled with 2-(1,3-dioxolan-2-
yl)aniline (3.9; 1.88 mmol) according to general procedure C. Dioxolane protection was 
then removed according to general procedure E with 0.38 mmol of TsOH·H2O, which 
after flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl 
acetate 80:20) afforded 0.339 g (58% after two steps) of the title compound. 1H NMR 
(500 MHz, CDCl3) δ 12.30 (s, 1H), 9.97 (s, 1H), 8.49 (d, J = 8.4 Hz, 1H), 7.70 (dd, J = 
7.6, 1.5 Hz, 1H), 7.51 (ddd, J = 8.7, 7.4, 1.7 Hz, 1H), 7.25 (t, J = 7.4 Hz, 1H), 7.15 (m, 
2H), 6.89 (m, 2H), 3.80 (s, 3H), 3.38 (t, J = 1.8 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
194.9, 162.1, 159.7, 158.9, 139.3, 136.3, 136.0, 135.8, 127.1, 123.9, 122.7, 120.1, 114.7, 
55.5, 39.1 (t, J = 21.5 Hz). HRMS (ESI) calcd for C17H16DN2O4
+ (MH+) 314.1246, found 
314.1255. 
 
 
 
 
4-Methoxy-N-(2H3)methylaniline (3.79ag-d3). Prepared according to a modified 
literature protocol [172]. 
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Step 1. N-(4-Methoxyphenyl)acetamide (4.6). To a solution of p-anisidine (3.74a; 
1.23 g, 10.0 mmol) in anhydrous DCM (120 mL), triethylamine (1.67 mL, 1.21 g, 
12.0 mmol) was added, followed by the dropwise addition of a solution of acetic 
anhydride (1.13 mL, 1.22 g, 12.0 mmol) in anhydrous DCM (30 mL). The mixture was 
stirred at ambient temperature overnight, and then volatiles were removed in vacuo. Solid 
residue was washed with water (50 mL), collected by filtration and dried to yield 1.40 g 
(85%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 7.38 (m, 2H), 7.13 (br s, 
1H), 6.85 (m, 2H), 3.79 (s, 3H), 2.15 (s, 3H). 
Step 2. N‐(4‐Methoxyphenyl)‐N‐(2H3)methylacetamide (4.7-d3). Under nitrogen, 4.6 
(0.731 g, 4.43 mmol) was dissolved in anhydrous THF (8 mL), the solution was cooled to 
0 °C and treated with sodium hydride (0.132 g, 5.50 mmol), followed by dropwise 
addition of iodomethane-d3 (0.33 mL, 0.77 g, 5.3 mmol). The mixture was stirred at 
ambient temperature overnight, after that it was partitioned between ethyl acetate 
(50 mL) and sat. aq. NH4Cl (10 mL). Product was extracted from aqueous layer with 
ethyl acetate (3×30 mL). The combined organic layers were washed with water 
(3×10 mL) and sat. aq. NaCl (10 mL), dried over anhydrous Na2SO4, and the solvent was 
removed in vacuo to yield 0.870 g of the title compound. The crude product was used for 
the next step without chromatographical purification. 1H NMR (500 MHz, CDCl3) δ 7.10 
(m, 2H), 6.91 (m, 2H), 3.83 (s, 3H), 1.85 (s, 3H). 
Step 3. 4-Methoxy-N-(2H3)methylaniline (3.79ag-d3) [173]. Crude 4.7-d3 was 
dissolved in ethylene glycol (3.33 mL) and treated with conc. HCl (1.11 mL). The 
mixture was refluxed for one day, after that it was partitioned between water (10 mL) and 
ethyl acetate (30 mL). 2N NaOH (4 mL) was added to the aqueous layer, and the product 
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was extracted with ethyl acetate (4×20 mL). The combined organic layers were washed 
with water (10 mL) and sat. aq. NaCl (10 mL), dried over anhydrous Na2SO4, and the 
solvent was removed in vacuo. Further purification by flash chromatography on silica gel 
(gradient elution: hexane → hexane–ethyl acetate 95:5) afforded 0.427 g (69% after two 
steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 6.81 (m, 2H), 6.60 (m, 2H), 
3.76 (s, 3H), 3.39 (br s, 1H). 13C NMR (126 MHz, CDCl3) δ 152.1, 143.8, 114.9, 113.6, 
55.9, 30.8 (sep, J = 20.6 Hz). HRMS (ESI) calcd for C8H8D3NOLi
+ (MLi+) 147.1183, 
found 147.1188. 
N'-(2-Formylphenyl)-N-(4-methoxyphenyl)-N-
(2H3)methylethanediamide (3.83ag-d3). 4-Methoxy-N-
(2H3)methylaniline (3.79ag-d3; 1.24 mmol) was coupled with 
oxalyl chloride (3.80; 19 mmol), and the resulting acyl chloride 
3.81ag-d3 was coupled with 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.885 mmol) according to 
general procedure C, with the following modifications: solution of 3.79ag-d3 in 
anhydrous DCM (10 mL) was added dropwise to a solution of oxalyl chloride in 
anhydrous DCM (50 mL) at 0 °C; second coupling step was performed in 6 mL of 
anhydrous DCM with DIPEA (1.9 mmol) as a base. Dioxolane protection was then 
removed according to general procedure E with 0.18 mmol of TsOH·H2O, which after 
flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 
80:20) afforded 0.205 g (73% after two steps) of the title compound. 1H NMR (500 MHz, 
CDCl3) δ 12.29 (s, 1H), 9.96 (d, J = 0.7 Hz, 1H), 8.48 (d, J = 8.4 Hz, 1H), 7.69 (dd, J = 
7.6, 1.7 Hz, 1H), 7.50 (ddd, J = 8.7, 7.4, 1.7 Hz, 1H), 7.24 (td, J = 7.5, 1.1 Hz, 1H), 7.14 
(m, 2H), 6.88 (m, 2H), 3.79 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.9, 162.1, 159.6, 
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158.9, 139.3, 136.3, 136.0, 135.8, 127.1, 123.9, 122.6, 120.1, 114.6, 55.5, 38.7 (sep, J = 
21.3 Hz). HRMS (ESI) calcd for C17H14D3N2O4
+ (MH+) 316.1371, found 316.1380. 
N'-Benzyl-N-(2-formylphenyl)-N'-(4-methoxyphenyl)ethanediamide (3.83ah). 
Step 1. N-Benzyl-4-methoxyaniline (3.79ah). General procedure A was 
followed on a 163 mmol scale of p-anisidine (3.74a) with 166 mmol of 
benzaldehyde (3.75h) in 250 mL of anhydrous DCM. The resulting imine 
was then reduced with 163 mmol of sodium borohydride in 250 mL of absolute methanol 
according to the same general procedure, which afforded 31.93 g of the title compound. 
The crude product was used for the next step without chromatographical purification. 
1H NMR (500 MHz, CDCl3) δ 7.35 (m, 4H), 7.28 (m, 1H), 6.78 (m, 2H), 6.61 (m, 2H), 
4.29 (s, 2H), 3.78 (br s, 1H), 3.74 (s, 3H). 
Step 2. N'-Benzyl-N-(2-formylphenyl)-N'-(4-methoxyphenyl) 
ethanediamide (3.83ah). 5.00 g of N-alkylaniline 3.79ah was 
coupled with oxalyl chloride (3.80; 236 mmol), and the resulting 
acyl chloride 3.81ah was coupled with 2-(1,3-dioxolan-2-yl)aniline 
(3.9; 21.1 mmol) according to general procedure C. Dioxolane protection was then 
removed according to general procedure E with 4.64 mmol of TsOH·H2O, which after 
flash chromatography on silica gel (gradient elution: hexane → ethyl acetate) afforded 
5.52 g (67% after two steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.33 
(s, 1H), 9.98 (s, 1H), 8.48 (d, J = 8.4 Hz, 1H), 7.69 (dd, J = 7.7, 1.6 Hz, 1H), 7.50 (ddd, J 
= 8.7, 7.4, 1.6 Hz, 1H), 7.26 (m, 6H), 6.94 (m, 2H), 6.79 (m, 2H), 4.97 (s, 2H), 3.77 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 195.0, 162.1, 159.8, 159.0, 139.4, 136.3, 136.1, 
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135.9, 134.5, 129.2, 128.7, 128.3, 127.9, 124.0, 122.7, 120.2, 114.4, 55.4, 55.2. HRMS 
(ESI) calcd for C23H21N2O4
+ (MH+) 389.1496, found 389.1500. 
N'-(2-Formylphenyl)-N-(4-methoxyphenyl)-N-[(thiophen-2-yl)methyl] 
ethanediamide (3.83ai). 
Step 1. 4-Methoxy-N-[(thiophen-2-yl)methyl]aniline (3.79ai). General 
procedure A was followed on a 12.1 mmol scale of p-anisidine (3.74a) 
with 12.7 mmol of 2-thiophenecarboxaldehyde (3.75i) in 20 mL of 
anhydrous DCM. The resulting imine was then reduced with 27.0 mmol of sodium 
cyanoborohydride in 20 mL of absolute methanol according to the same general 
procedure, which afforded 2.48 g of the title compound. The crude product was used for 
the next step without chromatographical purification. 1H NMR (500 MHz, CDCl3) δ 7.21 
(dd, J = 5.1, 1.2 Hz, 1H), 7.00 (dd, J = 3.4, 1.0 Hz, 1H), 6.96 (dd, J = 5.0, 3.5 Hz, 1H), 
6.79 (m, 2H), 6.65 (m, 2H), 4.47 (d, J = 0.8 Hz, 2H), 3.75 (s, 3H). 
Step 2. N'-(2-Formylphenyl)-N-(4-methoxyphenyl)-N-
[(thiophen-2-yl)methyl]ethanediamide (3.83ai). 0.228 g of 
N-alkylaniline 3.79ai was coupled with oxalyl chloride (3.80; 
16 mmol), and the resulting acyl chloride 3.81ai was coupled 
with 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.572 mmol) according to general procedure C, 
with the following modifications: solution of 3.79ai and TEA (1.0 mmol) in anhydrous 
DCM (6 mL) was added dropwise to a solution of oxalyl chloride in anhydrous DCM 
(20 mL); second coupling step was performed in 5 mL of anhydrous DCM with 
0.72 mmol of TEA. Dioxolane protection was then removed according to general 
procedure E with 0.11 mmol of TsOH·H2O, which after flash chromatography on silica 
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gel (gradient elution: hexane → hexane–ethyl acetate 85:15) afforded 0.157 g (69% after 
two steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.35 (s, 1H), 9.98 (d, J 
= 0.8 Hz, 1H), 8.47 (d, J = 8.4 Hz, 1H), 7.69 (dd, J = 7.6, 1.6 Hz, 1H), 7.51 (ddd, J = 8.8, 
7.7, 1.7 Hz, 1H), 7.24 (m, 2H), 6.99 (m, 2H), 6.91 (m, 2H), 6.83 (m, 2H), 5.09 (s, 2H), 
3.79 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.9, 161.7, 159.4, 159.2, 139.3, 138.0, 
136.1, 135.9, 134.2, 128.3, 126.7, 126.3, 124.0, 122.7, 120.2, 114.5, 100.1, 55.5, 49.9. 
HRMS (ESI) calcd for C21H19N2O4S
+ (MH+) 395.1060, found 395.1064. 
N-(Cyclopropylmethyl)-4-methoxyaniline (3.79aj) [174]. General 
procedure A was followed on a 11.2 mmol scale of p-anisidine (3.74a) 
with 11.2 mmol of cyclopropanecarboxaldehyde (3.75j) in 10 mL of 
anhydrous DCM. The resulting imine was then reduced with 16.8 mmol of sodium 
cyanoborohydride in 10 mL of absolute methanol according to the same general 
procedure, which after flash chromatography on silica gel (gradient elution: hexane → 
hexane–ethyl acetate 97:3) afforded 1.03 g (52%) of the title compound. 1H NMR (500 
MHz, CDCl3) δ 6.78 (m, 2H), 6.60 (m, 2H), 3.75 (s, 3H), 2.91 (d, J = 6.9 Hz, 2H), 1.09 
(m, 1H), 0.54 (m, 2H), 0.23 (m, 2H). 
N-(Cyclopropylmethyl)-N'-(2-formylphenyl)-N-(4-
methoxyphenyl)ethanediamide (3.83aj). 
N-(Cyclopropylmethyl)-4-methoxyaniline (3.79aj; 1.03 mmol) 
was coupled with oxalyl chloride (3.80; 10 mmol), and the 
resulting acyl chloride 3.81aj was coupled with 2-(1,3-dioxolan-2-yl)aniline (3.9; 
0.964 mmol) according to general procedure C. Dioxolane protection was then removed 
according to general procedure E with 0.19 mmol of TsOH·H2O, which after flash 
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chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 90:10) 
afforded 0.266 g (78% after two steps) of the title compound. 1H NMR (500 MHz, 
CDCl3) δ 12.27 (s, 1H), 9.97 (s, 1H), 8.49 (d, J = 8.4 Hz, 1H), 7.68 (dd, J = 7.6, 1.4 Hz, 
1H), 7.50 (ddd, J = 8.9, 7.5, 1.7 Hz, 1H), 7.24 (m, 1H), 7.18 (m, 2H), 6.88 (m, 2H), 3.80 
(s, 3H), 3.67 (d, J = 7.2 Hz, 2H), 1.07 (m, 1H), 0.48 (m, 2H), 0.21 (m, 2H). 13C NMR 
(126 MHz, CDCl3) δ 194.9, 161.9, 160.0, 159.0, 139.4, 136.0, 135.9, 134.9, 128.5, 123.9, 
122.7, 120.2, 114.4, 55.8, 55.5, 9.5, 3.9. HRMS (ESI) calcd for C20H20N2O4Na
+ (MNa+) 
375.1315, found 375.1324. 
N-(2,2-Dimethylpropyl)-N'-(2-formylphenyl)-N-(4-methoxyphenyl) 
ethanediamide (3.83al). 
Step 1. N-(2,2-Dimethylpropyl)-4-methoxyaniline (3.79al). General 
procedure B was followed on a 2.25 mmol scale of pivalaldehyde (3.75l) 
with 2.47 mmol of p-anisidine (3.74a; note: formation of insoluble solids 
was not observed), which afforded 0.443 g of the title compound. The crude product was 
used for the next step without chromatographical purification. 1H NMR (500 MHz, 
CDCl3) δ 6.77 (m, 2H), 6.59 (m, 2H), 3.74 (s, 3H), 2.84 (s, 2H), 0.98 (s, 9H).  
Step 2. N-(2,2-Dimethylpropyl)-N'-(2-formylphenyl)-N-(4-
methoxyphenyl)ethanediamide (3.83al). 0.243 g of N-alkylaniline 
3.79al was coupled with oxalyl chloride (3.80; 12 mmol), and the 
resulting acyl chloride 3.81al was coupled with 2-(1,3-dioxolan-
2-yl)aniline (3.9; 1.17 mmol) according to general procedure C. Dioxolane protection 
was then removed according to general procedure E, which after flash chromatography 
on silica gel (gradient elution: hexane → hexane–ethyl acetate 85:15) afforded 0.339 g 
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(79% after two steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 11.97 (s, 1H), 
9.94 (s, 1H), 8.45 (d, J = 8.4 Hz, 1H), 7.67 (dd, J = 7.6, 1.6 Hz, 1H), 7.51 (ddd, J = 8.8, 
7.5, 1.8 Hz, 1H), 7.23 (td, J = 7.6, 1.0 Hz, 1H), 7.20 (m, 2H), 6.83 (m, 2H), 3.77 (s, 3H), 
3.76 (s, 2H), 0.92 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 195.0, 163.7, 161.0, 158.7, 
139.5, 136.0, 135.9, 135.8, 128.1, 123.8, 122.5, 120.2, 114.4, 61.3, 55.5, 34.2, 28.6. 
HRMS (ESI) calcd for C21H25N2O4
+ (MH+) 369.1809, found 369.1813. 
 
 
 
 
 
N-(Cyclopent-2-en-1-yl)-4-methoxyaniline (3.79am). Solution of 3-bromo-
cyclopent-1-ene (3.77) in CCl4 was prepared from 40.0 mmol of cyclopentene (3.76) and 
10.0 mmol of NBS according to the reported procedure [175], and then reacted with 
27.5 mmol of p-anisidine (3.74a) according to the literature protocol [176], which after 
flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 
97:3) afforded 1.08 g (57% after two steps) of the title compound. 1H NMR (500 MHz, 
CDCl3) δ 6.78 (m, 2H), 6.61 (m, 2H), 5.95 (m, 1H), 5.85 (m, 1H), 4.49 (dd, J = 4.7, 2.2 
Hz, 1H), 3.75 (s, 3H), 3.35 (br s, 1H), 2.47 (tdq, J = 10.7, 6.0, 2.7 Hz, 1H), 2.33 (m, 2H), 
1.64 (ddq, J = 13.7, 9.7, 4.6 Hz, 1H).  
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N-(Cyclopent-2-en-1-yl)-N'-(2-formylphenyl)-N-(4-
methoxyphenyl)ethanediamide (3.83am). N-(Cyclopent-2-en-
1-yl)-4-methoxyaniline (3.79am; 2.00 mmol) was coupled with 
oxalyl chloride (3.80; 20 mmol), and the resulting acyl chloride 
3.81am was coupled with 2-(1,3-dioxolan-2-yl)aniline (3.9; 1.89 mmol) according to 
general procedure C. Dioxolane protection was then removed according to general 
procedure E, which after flash chromatography on silica gel (gradient elution: hexane → 
hexane–ethyl acetate 85:15) afforded 0.515 g (75% after two steps) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 12.18 (s, 1H), 9.96 (m, 1H), 8.45 (d, J = 8.5 
Hz, 1H), 7.68 (dd, J = 7.6, 1.6 Hz, 1H), 7.49 (ddd, J = 8.8, 7.4, 1.7 Hz, 1H), 7.23 (td, J = 
7.5, 1.0 Hz, 1H), 7.05 (m, 2H), 6.81 (m, 2H), 5.86 (ddt, J = 14.4, 6.2, 1.8 Hz, 2H), 5.69 
(dq, J = 5.6, 2.2 Hz, 1H), 3.78 (s, 3H), 2.32 (dtd, J = 14.1, 9.0, 5.4 Hz, 1H), 2.18 (dddq, J 
= 17.2, 9.0, 4.2, 2.1 Hz, 1H), 1.96 (dddd, J = 14.1, 11.5, 5.2, 2.6 Hz, 1H), 1.83 (ddt, J = 
13.2, 8.7, 4.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 195.0, 162.2, 160.2, 159.2, 139.5, 
136.3, 136.0, 135.9, 131.0, 130.4, 129.5, 123.8, 122.6, 120.2, 113.8, 63.5, 55.4, 31.6, 
27.9. HRMS (ESI) calcd for C21H20N2O4Na
+ (MNa+) 387.1315, found 387.1318. 
 
 
 
 
N-(4-Methoxyphenyl)-1-tosylindolin-3-amine (3.79an). Prepared according to a 
modified literature protocol [146]. In a high-pressure tube, 2-(2-bromophenyl)-1-
 170 
tosylaziridine [177] (3.78; 0.230 g, 0.653 mmol) and p-anisidine (3.74a; 0.084 g, 
0.69 mmol) were dissolved in anhydrous toluene (0.40 mL) under argon, and the solution 
was stirred at 65 °C overnight. After that, palladium acetate (0.031 g, 0.14 mmol), 
(±)-BINAP (0.165 g, 0.265 mmol), K2CO3 (0.227 g, 1.64 mmol) and anhydrous toluene 
(6.5 mL) were added under argon. The tube was sealed, and the mixture was stirred at 
120 °C overnight. Insoluble solids were filtered off, and toluene was removed in vacuo. 
Further purification by flash chromatography on 40–60 µm silica gel pre-treated with 
pyridine (gradient elution: hexane → hexane–ethyl acetate + 1% TEA 80:20) afforded 
0.153 g (59%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 
1H), 7.61 (m, 2H), 7.34 (tdd, J = 7.5, 1.3, 0.7 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.21 (m, 
2H), 7.05 (td, J = 7.5, 0.9 Hz, 1H), 6.77 (m, 2H), 6.40 (m, 2H), 4.79 (br m, 1H), 4.09 (dd, 
J = 11.7, 7.4 Hz, 1H), 3.83 (dd, J = 11.6, 3.5 Hz, 1H), 3.76 (s, 3H), 2.39 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 152.9, 144.3, 142.1, 139.9, 134.0, 132.7, 130.0, 129.9, 127.4, 
125.7, 124.4, 116.0, 115.1, 114.9, 56.7, 55.9, 54.3, 21.7. HRMS (ESI) calcd for 
C22H23N2O3S
+ (MH+) 395.1424, found 395.1433. 
N'‐(2‐Formylphenyl)‐N‐(4‐methoxyphenyl)‐N‐[1‐(4‐
methylbenzenesulfonyl)‐2,3‐dihydro‐1H‐indol‐3‐
yl]ethanediamide (3.83an). N-(4-Methoxyphenyl)-1-
tosylindolin-3-amine (3.79an; 0.342 mmol) was coupled 
with oxalyl chloride (3.80; 3.4 mmol), and the resulting acyl chloride 3.81an was coupled 
with 2-(1,3-dioxolan-2-yl)aniline (3.9; 0.325 mmol) according to general procedure C. 
Dioxolane protection was then removed according to general procedure E with 
0.13 mmol of TsOH·H2O, which after flash chromatography on silica gel (gradient 
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elution: hexane → hexane–ethyl acetate 70:30) afforded 0.158 g (85% after two steps) of 
the title compound. 1H NMR (500 MHz, CDCl3) δ 12.23 (s, 1H), 9.97 (s, 1H), 8.41 (d, J 
= 8.4 Hz, 1H), 7.69 (dd, J = 7.6, 1.5 Hz, 1H), 7.57 (m, 2H), 7.50 (m, 2H), 7.31 (d, J = 7.6 
Hz, 1H), 7.25 (m, 2H), 7.20 (m, 2H), 7.01 (td, J = 7.5, 0.8 Hz, 1H), 6.63 (br m, 4H), 6.37 
(dd, J = 8.5, 4.6 Hz, 1H), 4.04 (dd, J = 11.7, 4.6 Hz, 1H), 4.01 (dd, J = 11.7, 8.5 Hz, 1H), 
3.72 (s, 3H), 2.38 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 195.1, 162.8, 159.5, 159.4, 
144.4, 143.2, 139.2, 136.1, 136.0, 133.7, 130.3, 129.9, 129.7, 129.5, 128.5, 127.4, 126.8, 
124.1, 123.7, 122.6, 120.2, 114.1, 114.1, 56.0, 55.3, 53.2, 21.7. HRMS (ESI) calcd for 
C31H27N3O6SLi
+ (MLi+) 576.1775, found 576.1773. 
 
 
 
 
Methyl 2-(Benzylamino)-5-methoxybenzoate (3.79bh). Prepared according to a 
modified literature protocol [178]. Under nitrogen, methyl 2-methoxy-5-aminobenzoate 
(3.74b; 0.291 g, 1.61 mmol) was dissolved in absolute MeOH (4 mL), the solution was 
cooled to 0 °C and treated with benzaldehyde (3.75h; 0.33 mL, 0.34 g, 3.2 mmol), 
anhydrous ZnCl2 (0.374 g, 2.74 mmol) and sodium cyanoborohydride (0.172 g, 
2.74 mmol). The mixture was stirred at ambient temperature overnight. After that, the 
reaction was quenched with sat. aq. NH4Cl (5 mL), product was extracted with ethyl 
acetate (3×15 mL). The combined organic layers were washed with sat. aq. NaCl (5 mL), 
dried over anhydrous Na2SO4, and the solvent was removed in vacuo. Further purification 
by flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 
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97:3) afforded 0.277 g (63%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 7.84 
(t, J = 5.6 Hz, 1H), 7.45 (d, J = 3.0 Hz, 1H), 7.33 (m, 4H), 7.25 (m, 1H), 6.97 (dd, J = 
9.1, 3.1 Hz, 1H), 6.59 (d, J = 9.1 Hz, 1H), 4.42 (d, J = 5.6 Hz, 2H), 3.86 (s, 3H), 3.74 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 168.9, 149.6, 146.4, 139.4, 128.8, 127.2, 127.2, 
123.4, 114.6, 113.3, 110.2, 56.1, 51.7, 47.6. HRMS (ESI) calcd for C16H18NO3
+ (MH+) 
272.1281, found 272.1291. 
Methyl 2-{N-Benzyl-1-[(2-formylphenyl)carbamoyl] 
formamido}-5-methoxybenzoate (3.83bh). Methyl 2-
(benzylamino)-5-methoxybenzoate (3.79bh; 0.840 mmol) was 
coupled with oxalyl chloride (3.80; 8.4 mmol), and the 
resulting acyl chloride 3.81bh was coupled with 2-(1,3-dioxolan-2-yl)aniline (3.9; 
0.794 mmol) according to general procedure C. Dioxolane protection was then removed 
according to general procedure E, which after flash chromatography on silica gel 
(gradient elution: hexane → hexane–ethyl acetate 85:15) afforded 0.239 g (68% after two 
steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.53 (s, 1H), 10.00 (s, 1H), 
8.45 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 7.6 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H), 7.38 (d, J = 
2.4 Hz, 1H), 7.23 (m, 6H), 7.02 (dd, J = 8.8, 2.3 Hz, 1H), 6.99 (d, J = 8.7 Hz, 1H), 5.03 
(d, J = 13.9 Hz, 1H), 4.79 (d, J = 13.9 Hz, 1H), 3.83 (s, 3H), 3.63 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 194.6, 165.7, 161.4, 159.3, 158.4, 139.2, 135.9, 135.6, 135.6, 134.5, 
130.7, 129.8, 128.5, 128.4, 127.9, 123.7, 122.7, 120.0, 119.0, 115.6, 55.7, 55.5, 52.4. 
HRMS (ESI) calcd for C25H23N2O6
+ (MH+) 447.1551, found 447.1561. 
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N'-Benzyl-N'-(2,6-dimethoxyphenyl)-N-(2-formylphenyl)ethanediamide (3.83dh). 
Step 1. tert-Butyl 2,6-dimethoxyphenylcarbamate (4.9). Prepared according to a 
modified literature protocol [179]. Mixture of 2,6-dimethoxyaniline (3.74d; 0.620 g, 
4.05 mmol) and Boc2O (2.65 g, 12.2 mmol) was stirred at 70 °C for 4 h. Further 
purification by flash chromatography on silica gel (gradient elution: hexane → hexane–
ethyl acetate 80:20) afforded 0.916 g (89%) of the title compound. 1H NMR (500 MHz, 
CDCl3) δ 7.13 (t, J = 8.4 Hz, 1H), 6.57 (d, J = 8.4 Hz, 2H), 5.81 (br s, 1H), 3.84 (s, 6H), 
1.49 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 155.5, 154.2, 127.1, 115.2, 104.4, 79.9, 56.1, 
28.4. HRMS (ESI) calcd for C13H19LiNO4
+ (MLi+) 260.1469, found 260.1472. 
Step 2. N-Benzyl-2,6-dimethoxyaniline (3.79dh). Prepared according to a modified 
literature protocol [180]. Under argon, sodium hydride (0.107 g, 4.45 mmol) was 
suspended in anhydrous DMF (9 mL), the mixture was cooled to 0 °C, and then solution 
of 4.9 (0.916 g, 3.61 mmol) in anhydrous DMF (9 mL) was added dropwise. After 
stirring for 30 min, benzyl bromide (0.48 mL, 0.68 g, 4.0 mmol) was added, and the 
mixture was stirred at ambient temperature overnight. DMF was removed under high 
vacuum (50 °C/0.15 Torr), and the residue was partitioned between ethyl acetate (30 mL) 
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and water (15 mL). Product was extracted from aqueous layer with ethyl acetate 
(2×30 mL). The combined organic layers were washed with water (15 mL) and sat. aq. 
NaCl (15 mL), dried over anhydrous Na2SO4, and the solvent was removed in vacuo. 
Residue (crude 4.10) was redissolved in DCM (9 mL) and treated with TFA (9 mL) at 0 
°C. The mixture was stirred at ambient temperature overnight. After that, volatiles were 
removed in vacuo, the residue was redissolved in DCM (30 mL) and washed with 2 N 
NaOH (15 mL). Aqueous layer was extracted with DCM (2×20 mL). The combined 
organic layers were washed with water (15 mL) and sat. aq. NaCl (15 mL), dried over 
anhydrous Na2SO4, and the solvent was removed in vacuo to yield 0.954 g of 3.79dh. 
The crude product was used for the next step without chromatographical purification. 1H 
NMR (500 MHz, CDCl3) δ 7.33 (d, J = 7.1 Hz, 2H), 7.29 (t, J = 7.5 Hz, 2H), 7.22 (t, J = 
7.2 Hz, 1H), 6.81 (t, J = 8.3 Hz, 1H), 6.54 (d, J = 8.3 Hz, 2H), 4.41 (s, 2H), 3.81 (s, 6H). 
Step 3. N'-Benzyl-N'-(2,6-dimethoxyphenyl)-N-(2-formylphenyl)ethanediamide 
(3.83gh). 0.947 g of N-alkylaniline 3.79dh was coupled with oxalyl chloride (3.80; 
35 mmol), and the resulting acyl chloride 3.81dh was coupled with 2-(1,3-dioxolan-2-
yl)aniline (3.9; 3.39 mmol) according to general procedure C. Dioxolane protection was 
then removed according to general procedure E, which after flash chromatography on 
silica gel (gradient elution: hexane → hexane–ethyl acetate 60:40) afforded 1.22 g (86% 
after two steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.29 (s, 1H), 9.99 
(s, 1H), 8.52 (d, J = 8.5 Hz, 1H), 7.68 (dd, J = 7.6, 1.6 Hz, 1H), 7.48 (ddd, J = 8.7, 7.2, 
1.7 Hz, 1H), 7.21 (m, 6H), 7.16 (t, J = 8.4 Hz, 1H), 6.46 (d, J = 8.4 Hz, 2H), 4.92 (s, 2H), 
3.57 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 194.7, 163.1, 159.7, 155.6, 139.7, 136.6, 
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136.0, 135.7, 129.9, 128.8, 127.8, 127.4, 123.5, 122.7, 120.3, 119.5, 104.5, 56.0, 52.3. 
HRMS (ESI) calcd for C24H23N2O5
+ (MH+) 419.1601, found 419.1610. 
 
 
 
 
N'‐Benzyl‐N‐(2‐formylphenyl)‐N'‐(4‐hydroxyphenyl)ethanediamide (3.83eh). 
Prepared according to a modified literature protocol [147]. Under argon, 3.83ah (0.380 g, 
0.978 mmol) was dissolved in anhydrous DCM (12 mL), and the solution was cooled to –
78 °C. Solution of BBr3 (0.40 mL, 1.0 g, 4.0 mmol) in anhydrous DCM (24 mL) was 
added dropwise under argon over 1 h, maintaining the temperature below –60 °C. The 
mixture was stirred for 12 h (note: longer reaction time leads to formation of by-
products), after that it was cooled to 0 °C, carefully quenched with sat. aq. NaHCO3 
(20 mL) and stirred until effervescence ceased. The mixture was transferred to separatory 
funnel, shaken, and layers were separated. Aqueous layer was extracted with ethyl acetate 
(3×25 mL). The combined organic layers were washed with sat. aq. NaCl (20 mL), dried 
over anhydrous Na2SO4, and the solvent was removed in vacuo. Further purification by 
flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 
75:25) afforded 0.313 g (86%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 
12.34 (s, 1H), 9.97 (s, 1H), 8.46 (d, J = 8.4 Hz, 1H), 7.70 (dd, J = 7.6, 1.5 Hz, 1H), 7.51 
(ddd, J = 8.9, 7.4, 1.7 Hz, 1H), 7.27 (m, 6H), 6.87 (m, 2H), 6.67 (m, 2H), 5.25 (s, 1H), 
4.95 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 195.0, 162.2, 160.1, 155.6, 139.2, 136.2, 
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136.1, 136.0, 134.1, 129.2, 128.7, 128.4, 127.9, 124.2, 122.8, 120.2, 116.2, 55.1. HRMS 
(ESI) calcd for C22H19N2O4
+ (MH+) 375.1339, found 375.1349. 
N'-(2-Acetylphenyl)-N-benzyl-N-(4-methoxyphenyl) 
ethanediamide (3.84ah). 0.201 g of N-alkylaniline 3.79ah was 
coupled with oxalyl chloride (3.80; 9.4 mmol), and the resulting 
acyl chloride 3.81ah was coupled with 2'-aminoacetophenone 
(3.48; 0.889 mmol) according to general procedure C, which after flash chromatography 
on silica gel (gradient elution: hexane → hexane–ethyl acetate 80:20) afforded 0.321 g 
(90%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.82 (s, 1H), 8.47 (d, J = 
8.3 Hz, 1H), 7.89 (dd, J = 8.0, 1.3 Hz, 1H), 7.44 (ddd, J = 8.7, 7.3, 1.7 Hz, 1H), 7.28 (m, 
5H), 7.13 (m, 1H), 6.94 (m, 2H), 6.78 (m, 2H), 4.96 (s, 2H), 3.76 (s, 3H), 2.68 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 202.2, 162.5, 159.8, 158.8, 139.4, 136.3, 134.8, 134.5, 
131.6, 129.1, 128.5, 128.2, 127.7, 123.3, 122.7, 120.8, 114.3, 55.3, 54.9, 28.5. HRMS 
(ESI) calcd for C24H23N2O4
+ (MH+) 403.1652, found 403.1652. 
N'‐(2‐Acetylphenyl)‐N‐(2‐oxo‐2,3‐dihydro‐1H‐indol‐5‐yl)‐N‐[(pyridin‐3‐
yl)methyl]ethanediamide (3.84ck).  
Step 1. 5-(Pyridin-3-ylmethylamino)indolin-2-one (3.79ck). General 
procedure B was followed on a 1.91 mmol scale of nicotinaldehyde 
(3.75k) with 2.10 mmol of 5-aminooxindole (3.74c), with the one 
modification: insoluble solids after aqueous workup were combined with 
organic extracts. 0.483 g of the title compound was obtained. The crude product was used 
for the next step without chromatographical purification. 1H NMR (500 MHz, DMSO) δ 
9.95 (s, 1H), 8.56 (dd, J = 2.3, 0.8 Hz, 1H), 8.42 (dd, J = 4.8, 1.6 Hz, 1H), 7.73 (m, 1H), 
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7.33 (ddd, J = 7.8, 4.8, 0.8 Hz, 1H), 6.57 (d, J = 2.0 Hz, 1H), 6.54 (d, J = 8.3 Hz, 1H), 
6.39 (dd, J = 8.3, 2.1 Hz, 1H), 5.91 (t, J = 6.1 Hz, 1H), 4.24 (m, 2H), 3.32 (m, 2H).  
Step 2. N'‐(2‐Acetylphenyl)‐N‐(2‐oxo‐2,3‐dihydro‐1H‐indol‐5‐
yl)‐N‐[(pyridin‐3‐yl)methyl]ethanediamide (3.84ck). 
2'-Aminoacetophenone (3.48; 1.80 mmol) was coupled with 
oxalyl chloride (3.80; 18 mmol), and the resulting acyl 
chloride 3.82 was coupled with 0.231 g of N-alkylaniline 3.79ck according to general 
procedure D, with the following modifications: for the second coupling step, 3.79ck was 
used as solution in anhydrous DMF (10 mL); upon completion of the reaction, DMF was 
evaporated under high vacuum (50 °C/0.15 Torr), the crude product was redissolved in 
DCM (100 mL) and subjected to aqueous workup, as described in general procedure D. 
Further purification by flash chromatography on silica gel (gradient elution: chloroform 
→ chloroform–methanol 95:5) afforded 0.194 g (50% after two steps) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 12.95 (s, 1H), 9.20 (s, 1H), 8.53 (dd, J = 4.8, 
1.5 Hz, 1H), 8.42 (dd, J = 8.5, 0.9 Hz, 1H), 8.38 (d, J = 1.8 Hz, 1H), 7.90 (dd, J = 8.0, 1.4 
Hz, 1H), 7.76 (dt, J = 7.9, 1.9 Hz, 1H), 7.43 (ddd, J = 8.7, 7.5, 1.5 Hz, 1H), 7.26 (m, 1H), 
7.13 (ddd, J = 8.0, 7.4, 1.2 Hz, 1H), 6.92 (d, J = 2.1 Hz, 1H), 6.81 (dd, J = 8.2, 2.1 Hz, 
1H), 6.74 (d, J = 8.2 Hz, 1H), 4.96 (s, 2H), 3.46 (s, 2H), 2.67 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 202.4, 177.4, 162.3, 159.0, 150.2, 149.4, 142.6, 139.2, 137.2, 136.0, 
134.9, 131.9, 131.8, 126.9, 126.6, 123.8, 123.7, 123.5, 122.9, 120.8, 110.2, 52.9, 36.4, 
28.6. HRMS (ESI) calcd for C24H21N4O4
+ (MH+) 429.1557, found 429.1560. 
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tert‐Butyl N‐(4‐{1‐[(2‐acetylphenyl)carbamoyl]‐N‐[(2‐fluoropyridin‐3‐
yl)methyl]formamido}phenyl)carbamate (3.84fo).  
Step 1. tert-Butyl 4-((2-fluoropyridin-3-yl)methylamino)phenylcarbamate 
(3.79fo). General procedure A was followed on a 1.91 mmol scale of 
N-Boc-p-phenylenediamine (3.74f) with 2.00 mmol of 2-fluoro-3-
pyridinecarboxaldehyde (3.75o) in 7 mL of anhydrous DCM. The 
resulting imine was then reduced with 2.0 mmol of sodium borohydride in 10 mL of 
absolute methanol according to the same general procedure, which afforded 0.538 g of 
the title compound. The crude product was used for the next step without 
chromatographical purification. 1H NMR (500 MHz, MeOD) δ 8.05 (ddd, J = 4.9, 1.9, 
0.9 Hz, 1H), 7.90 (m, 1H), 7.24 (ddd, J = 7.0, 4.9, 1.7 Hz, 1H), 7.10 (br m, 2H), 6.56 (m, 
2H), 4.35 (s, 2H), 1.48 (s, 9H).  
Step 2. tert‐Butyl N‐(4‐{1‐[(2‐acetylphenyl)carbamoyl]‐N‐[(2‐
fluoropyridin‐3‐yl)methyl]formamido}phenyl) 
carbamate (3.84fo). 2'-Aminoacetophenone (3.48; 3.05 mmol) 
was coupled with oxalyl chloride (3.80; 30 mmol), and the 
resulting acyl chloride 3.82 was coupled with 0.535 g of N-alkylaniline 3.79fo according 
to general procedure D, which after flash chromatography on silica gel (gradient elution: 
hexane → hexane–ethyl acetate 55:45) afforded 0.687 g (71% after two steps) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 12.86 (s, 1H), 8.46 (d, J = 8.5 Hz, 1H), 8.13 
(d, J = 3.9 Hz, 1H), 7.96 (ddd, J = 9.4, 7.5, 2.0 Hz, 1H), 7.91 (dd, J = 8.0, 1.4 Hz, 1H), 
7.45 (ddd, J = 8.6, 7.4, 1.3 Hz, 1H), 7.32 (m, 2H), 7.19 (ddd, J = 6.9, 4.8, 1.5 Hz, 1H), 
7.14 (ddd, J = 8.3, 7.3, 1.1 Hz, 1H), 7.02 (m, 2H), 6.52 (s, 1H), 5.02 (s, 2H), 2.68 (s, 3H), 
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1.48 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 202.4, 163.0, 161.7 (d, J = 239.7 Hz), 159.2, 
152.5, 147.2 (d, J = 14.6 Hz), 141.9 (d, J = 4.7 Hz), 139.4, 138.4, 136.2, 135.0, 131.7, 
127.3, 123.6, 122.9, 121.9 (d, J = 4.3 Hz), 121.0, 118.9, 118.4 (d, J = 30.0 Hz), 81.0, 
48.2, 28.6, 28.4 (note: multiplet assignments for 2-fluoropyridine fragment were made in 
accordance with ref. [181]). HRMS (ESI) calcd for C27H28FN4O5
+ (MH+) 507.2038, 
found 507.2047. 
Methyl 2-((4-(tert-Butoxycarbonylamino)phenylamino)methyl) 
benzoate (3.79fp). General procedure A was followed on a 
2.39 mmol scale of N-Boc-p-phenylenediamine (3.74f) with 
2.52 mmol of methyl o-formylbenzoate (3.75p) in 10 mL of 
anhydrous DCM. The resulting imine was then reduced with 2.4 mmol of sodium 
borohydride in 10 mL of anhydrous methanol according to the same general procedure, 
with the following modifications: reaction mixture was stirred for 2 h (note: longer 
reaction time leads to reduced yield), after that methanol was evaporated, the crude 
product was partitioned between ethyl acetate (60 mL) and water (5 mL) and subjected to 
aqueous workup, as described in general procedure A. Further purification by flash 
chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 85:15) 
afforded 0.494 g (58%) of the title compound. 1H NMR (500 MHz, MeOD) δ 7.90 (dd, J 
= 7.8, 1.4 Hz, 1H), 7.52 (dd, J = 7.8, 1.0 Hz, 1H), 7.44 (td, J = 7.6, 1.4 Hz, 1H), 7.30 (td, 
J = 7.6, 1.2 Hz, 1H), 7.07 (br m, 2H), 6.53 (m, 2H), 4.58 (s, 2H), 3.88 (s, 3H), 1.47 (s, 
9H). 13C NMR (126 MHz, MeOD) δ 169.5, 156.1, 146.1, 143.1, 133.2, 131.7, 130.4, 
130.2, 130.1, 127.9, 122.4, 114.5, 80.3, 52.6, 47.9, 28.8. HRMS (ESI) calcd for 
C20H25N2O4
+ (MH+) 357.1809, found 357.1819. 
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Methyl 2-({1-[(2-Acetylphenyl)carbamoyl]-N-(4-{[(tert-
butoxy)carbonyl]amino}phenyl)formamido} 
methyl)benzoate (3.84fp). 2'-Aminoacetophenone (3.48; 
2.01 mmol) was coupled with oxalyl chloride (3.80; 
20 mmol), and the resulting acyl chloride 3.82 was coupled with N-alkylaniline 3.79fp 
(0.993 mmol) according to general procedure D, which after flash chromatography on 
silica gel (gradient elution: hexane → hexane–ethyl acetate 70:30) afforded 0.476 g 
(88%) of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.80 (s, 1H), 8.48 (d, J = 
8.4 Hz, 1H), 7.89 (td, J = 7.9, 1.3 Hz, 2H), 7.59 (d, J = 7.8 Hz, 1H), 7.51 (td, J = 7.6, 1.4 
Hz, 1H), 7.45 (ddd, J = 8.7, 7.3, 1.6 Hz, 1H), 7.32 (td, J = 7.8, 1.3 Hz, 1H), 7.26 (m, 2H), 
7.13 (ddd, J = 8.1, 7.4, 1.2 Hz, 1H), 7.01 (m, 2H), 6.48 (s, 1H), 5.46 (s, 2H), 3.80 (s, 3H), 
2.67 (s, 3H), 1.47 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 202.2, 167.6, 163.0, 159.9, 
152.5, 139.5, 137.9, 137.6, 136.7, 134.9, 132.6, 131.7, 130.9, 129.6, 129.2, 127.4, 127.3, 
123.5, 122.9, 121.0, 118.7, 80.9, 52.5, 52.2, 28.6, 28.4. HRMS (ESI) calcd for 
C30H32N3O7
+ (MH+) 546.2235, found 546.2231. 
tert-Butyl N-(4-{1-[(2-acetylphenyl)carbamoyl]-N-[(3,5-dimethoxyphenyl)methyl] 
formamido}phenyl)carbamate (3.84fq). 
Step 1. tert-Butyl 4-(3,5-dimethoxybenzylamino)phenylcarbamate 
(3.79fq). General procedure B was followed on a 1.90 mmol scale 
of 3,5-dimethoxybenzaldehyde (3.75q) with 2.09 mmol of N-Boc-
phenylenediamine (3.74f), which afforded 0.683 g of the title compound. The crude 
product was used for the next step without chromatographical purification. 1H NMR (500 
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MHz, CDCl3) δ 7.14 (br m, 2H), 6.58 (m, 2H), 6.52 (d, J = 2.3 Hz, 2H), 6.36 (t, J = 2.3 
Hz, 1H), 6.22 (br s, 1H), 4.24 (s, 2H), 3.77 (s, 6H), 1.49 (s, 9H). 
Step 2. tert-Butyl N-(4-{1-[(2-acetylphenyl)carbamoyl]-
N-[(3,5-dimethoxyphenyl)methyl]formamido} 
phenyl)carbamate (3.84fq). 2'-Aminoacetophenone 
(3.48; 2.33 mmol) was coupled with oxalyl chloride 
(3.80; 24 mmol), and the resulting acyl chloride 3.82 was coupled with 0.418 g of N-
alkylaniline 3.79fq according to general procedure D, which after flash chromatography 
on silica gel (gradient elution: hexane → hexane–ethyl acetate 65:35) afforded 0.578 g 
(91% after two steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 12.81 (s, 1H), 
8.44 (d, J = 8.4 Hz, 1H), 7.88 (dd, J = 8.0, 1.2 Hz, 1H), 7.42 (ddd, J = 8.7, 7.4, 1.6 Hz, 
1H), 7.28 (m, 2H), 7.11 (m, 1H), 6.97 (m, 2H), 6.65 (s, 1H), 6.42 (d, J = 2.2 Hz, 2H), 
6.35 (t, J = 2.2 Hz, 1H), 4.88 (s, 2H), 3.73 (s, 6H), 2.65 (s, 3H), 1.46 (s, 9H). 13C NMR 
(126 MHz, CDCl3) δ 202.2, 162.6, 160.9, 159.8, 152.6, 139.4, 138.6, 138.1, 136.4, 134.8, 
131.6, 127.6, 123.4, 122.8, 120.9, 118.7, 106.8, 100.0, 80.7, 55.4, 54.8, 28.5, 28.4. 
HRMS (ESI) calcd for C30H34N3O7
+ (MH+) 548.2391, found 548.2393. 
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Photochemical Reactions 
 
 
 
 
 
 
 
General Procedure F for the Photochemical Reaction. Photoprecursor (3.83, 3.84; 
0.394 mmol) was dissolved in DMSO (131 mL), and the solution was degassed by 
bubbling nitrogen or argon for 1 h. The mixture was irradiated with UV LED-based 
illuminator, seven 2.9 W @ 365 nm LED Engin chips (or two for 3.83ai) with the 
reaction progress monitored by 1H NMR. After completion, DMSO was evaporated 
under high vacuum (60 °C/0.15 Torr). Crude photoproducts 3.88fo and 3.88fp were 
directly subjected to the post-photochemical modifications according to general 
procedure G; in all other cases, photoproducts (3.87, 3.88) were purified by flash 
chromatography on silica gel. 
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Table 4.2: Irradiation Times 
Photoprecursor Photoproduct(s) 
LED 
power (W) 
Reaction 
Time (h) 
  
20  2.5 
  
20  4 
  
 6  7 
  
20  6 
  
20  6.5 
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Photoprecursor Photoproduct(s) 
LED 
power (W) 
Reaction 
Time (h) 
  
20  1.5 
  
20  2.5 
  
20  7.5 
  
20  2.5 
  
20  8.5 
  
20 32 
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Photoprecursor Photoproduct(s) 
LED 
power (W) 
Reaction 
Time (h) 
  
20 13 
  
20 25 
  
20 23 
  
20 31.5 
 
(±)-(1S,3R,4S,15S)‐4‐Hydroxy‐1‐methoxy‐11,14‐diazapentacyclo 
[12.3.1.03,15.05,10.011,15]octadeca‐5,7,9,16‐tetraene‐12,13‐dione (3.87ag). General 
procedure F was followed on a 0.103 g (0.330 mmol) scale of 3.83ag, which after flash 
chromatography on silica gel (gradient elution: DCM → DCM–methanol 98:2) afforded 
0.040 g (39%) of 3.87ag. 
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3.87ag: 1H NMR (500 MHz, CDCl3) δ 8.31 (d, J = 9.0 Hz, 1H), 
7.66 (d, J = 7.8 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.31 (t, J = 7.6 
Hz, 1H), 6.70 (d, J = 8.8 Hz, 1H), 6.16 (d, J = 8.8 Hz, 1H), 4.30 
(t, J = 9.9 Hz, 1H), 3.61 (d, J = 11.0 Hz, 1H), 3.51 (s, 3H), 3.47 
(dd, J = 10.9, 2.9 Hz, 1H), 2.34 (dd, J = 12.2, 9.4 Hz, 1H), 2.17 (td, J = 10.0, 4.0 Hz, 1H), 
2.02 (d, J = 9.8 Hz, 1H), 1.98 (dt, J = 12.8, 3.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
156.8, 155.0, 138.3, 132.0, 129.6, 128.9, 128.1, 127.8, 126.5, 120.6, 72.0, 69.1, 52.4, 
46.3, 45.6, 32.7, 31.1. HRMS (ESI) calcd for C17H17N2O4
+ (MH+) 313.1183, found 
313.1190. 
(±)-(1S,3R,4S,15S,18R)-4-Hydroxy-1-methoxy-18-phenyl-11,14-diazapentacyclo 
[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione (3.87ah). General 
procedure F was followed on a 0.153 g (0.394 mmol) scale of 3.83ah, which after flash 
chromatography on silica gel (gradient elution: hexane → hexane–ethyl acetate 50:50) 
afforded 0.054 g (35%) of 3.87ah. 
3.87ah: 1H NMR (500 MHz, DMSO) δ 8.25 (d, J = 8.2 Hz, 1H), 
7.65 (d, J = 8.0 Hz, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.35 (m, 6H), 
7.02 (d, J = 8.8 Hz, 1H), 6.42 (d, J = 8.8 Hz, 1H), 6.00 (d, J = 
7.2 Hz, 1H), 4.78 (s, 1H), 4.16 (dd, J = 10.0, 7.3 Hz, 1H), 3.43 (s, 3H), 2.63 (td, J = 9.9, 
4.1 Hz, 1H), 1.76 (dd, J = 12.6, 9.4 Hz, 1H), 1.62 (ddd, J = 13.2, 4.1, 1.4 Hz, 1H). 13C 
NMR (126 MHz, DMF) δ 157.9, 155.9, 138.8, 134.5, 133.7, 132.0, 131.0, 129.4, 129.3, 
129.3, 129.1, 128.9, 126.5, 120.1, 80.7, 71.7, 70.6, 60.8, 52.9, 44.1, 28.9. HRMS (ESI) 
calcd for C23H20N2O4Na
+ (MNa+) 411.1315, found 411.1321. 
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(±)-(1S,3R,4S,15S,18S)-4-Hydroxy-1-methoxy-18-(thiophen-2-yl)-11,14-
diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione 
(3.87ai). General procedure F was followed on a 0.143 g (0.362 mmol) scale of 3.83ai, 
which after flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl 
acetate 65:35) afforded 0.052 g (36%) of 3.87ai.  
3.87ai: 1H NMR (500 MHz, CDCl3) δ 8.48 (dd, J = 8.2, 1.3 Hz, 
1H), 7.67 (d, J = 7.9 Hz, 1H), 7.47 (td, J = 7.7, 1.4 Hz, 1H), 
7.32 (m, 2H), 7.02 (m, 2H), 6.86 (dd, J = 8.6, 0.9 Hz, 1H), 6.28 
(dd, J = 8.9, 1.3 Hz, 1H), 5.08 (d, J = 1.9 Hz, 1H), 4.34 (t, J = 
10.0 Hz, 1H), 3.55 (s, 3H), 2.39 (dt, J = 9.8, 4.4 Hz, 1H), 2.28 (dd, J = 12.5, 9.4 Hz, 1H), 
1.84 (d, J = 9.6 Hz, 1H), 1.79 (ddd, J = 13.0, 4.3, 1.7 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ 156.3, 155.2, 138.1, 135.3, 132.0, 129.7, 129.6, 128.8, 127.8, 127.1, 127.1, 
126.4, 125.9, 120.0, 79.8, 72.0, 69.6, 56.1, 52.6, 44.1, 29.0. HRMS (ESI) calcd for 
C21H19N2O4S
+ (MH+) 395.1060, found 395.1068. 
(±)-(1S,3R,4S,15S,18S)-18-Cyclopropyl-4-hydroxy-1-methoxy-11,14-
diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione (3.87aj) 
and (±)-(1S,3R,4S,15S,18R)-18-Cyclopropyl-4-hydroxy-1-methoxy-11,14-
diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione 
(3.87aj'). General procedure F was followed on a 0.214 g (0.607 mmol) scale of 3.83aj, 
which after flash chromatography on silica gel (gradient elution: hexane → ethyl acetate) 
afforded 0.103 g (48%) of 3.87aj and 0.020 g (9%) of 3.87aj'.  
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3.87aj: 1H NMR (500 MHz, DMSO) δ 7.97 (dd, J = 8.2, 1.2 Hz, 
1H), 7.62 (dt, J = 8.0, 1.3 Hz, 1H), 7.43 (dddd, J = 8.2, 7.4, 1.7, 
0.7 Hz, 1H), 7.32 (td, J = 7.6, 1.3 Hz, 1H), 6.65 (d, J = 8.8 Hz, 
1H), 6.31 (dd, J = 8.8, 0.9 Hz, 1H), 5.86 (d, J = 7.8 Hz, 1H), 4.08 (dd, J = 10.5, 7.8 Hz, 
1H), 3.54 (dd, J = 8.4, 0.9 Hz, 1H), 3.41 (s, 3H), 2.28 (dd, J = 11.6, 9.5 Hz, 1H), 2.11 (td, 
J = 10.4, 4.1 Hz, 1H), 1.77 (dd, J = 12.2, 3.6 Hz, 1H), 0.77 (m, 1H), 0.50 (m, 4H). 13C 
NMR (126 MHz, DMSO) δ 157.1, 153.9, 138.0, 131.7, 131.1, 128.2, 128.1, 126.7, 125.7, 
120.3, 79.7, 70.1, 69.2, 63.0, 51.3, 45.7, 30.0, 10.6, 4.5, 3.1. HRMS (ESI) calcd for 
C20H21N2O4
+ (MH+) 353.1496, found 353.1505.  
3.87aj': 1H NMR (500 MHz, DMSO) δ 8.25 (dd, J = 8.2, 1.0 Hz, 
1H), 7.63 (dt, J = 7.8, 1.3 Hz, 1H), 7.42 (dddd, J = 8.2, 7.3, 1.6, 
0.7 Hz, 1H), 7.30 (td, J = 7.6, 1.2 Hz, 1H), 6.86 (d, J = 8.8 Hz, 
1H), 6.29 (dd, J = 8.8, 1.1 Hz, 1H), 5.96 (d, J = 7.6 Hz, 1H), 4.08 (dd, J = 10.3, 7.6 Hz, 
1H), 3.42 (s, 3H), 3.32 (m, 1H, overlaps with HDO), 2.47 (t, J = 12.6, 9.3 Hz, 1H), 2.29 
(td, J = 9.6, 4.5 Hz, 1H), 1.70 (ddd, J = 12.6, 4.2, 1.4 Hz, 1H), 1.01 (dddd, J = 13.4, 10.1, 
6.5, 4.1 Hz, 1H), 0.72 (ddt, J = 9.4, 4.5, 1.9 Hz, 1H), 0.60 (m, 1H), 0.52 (m, 2H). 13C 
NMR (126 MHz, DMSO) δ 156.3, 155.4, 137.5, 131.8, 130.4, 129.3, 128.2, 128.0, 125.4, 
118.5, 79.3, 70.1, 69.1, 58.8, 51.8, 41.8, 29.5, 9.3, 3.0, 2.4. HRMS (ESI) calcd for 
C20H21N2O4
+ (MH+) 353.1496, found 353.1505. 
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(±)-(1S,3R,4S,15S,18R)-18-tert-Butyl-4-hydroxy-1-methoxy-11,14-
diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione (3.87al) 
and (±)-(1S,3R,4S,15S,18S)-18-tert-butyl-4-hydroxy-1-methoxy-11,14-
diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione 
(3.87al'). General procedure F was followed on a 0.276 g (0.750 mmol) scale of 3.83al, 
which after flash chromatography on silica gel (gradient elution: chloroform → 
chloroform–methanol 98:2) afforded 0.074 g (27%) of 3.87al and crude 3.87al' which 
was additionally purified by flash chromatography on silica gel (gradient elution: hexane 
→ ethyl acetate) to yield 0.027 g (10%) of pure 3.87al'.  
3.87al: 1H NMR (500 MHz, CDCl3) δ 8.52 (dd, J = 8.3, 1.1 Hz, 
1H), 7.66 (dt, J = 7.8, 1.3 Hz, 1H), 7.40 (tdd, J = 8.2, 1.6, 0.8 Hz, 
1H), 7.27 (td, J = 7.6, 1.2 Hz, 1H), 6.67 (dd, J = 8.6, 1.0 Hz, 
1H), 6.12 (dd, J = 8.6, 1.1 Hz, 1H), 4.30 (t, J = 9.5 Hz, 1H), 3.68 (d, J = 1.9 Hz, 1H), 
3.45 (s, 3H), 2.66 (ddd, J = 12.8, 8.8, 0.9 Hz, 1H), 2.56 (d, J = 9.0 Hz, 1H), 2.34 (dddd, J 
= 10.2, 8.9, 4.8, 1.1 Hz, 1H), 1.82 (ddd, J = 13.0, 4.8, 2.1 Hz, 1H), 1.25 (s, 9H). 13C NMR 
(126 MHz, CDCl3) δ 157.6, 156.3, 139.9, 132.0, 130.3, 129.5, 128.5, 127.5, 126.1, 119.3, 
80.8, 72.3, 70.3, 63.1, 51.9, 42.1, 36.4, 31.0, 30.8. HRMS (ESI) calcd for C21H25N2O4
+ 
(MH+) 369.1809, found 369.1805.  
3.87al': 1H NMR (500 MHz, DMSO) δ 7.76 (dd, J = 8.2, 1.2 Hz, 
1H), 7.61 (d, J = 7.8 Hz, 1H), 7.44 (td, J = 7.8, 1.7 Hz, 1H), 7.34 
(td, J = 7.6, 1.3 Hz, 1H), 6.71 (d, J = 8.9 Hz, 1H), 6.22 (d, J = 
9.0 Hz, 1H), 5.80 (d, J = 8.0 Hz, 1H), 4.10 (s, 1H), 4.03 (dd, J = 10.6, 7.9 Hz, 1H), 3.39 
(s, 3H), 2.31 (dd, J = 12.5, 9.3 Hz, 1H), 1.93 (td, J = 10.0, 3.2 Hz, 1H), 1.73 (dd, J = 
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12.5, 3.5 Hz, 1H), 1.05 (s, 9H). 13C NMR (126 MHz, DMSO) δ 157.7, 155.0, 138.1, 
131.6, 131.6, 128.2, 128.1, 126.1, 124.1, 121.8, 80.5, 70.5, 70.3, 65.6, 50.8, 48.6, 37.0, 
31.2, 30.8. HRMS (ESI) calcd for C21H25N2O4
+ (MH+) 369.1809, found 369.1812. 
(±)-(1S,1'S,3'R,4'S,15'R)-4'-Hydroxy-1'-methoxy-11',14'-diazaspiro 
[cyclopentane-1,18'-pentacyclo[12.3.1.03,15.05,10.011,15]octadecane]-2,5',7',9',16'-
pentaene-12',13'-dione (3.87am) and (±)-(1R,1'S,3'R,4'S,15'R)-4'-Hydroxy-1'-
methoxy-11',14'-diazaspiro[cyclopentane-1,18'-pentacyclo[12.3.1.03,15.05,10.011,15] 
octadecane]-2,5',7',9',16'-pentaene-12',13'-dione (3.87am'). General procedure F was 
followed on a 0.160 g (0.439 mmol) scale of 3.83am, which after flash chromatography 
on silica gel (gradient elution: DCM → DCM–methanol 90:10) afforded 0.084 g (53%) 
of 3.87am and 3.87am' as an inseparable mixture of diastereomers (one pure fraction 
was obtained; the structure was determined as 3.87am on the basis of NOE correlation 
between low-field cyclohexene and high-field cyclopentene alkenic protons [130]).  
3.87am: 1H NMR (500 MHz, DMSO) δ 8.04 (dd, J = 8.2, 1.0 
Hz, 1H), 7.63 (dt, J = 8.0, 1.2 Hz, 1H), 7.42 (td, J = 7.8, 1.6 Hz, 
1H), 7.31 (td, J = 7.6, 1.2 Hz, 1H), 6.86 (d, J = 8.9 Hz, 1H), 6.34 
(dd, J = 8.9, 1.1 Hz, 1H), 6.05 (dt, J = 5.3, 2.1 Hz, 1H), 5.91 (d, 
J = 7.5 Hz, 1H), 5.12 (dt, J = 5.6, 2.0 Hz, 1H), 4.10 (dd, J = 10.3, 7.6 Hz, 1H), 3.40 (s, 
3H), 2.68 (m, 1H), 2.39 (m, 2H), 2.29 (td, J = 9.5, 3.3 Hz, 1H), 2.12 (dd, J = 12.6, 9.3 Hz, 
1H), 2.05 (m, 1H), 1.95 (dd, J = 12.8, 4.1 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 156.9, 
152.7, 137.4, 137.1, 131.7, 130.8, 128.2, 128.0, 128.0, 127.4, 125.4, 119.7, 79.8, 75.3, 
70.2, 69.5, 51.9, 43.9, 32.0, 28.2, 27.8. HRMS (ESI) calcd for C21H21N2O4
+ (MH+) 
365.1496, found 365.1505. 
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(±)-(1'S,3S,3'R,4'S,15'R)-4'-Hydroxy-1'-methoxy-1-(4-methylbenzenesulfonyl)-
1,2-dihydro-11',14'-diazaspiro[indole-3,18'-pentacyclo[12.3.1.03,15.05,10.011,15] 
octadecane]-5',7',9',16'-tetraene-12',13'-dione (3.87an) and (±)-(1'S,3R,3'R,4'S,15'R)-
4'-Hydroxy-1'-methoxy-1-(4-methylbenzenesulfonyl)-1,2-dihydro-11',14'-
diazaspiro[indole-3,18'-pentacyclo[12.3.1.03,15.05,10.011,15]octadecane]-5',7',9',16'-
tetraene-12',13'-dione (3.87an'). General procedure F was followed on a 0.151 g 
(0.265 mmol) scale of 3.83an, which after flash chromatography on silica gel (gradient 
elution: chloroform → chloroform–methanol 97:3) afforded 0.061 g (40%) of 3.87an and 
3.87an' as an inseparable mixture of diastereomers.  
3.87an or 3.87an': 1H NMR (500 MHz, DMSO) δ 8.12 (dd, J 
= 8.2, 1.1 Hz, 1H), 7.79 (m, 2H), 7.65 (dt, J = 8.0, 1.3 Hz, 1H), 
7.49 (dd, J = 8.4, 0.9 Hz, 1H), 7.44 (tdd, J = 8.1, 1.6, 0.6 Hz, 
1H), 7.40 (m, 2H), 7.32 (m, 2H), 7.25 (dd, J = 7.7, 1.2 Hz, 
1H), 7.02 (td, J = 7.6, 1.0 Hz, 1H), 6.99 (dd, J = 8.9, 0.5 Hz, 1H), 6.47 (dd, J = 8.8, 0.8 
Hz, 1H), 5.99 (d, J = 7.2 Hz, 1H), 4.15 (dd, J = 10.1, 7.2 Hz, 1H), 4.15 (d, J = 11.1 Hz, 
1H), 4.04 (d, J = 11.1 Hz, 1H), 2.94 (s, 3H), 2.69 (td, J = 9.5, 3.9 Hz, 1H), 2.37 (s, 3H), 
2.19 (dd, J = 12.9, 9.2 Hz, 1H), 1.84 (dd, J = 13.3, 4.2 Hz, 1H). 13C NMR (126 MHz, 
DMSO) δ 156.5, 153.0, 144.1, 143.1, 137.2, 134.1, 131.9, 130.9, 130.6, 130.1, 129.7, 
128.2, 128.1, 127.4, 126.2, 125.5, 125.2, 122.9, 119.4, 112.8, 81.2, 70.1, 69.5, 67.2, 54.7, 
51.6, 43.2, 25.6, 21.0. HRMS (ESI) calcd for C31H28N3O6S
+ (MH+) 570.1693, found 
570.1692. 
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(±)-Methyl (1S,3R,4S,15R,18R)-4-Hydroxy-1-methoxy-12,13-dioxo-18-phenyl-
11,14-diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-16-
carboxylate (3.87bh) and (±)-Methyl (1S,3S,4R,15S,18R)-4-Hydroxy-1-methoxy-
12,13-dioxo-18-phenyl-11,14-diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-
5,7,9,16-tetraene-3-carboxylate (3.87bh'): General procedure F was followed on a 
0.233 g (0.522 mmol) scale of 3.83bh, which after flash chromatography on silica gel 
(gradient elution: DCM → DCM–methanol 90:10) afforded 0.116 g (50%) of 3.87bh' 
and 0.078 g (33%) of 3.87bh.  
3.87bh': 1H NMR (500 MHz, DMSO) δ 8.28 (dd, J = 8.3, 1.3 
Hz, 1H), 7.81 (s, 1H), 7.59 (dt, J = 7.8, 1.3 Hz, 1H), 7.41 (m, 
3H), 7.37 (m, 3H), 7.26 (td, J = 7.6, 1.1 Hz, 1H), 5.97 (d, J = 7.2 
Hz, 1H), 4.89 (d, J = 1.2 Hz, 1H), 4.05 (dd, J = 10.6, 7.2 Hz, 
1H), 3.48 (s, 3H), 3.46 (s, 3H), 2.77 (ddd, J = 10.7, 9.1, 4.7 Hz, 1H), 1.78 (dd, J = 12.9, 
9.1 Hz, 1H), 1.73 (dd, J = 13.1, 4.1 Hz, 1H). 13C NMR (126 MHz, DMF) δ 161.6, 157.1, 
155.1, 146.8, 134.8, 133.0, 132.3, 130.6, 128.7, 128.4, 128.3, 128.3, 127.8, 125.2, 119.0, 
79.9, 70.4, 70.2, 59.1, 52.5, 51.9, 43.5, 26.9. HRMS (ESI) calcd for C25H23N2O6
+ (MH+) 
447.1551, found 447.1557.  
3.87bh: 1H NMR (500 MHz, DMSO) δ 8.25 (dd, J = 8.2, 1.2 Hz, 
1H), 7.61 (dt, J = 7.8, 1.2 Hz, 1H), 7.48 (t, J = 7.4 Hz, 1H), 7.39 
(m, 2H), 7.32 (m, 2H), 7.14 (d, J = 8.6 Hz, 1H), 7.03 (m, 2H), 
6.49 (d, J = 6.6 Hz, 1H), 6.33 (d, J = 8.6 Hz, 1H), 4.85 (s, 1H), 
4.57 (d, J = 6.6 Hz, 1H), 3.51 (s, 3H), 3.48 (s, 3H), 2.23 (d, J = 13.5 Hz, 1H), 2.15 (dd, J 
= 13.6, 1.5 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 169.8, 156.2, 155.9, 138.0, 132.9, 
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132.0, 130.4, 128.4, 128.3, 128.0, 127.9, 127.8, 127.7, 125.3, 118.6, 79.1, 72.9, 69.5, 
59.5, 52.3, 52.2, 49.8, 31.2. HRMS (ESI) calcd for C25H23N2O6
+ (MH+) 447.1551, found 
447.1558. 
(±)-(1R,3S,4R,15S,18S)-4-Hydroxy-3,16-dimethoxy-18-phenyl-11,14-
diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione 
(3.87dh). General procedure F was followed on a 0.313 g (0.748 mmol) scale of 3.83dh, 
which after flash chromatography on silica gel (gradient elution: DCM → DCM–
methanol 97:3) afforded 0.234 g (75%) of 3.87dh.  
3.87dh: 1H NMR (500 MHz, DMSO) δ 8.21 (dd, J = 8.2, 1.1 Hz, 
1H), 7.64 (dt, J = 7.8, 1.4 Hz, 1H), 7.38 (m, 5H), 7.30 (m, 2H), 
6.39 (d, J = 6.7 Hz, 1H), 5.49 (d, J = 7.4 Hz, 1H), 4.81 (d, J = 2.6 
Hz, 1H), 4.50 (d, J = 6.7 Hz, 1H), 3.46 (s, 3H), 3.24 (s, 3H), 3.20 
(dq, J = 7.8, 2.8 Hz, 1H), 1.78 (ddd, J = 14.0, 3.5, 1.0 Hz, 1H), 1.69 (dd, J = 14.1, 2.5 Hz, 
1H). 13C NMR (126 MHz, DMSO) δ 157.4, 155.3, 155.2, 135.7, 133.4, 129.1, 128.2, 
127.6, 127.3, 127.1, 126.9, 125.1, 118.0, 98.1, 74.0, 73.9, 73.3, 59.5, 56.1, 53.7, 37.1, 
23.6. HRMS (ESI) calcd for C24H23N2O5
+ (MH+) 419.1601, found 419.1606. 
(±)-(1S,3R,4S,15S,18R)-1,4-Dihydroxy-18-phenyl-11,14-diazapentacyclo 
[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione (3.87eh). General 
procedure F was followed on a 0.137 g (0.365 mmol) scale of 3.83eh, which after flash 
chromatography on silica gel (gradient elution: chloroform → chloroform–methanol 
97:3) afforded 0.085 g (62%) of 3.87eh.  
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3.87eh: 1H NMR (500 MHz, DMF) δ 8.34 (dd, J = 8.2, 1.1 Hz, 
1H), 7.77 (dt, J = 7.8, 1.1 Hz, 1H), 7.53 (m, 2H), 7.49 (dddd, J = 
8.1, 7.4, 1.6, 0.7 Hz, 1H), 7.38 (m, 4H), 6.77 (dd, J = 8.5, 0.7 Hz, 
1H), 6.42 (dd, J = 8.5, 1.0 Hz, 1H), 6.21 (s, 1H), 6.07 (d, J = 7.2 
Hz, 1H), 4.59 (d, J = 1.5 Hz, 1H), 4.35 (dd, J = 10.4, 7.2 Hz, 1H), 2.71 (td, J = 9.8, 3.9 
Hz, 1H), 2.05 (dd, J = 12.9, 9.2 Hz, 1H), 1.60 (ddd, J = 12.9, 4.1, 1.5 Hz, 1H). 13C NMR 
(126 MHz, DMF) δ 157.2, 155.1, 143.4, 133.8, 132.9, 131.4, 128.7, 128.6, 128.4, 128.4, 
128.2, 127.9, 125.6, 119.3, 74.1, 71.0, 70.1, 62.6, 43.8, 31.0. HRMS (ESI) calcd for 
C22H19N2O4
+ (MH+) 375.1339, found 375.1351. 
(±)-(1S,3R,4S,15S,18R)-4-Hydroxy-1-methoxy-4-methyl-18-phenyl-11,14-
diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-5,7,9,16-tetraene-12,13-dione 
(3.88ah). General procedure F was followed on a 0.284 g (0.706 mmol) scale of 3.84ah, 
which after flash chromatography on silica gel (gradient elution: hexane → hexane–ethyl 
acetate 50:50) afforded 0.115 g (40%) of 3.88ah.  
3.88ah: 1H NMR (500 MHz, CDCl3) δ 8.33 (dd, J = 8.2, 1.0 Hz, 
1H), 7.68 (dd, J = 7.9, 1.3 Hz, 1H), 7.38 (ddd, J = 8.3, 7.4, 1.6 
Hz, 1H), 7.34 (m, 3H), 7.29 (m, 1H), 7.26 (m, 2H), 6.82 (d, J = 
8.7 Hz, 1H), 6.27 (dd, J = 8.7, 0.8 Hz, 1H), 4.70 (s, 1H), 3.46 (s, 3H), 2.83 (t, J = 7.3 Hz, 
1H), 2.31 (s, 1H), 1.94 (d, J = 7.5 Hz, 2H), 1.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
157.2, 155.0, 137.2, 134.1, 131.9, 131.0, 129.6, 129.2, 128.6, 128.5, 127.9, 127.6, 126.6, 
120.6, 79.7, 71.6, 69.9, 60.0, 52.6, 48.1, 28.5, 24.0. HRMS (ESI) calcd for 
C24H22N2O4Na
+ (MNa+) 425.1472, found 425.1475. 
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(±)-(1R,5S,6R,7S,18S,21R)-7-Hydroxy-7-methyl-21-(pyridin-3-yl)-2,14,17-
triazahexacyclo[15.3.1.01,5.06,18.08,13.014,18]henicosa-8,10,12,19-tetraene-3,15,16-trione 
(3.88ck) and (±)-(3R,4S,15S,21R)-4-Hydroxy-4-methyl-21-(pyridin-3-yl)-11,14,20-
triazahexacyclo[12.6.1.01,17.03,15.05,10.011,15]henicosa-5,7,9,16-tetraene-12,13,19-trione 
(3.88ck'). General procedure F was followed on a 0.164 g (0.383 mmol) scale of 3.84ck, 
which after flash chromatography on silica gel (gradient elution: chloroform → 
chloroform–methanol 90:10) afforded 0.065 g (40%) of 3.88ck and 0.050 g (30%) of 
3.88ck'.  
3.88ck: 1H NMR (500 MHz, DMSO) δ 8.67 (d, J = 2.2 Hz, 
1H), 8.55 (s, 1H), 8.54 (dd, J = 4.9, 1.6 Hz, 1H), 8.30 (dd, J = 
8.3, 1.2 Hz, 1H), 7.89 (dt, J = 8.0, 2.3 Hz, 1H), 7.68 (dd, J = 
7.9, 1.5 Hz, 1H), 7.41 (m, 2H), 7.32 (td, J = 7.6, 1.3 Hz, 1H), 
6.75 (d, J = 8.3 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H), 5.62 (s, 1H), 4.69 (s, 1H), 3.29 (m, 
1H), 2.50 (m, 2H, overlaps with DMSO), 2.21 (m, 1H), 1.41 (s, 3H). 13C NMR (126 
MHz, DMSO) δ 176.0, 157.1, 155.9, 149.6, 149.1, 137.4, 136.7, 135.7, 132.4, 131.2, 
127.7, 126.6, 125.6, 123.1, 123.1, 119.1, 71.8, 71.1, 63.1, 58.5, 47.5, 36.0, 32.9, 32.1. 
HRMS (ESI) calcd for C24H21N4O4
+ (MH+) 429.1557, found 429.1561.  
3.88ck': 1H NMR (500 MHz, DMSO) δ 8.60 (d, J = 4.8 Hz, 
1H), 8.58 (s, 1H), 8.38 (s, 1H), 8.18 (d, J = 8.1 Hz, 1H), 7.78 (d, 
J = 7.9 Hz, 1H), 7.71 (d, J = 7.5 Hz, 1H), 7.44 (m, 2H), 7.33 (t, 
J = 7.3 Hz, 1H), 6.29 (t, J = 2.0 Hz, 1H), 5.42 (s, 1H), 4.72 (s, 
1H), 3.28 (dd, J = 22.4, 2.3 Hz, 1H), 3.13 (dd, J = 22.2, 2.1 Hz, 1H), 3.06 (dd, J = 9.4, 
5.1 Hz, 1H), 1.96 (dd, J = 13.6, 9.9 Hz, 1H), 1.54 (dd, J = 13.7, 4.3 Hz, 1H), 1.25 (s, 3H). 
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13C NMR (126 MHz, DMSO) δ 174.6, 157.0, 154.4, 149.2, 148.8, 144.4, 136.1, 135.0, 
130.9, 128.3, 127.8, 127.8, 125.8, 123.6, 120.8, 119.6, 70.6, 70.2, 63.5, 59.2, 47.1, 33.1, 
28.3, 25.6. HRMS (ESI) calcd for C24H21N4O4
+ (MH+) 429.1557, found 429.1560. 
Post-Photochemical Modifications 
 
 
 
 
 
 
 
 
 
 
 
 
General Procedure G for Acid-Promoted Dehydration/Cyclization. The crude 
photoproduct (0.395 mmol) was dissolved in TFA (8 mL). Solution was refluxed or 
stirred in a sealed tube at 80 °C for 1 day. Volatiles were removed in vacuo, and the 
residue was redissolved in DCM (50 mL). Solution was washed 2 times with sat. aq. 
NaHCO3 (5 mL) diluted with water (5 mL). Aqueous layer was extracted with DCM 
(2×10 mL). The combined organic layers were washed with water (10 mL) and sat. aq. 
NaCl (10 mL), dried over anhydrous Na2SO4, and the solvent was removed in vacuo. 
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Further purification by flash chromatography on silica gel yielded modified 
photoproduct. 
(±)-(1S,9R,22S)-20-Methyl-2,4,10,13-
tetraazaheptacyclo[19.3.1.01,9.03,8.010,22.013,22.014,19] 
pentacosa-3(8),4,6,14,16,18,20,23-octaene-11,12-dione 
(3.96). General procedure F was followed on a 0.200 g (0.395 mmol) scale of 3.84fo, 
which afforded crude 3.88fo. The obtained photoproduct was then subjected to general 
procedure G, which after flash chromatography on silica gel (gradient elution: 
chloroform → chloroform–methanol 97:3) afforded 0.076 g (52% after two steps) of the 
title compound. 1H NMR (500 MHz, CDCl3) δ 8.06 (dt, J = 5.6, 1.1 Hz, 1H), 7.91 (m, 
2H), 7.37 (ddd, J = 7.9, 6.8, 2.2 Hz, 1H), 7.27 (m, 2H), 6.83 (dd, J = 7.2, 5.3 Hz, 1H), 
6.78 (d, J = 8.6 Hz, 1H), 6.53 (dd, J = 8.5, 0.5 Hz, 1H), 5.17 (s, 1H), 4.69 (d, J = 1.2 Hz, 
1H), 2.75 (d, J = 16.2 Hz, 1H), 2.40 (dt, J = 16.3, 1.0 Hz, 1H), 1.86 (t, J = 1.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 162.6, 158.5, 157.7, 147.8, 135.4, 135.1, 130.6, 129.8, 
129.8, 128.6, 127.1, 127.1, 123.9, 123.1, 122.6, 118.5, 116.7, 73.6, 67.0, 63.3, 30.3, 13.4. 
HRMS (ESI) calcd for C22H17N4O2
+ (MH+) 369.1346, found 369.1355. 
(±)-(1S,10R,23S)-21-Methyl-2,11,14-
triazaheptacyclo[20.3.1.01,10.04,9.011,23.014,23.015,20]hexacosa-
4(9),5,7,15,17,19,21,24-octaene-3,12,13-trione (3.97). 
General procedure F was followed on a 0.196 g (0.359 mmol) scale of 3.84fp, which 
afforded crude 3.88fp. The obtained photoproduct was then subjected to general 
procedure G, which after flash chromatography on silica gel (gradient elution: 
chloroform → chloroform–methanol 97:3) afforded 0.078 g (55% after two steps) of the 
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title compound. 1H NMR (500 MHz, CDCl3) δ 8.13 (dd, J = 7.7, 1.2 Hz, 1H), 8.08 (dd, J 
= 8.0, 0.9 Hz, 1H), 7.67 (s, 1H), 7.61 (td, J = 7.5, 1.4 Hz, 1H), 7.55 (dtd, J = 7.8, 1.3, 0.5 
Hz, 1H), 7.51 (tt, J = 7.5, 1.1 Hz, 1H), 7.38 (ddd, J = 8.0, 7.1, 1.9 Hz, 1H), 7.26 (m, 2H), 
6.76 (dd, J = 8.3, 0.5 Hz, 1H), 6.49 (dd, J = 8.3, 0.7 Hz, 1H), 5.08 (s, 1H), 2.79 (d, J = 
16.0 Hz, 1H), 2.48 (dt, J = 16.7, 1.3 Hz, 1H), 1.83 (t, J = 1.3 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 164.9, 158.8, 157.3, 134.8, 134.2, 133.9, 133.5, 130.4, 129.1, 129.0, 
128.7, 127.9, 127.1, 126.9, 126.4, 126.2, 124.7, 124.1, 121.6, 72.9, 57.7, 57.7, 32.1, 13.6. 
HRMS (ESI) calcd for C24H18N3O3
+ (MH+) 396.1343, found 396.1346. 
 
 
 
 
General Procedure H for Pictet–Spengler Reaction. Photoproduct (3.88fq; 
0.369 mmol) was dissolved in TFA (7 mL). Aldehyde (3.75; 1.81 mmol) was added, and 
the mixture was refluxed for 1 day. Volatiles were removed in vacuo, and the residue was 
redissolved in DCM (50 mL). Solution was washed with sat. aq. NaHCO3 (2×10 mL). 
Aqueous layer was extracted with DCM (3×20 mL). The combined organic layers were 
washed with water (3×15 mL) and sat. aq. NaCl (15 mL), dried over anhydrous Na2SO4, 
and the solvent was removed in vacuo. Further purification by flash chromatography on 
silica gel yielded modified photoproduct. 
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(±)-(1S,3R,10R,23S)-5,7-Dimethoxy-21-methyl-3-phenyl-2,11,14-triazaheptacyclo 
[20.3.1.01,10.04,9.011,23.014,23.015,20]hexacosa-4(9),5,7,15,17,19,21,24-octaene-12,13-dione 
(3.100). 
Step 1. (±)-tert-Butyl N-[(1S,3R,4S,15S,18R)-18-(3,5-
dimethoxyphenyl)-4-hydroxy-4-methyl-12,13-dioxo-
11,14-diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-
5,7,9,16-tetraen-1-yl]carbamate (3.88fq). General 
procedure F was followed on a 0.202 g (0.369 mmol) scale of 3.84fq, which after flash 
chromatography on silica gel (gradient elution: chloroform → chloroform–methanol 
97:3) afforded 0.165 g of 3.88fq. 1H NMR (500 MHz, CDCl3) δ 8.31 (dd, J = 8.2, 1.1 Hz, 
1H), 7.72 (dd, J = 7.9, 1.6 Hz, 1H), 7.38 (ddd, J = 8.2, 7.5, 1.6 Hz, 1H), 7.29 (td, J = 7.6, 
1.3 Hz, 1H), 6.91 (d, J = 8.6 Hz, 1H), 6.40 (t, J = 2.2 Hz, 1H), 6.35 (d, J = 1.8 Hz, 2H), 
6.20 (d, J = 8.5 Hz, 1H), 5.07 (s, 1H), 4.79 (s, 1H), 3.74 (s, 6H), 2.94 (dd, J = 9.4, 4.9 Hz, 
1H), 2.01 (dd, J = 12.6, 10.4 Hz, 1H), 1.78 (dd, J = 13.1, 4.0 Hz, 1H), 1.49 (s, 9H), 1.35 
(s, 3H). 13C NMR (126 MHz, CDCl3 + DMSO) δ 161.2, 157.3, 155.0, 154.6, 139.6, 
135.2, 134.3, 131.0, 128.7, 127.9, 127.5, 126.4, 120.6, 106.1, 100.1, 80.8, 70.9, 70.0, 
58.9, 57.7, 55.5, 48.0, 28.5, 28.4, 26.5. HRMS (ESI) calcd for C30H34N3O7
+ (MH+) 
548.2391, found 548.2391. 
Step 2. (±)-(1S,3R,10R,23S)-5,7-Dimethoxy-21-methyl-3-
phenyl-2,11,14-triazaheptacyclo 
[20.3.1.01,10.04,9.011,23.014,23.015,20]hexacosa-
4(9),5,7,15,17,19,21,24-octaene-12,13-dione (3.100). 
0.165 g of photoproduct 3.88fq was subjected to general procedure H with 1.81 mmol of 
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benzaldehyde (3.75h), which after flash chromatography on silica gel (gradient elution: 
hexane → hexane–ethyl acetate 50:50) afforded 0.063 g (33% after two steps) of the title 
compound. 1H NMR (500 MHz, CDCl3) δ 8.07 (dd, J = 8.0, 1.1 Hz, 1H), 7.34 (td, J = 
7.7, 1.6 Hz, 1H), 7.27 (m, 7H), 6.88 (dd, J = 2.4, 0.9 Hz, 1H), 6.60 (d, J = 8.2 Hz, 1H), 
6.39 (dd, J = 2.4, 0.4 Hz, 1H), 6.22 (d, J = 8.3 Hz, 1H), 5.38 (d, J = 0.5 Hz, 1H), 4.66 (s, 
1H), 3.77 (s, 3H), 3.52 (s, 3H), 2.76 (dd, J = 16.2, 0.9 Hz, 1H), 2.34 (d, J = 16.0 Hz, 1H), 
1.85 (t, J = 1.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.4, 159.2, 157.9, 157.0, 
144.9, 137.5, 135.1, 132.4, 130.5, 129.1, 128.6, 128.5, 127.5, 127.3, 126.7, 126.6, 123.8, 
123.5, 121.3, 117.5, 103.9, 99.4, 73.3, 58.3, 58.0, 55.6, 55.5, 54.9, 30.9, 13.5. HRMS 
(ESI) calcd for C32H28N3O4
+ (MH+) 518.2074, found 518.2072. 
(±)-(1S,3R,10R,23S)-5,7-Dimethoxy-21-methyl-3-(pyridin-3-yl)-2,11,14-
triazaheptacyclo[20.3.1.01,10.04,9.011,23.014,23.015,20]hexacosa-4(9),5,7,15,17,19,21,24-
octaene-12,13-dione (3.101). 
Step 1. (±)-tert-Butyl N-[(1S,3R,4S,15S,18R)-18-(3,5-
dimethoxyphenyl)-4-hydroxy-4-methyl-12,13-dioxo-
11,14-diazapentacyclo[12.3.1.03,15.05,10.011,15]octadeca-
5,7,9,16-tetraen-1-yl]carbamate (3.88fq). General 
procedure F was followed on a 0.365 g (0.667 mmol) scale of 3.84fq, which after flash 
chromatography on silica gel (gradient elution: hexane → ethyl acetate) afforded 0.190 g 
of 3.88fq.  
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Step 2. (±)-(1S,3R,10R,23S)-5,7-Dimethoxy-21-methyl-3-
(pyridin-3-yl)-2,11,14-triazaheptacyclo 
[20.3.1.01,10.04,9.011,23.014,23.015,20]hexacosa-
4(9),5,7,15,17,19,21,24-octaene-12,13-dione (3.101). 
0.179 g of the photoproduct 3.88fq was subjected to general procedure H with 3.17 mmol 
of nicotinaldehyde (3.75k), which after flash chromatography on silica gel (gradient 
elution: chloroform → chloroform–methanol 97:3) afforded 0.110 g (34% after two 
steps) of the title compound. 1H NMR (500 MHz, CDCl3) δ 8.64 (d, J = 1.7 Hz, 1H), 8.48 
(dd, J = 4.8, 1.4 Hz, 1H), 8.07 (dd, J = 8.0, 0.9 Hz, 1H), 7.53 (dt, J = 7.9, 1.8 Hz, 1H), 
7.34 (ddd, J = 8.0, 7.3, 1.7 Hz, 1H), 7.24 (m, 3H), 6.89 (dd, J = 2.3, 0.8 Hz, 1H), 6.62 (d, 
J = 8.3 Hz, 1H), 6.38 (d, J = 2.2 Hz, 1H), 6.24 (d, J = 8.3 Hz, 1H), 5.42 (d, J = 0.7 Hz, 
1H), 4.69 (s, 1H), 3.76 (s, 3H), 3.54 (s, 3H), 2.78 (d, J = 16.4 Hz, 1H), 2.33 (dt, J = 16.2, 
1.4 Hz, 1H), 1.85 (t, J = 1.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.7, 159.3, 157.8, 
156.6, 149.4, 148.2, 140.7, 137.3, 135.4, 135.2, 132.5, 130.5, 128.8, 128.6, 126.7, 126.6, 
123.9, 123.7, 123.7, 121.3, 116.2, 104.1, 99.3, 73.3, 58.1, 58.0, 55.6, 55.3, 52.7, 31.0, 
13.5. HRMS (ESI) calcd for C31H27N4O4
+ (MH+) 519.2027, found 519.2031. 
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(±)-(1S,3R,14R,15S,18S)-15-Methoxy-14-phenyl-2-oxa-10,13-diazahexacyclo 
[13.3.1.01,3.04,9.010,18.013,18]nonadeca-4,6,8,16-tetraene-11,12-dione (3.103), 
(±)-(1S,16R,20S,21R)-1-Methoxy-19,21-diphenyl-17-oxa-11,14,18-
triazahexacyclo[12.6.1.03,15.05,10.011,15.016,20]henicosa-3,5(10),6,8,18-pentaene-12,13-
dione (3.105) and (±)-(1S,16R,22R,23S,24R)-1-Methoxy-19,22,24-triphenyl-17,21-
dioxa-11,14,18,20-tetraazaheptacyclo[12.9.1.03,15.05,10.011,15.016,23.018,22]tetracosa-
3,5(10),6,8,19-pentaene-12,13-dione (3.106). 
Step 1. (±)-(1S,15S,18R)-1-Methoxy-18-phenyl-11,14-diazapentacyclo 
[12.3.1.03,15.05,10.011,15]octadeca-3,5,7,9,16-pentaene-12,13-dione (3.102). General 
procedure F was followed on a 0.297 g (0.765 mmol) scale of 3.83ah, which afforded 
crude 3.87ah. The obtained photoproduct was then subjected to general procedure G, 
which afforded 0.271 g of crude 3.102. 1H NMR (500 MHz, CDCl3) δ 7.98 (dq, J = 8.0, 
0.5 Hz, 1H), 7.35 (m, 4H), 7.25 (m, 2H), 7.21 (td, J = 7.6, 1.2 Hz, 1H), 7.11 (dd, J = 7.5, 
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1.4 Hz, 1H), 6.74 (dd, J = 8.7, 0.7 Hz, 1H), 6.65 (dd, J = 8.7, 0.8 Hz, 1H), 6.20 (t, J = 1.9 
Hz, 1H), 4.84 (d, J = 1.7 Hz, 1H), 3.45 (s, 3H), 2.61 (dd, J = 16.7, 2.0 Hz, 1H), 2.49 (dt, J 
= 16.8, 1.9 Hz, 1H). 
Step 2a. (±)-(1S,3R,14R,15S,18S)-15-Methoxy-14-phenyl-2-oxa-10,13-
diazahexacyclo [13.3.1.01,3.04,9.010,18.013,18]nonadeca-4,6,8,16-tetraene-11,12-dione 
(3.103). 0.135 g of crude 3.102 was dissolved in chloroform (15 mL). The solution was 
treated with mCPBA (0.200 g, 1.16 mmol) and refluxed for 4 h. The mixture was then 
diluted with DCM (50 mL) and washed 2 times with sat. aq. NaHCO3 (5 mL) diluted 
with water (5 mL). Aqueous layer was extracted with DCM (2×10 mL). The combined 
organic layers were washed with water (10 mL) and sat. aq. NaCl (10 mL), dried over 
anhydrous Na2SO4, and the solvent was removed in vacuo. Further purification by flash 
chromatography on silica gel pre-treated with pyridine (gradient elution: hexane → 
hexane–ethyl acetate + 1% TEA 60:40) afforded 0.040 g (27% after three steps) of 3.103.  
3.103: 1H NMR (500 MHz, CDCl3) δ 7.92 (ddd, J = 7.9, 1.2, 0.6 
Hz, 1H), 7.50 (m, 2H), 7.41 (m, 4H), 7.35 (m, 1H), 7.29 (td, J = 
7.6, 1.2 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.38 (d, J = 8.8 Hz, 
1H), 4.90 (d, J = 1.5 Hz, 1H), 4.01 (s, 1H), 3.42 (s, 3H), 2.36 (dd, J = 13.8, 1.7 Hz, 1H), 
2.09 (d, J = 13.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 157.3, 154.7, 140.6, 131.8, 
131.6, 130.8, 130.6, 128.8, 128.8, 128.7, 128.5, 126.8, 124.4, 123.3, 80.1, 69.9, 67.0, 
60.8, 59.1, 52.7, 29.9. HRMS (ESI) calcd for C23H19N2O4
+ (MH+) 387.1339, found 
387.1342. 
Step 2b. (±)-(1S,16R,20S,21R)-1-Methoxy-19,21-diphenyl-17-oxa-11,14,18-
triazahexacyclo [12.6.1.03,15.05,10.011,15.016,20]henicosa-3,5(10),6,8,18-pentaene-12,13-
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dione (3.105) and (±)-(1S,16R,22R,23S,24R)-1-Methoxy-19,22,24-triphenyl-17,21-dioxa-
11,14,18,20-tetraazaheptacyclo[12.9.1.03,15.05,10.011,15.016,23.018,22]tetracosa-
3,5(10),6,8,19-pentaene-12,13-dione (3.106). Under nitrogen, 0.135 g of crude 3.102 was 
dissolved in anhydrous DCM (8 mL), and the solution was treated with 
N-hydroxybenzimidoyl chloride [182] (3.104; 0.598 g, 3.85 mmol) and potassium 
bicarbonate (0.460 g, 4.60 mmol). The mixture was stirred at ambient temperature for 
1 day, and then quenched with water (5 mL). Aqueous layer was extracted with DCM 
(3×20 mL). The combined organic layers were washed with water (2×10 mL) and sat. aq. 
NaCl (10 mL), dried over anhydrous Na2SO4, and the solvent was removed in vacuo. 
Further purification by flash chromatography on silica gel (gradient elution: hexane → 
hexane–ethyl acetate 60:40) afforded 0.049 g (26% after three steps) of 3.105 and crude 
3.106 which was additionally purified by flash chromatography on silica gel (gradient 
elution: hexane → chloroform) to yield 0.022 g (9% after three steps) of pure 3.106.  
3.105: 1H NMR (500 MHz, CDCl3) δ 7.47 (m, 2H), 7.37 (m, 5H), 
7.32 (m, 3H), 7.26 (td, J = 7.6, 1.3 Hz, 1H), 7.20 (m, 3H), 6.41 (t, 
J = 2.3 Hz, 1H), 5.65 (d, J = 1.5 Hz, 1H), 5.38 (d, J = 11.5 Hz, 
1H), 4.64 (d, J = 11.5 Hz, 1H), 3.43 (s, 3H), 2.77 (dd, J = 18.2, 2.4 Hz, 1H), 2.70 (dt, J = 
18.3, 1.7 Hz, 1H). 13C NMR (126 MHz, CDCl3+DMSO) δ 156.2, 154.4, 154.0, 132.9, 
131.5, 131.1, 130.0, 129.6, 129.3, 128.6, 128.5, 128.0, 127.8, 127.7, 127.6, 127.0, 124.6, 
122.2, 122.2, 81.7, 76.3, 70.2, 57.4, 56.1, 52.5, 28.2. HRMS (ESI) calcd for C30H24N3O4
+ 
(MH+) 490.1761, found 490.1769.  
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3.106: 1H NMR (500 MHz, CDCl3) δ 7.99 (m, 2H), 7.49 (m, 
8H), 7.40 (m, 2H), 7.32 (m, 3H), 7.26 (td, J = 7.6, 1.2 Hz, 1H), 
7.15 (m, 3H), 6.30 (t, J = 2.2 Hz, 1H), 5.86 (d, J = 1.4 Hz, 1H), 
4.99 (d, J = 9.1 Hz, 1H), 3.89 (d, J = 9.1 Hz, 1H), 3.20 (s, 3H), 
2.65 (dd, J = 18.2, 2.3 Hz, 1H), 2.57 (dt, J = 18.2, 1.8 Hz, 1H). 13C NMR (126 MHz, 
CD2Cl2) δ 159.9, 156.4, 155.2, 133.5, 133.3, 132.8, 132.2, 130.7, 130.2, 129.9, 129.7, 
129.6, 129.5, 128.9, 128.8, 128.2, 127.9, 127.5, 126.5, 125.8, 125.3, 123.1, 122.7, 108.7, 
80.4, 77.4, 70.6, 58.5, 57.3, 52.3, 27.8. HRMS (ESI) calcd for C37H29N4O5
+ (MH+) 
609.2132, found 609.2144. 
 
 
(±)-(1R,3R,4S,16S,20S,21R)-17-Bromo-4-hydroxy-1-methoxy-21-phenyl-19-oxa-
11,14,18-triazahexacyclo[12.6.1.03,15.05,10.011,15.016,20]henicosa-5(10),6,8,17-tetraene-
12,13-dione (3.108). Photoprecursor 3.83ah (0.241 g, 0.620 mmol) was dissolved in 
anhydrous DMF (25 mL), and the solution was degassed by bubbling argon for 1 h. The 
mixture was irradiated with UV LED-based illuminator (seven 2.9 W @ 365 nm LED 
Engin chips) with reaction progress monitored by 1H NMR. After completion (reaction 
time = 10 h), the solution was treated with dibromoformaldoxime (3.107; 0.509 g, 
2.51 mmol) and potassium bicarbonate (0.501 g, 5.01 mmol). The mixture was stirred at 
ambient temperature for 1 day, and then DMF was evaporated under high vacuum 
(50 °C/0.15 Torr). The residue was redissolved in ethyl acetate (100 mL) and washed 
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with water (20 mL). The aqueous layer was extracted with ethyl acetate (3×30 mL). The 
combined organic layers were washed with water (3×25 mL) and sat. aq. NaCl 
(2×25 mL), dried over anhydrous Na2SO4, and the solvent was removed in vacuo. Further 
purification by flash chromatography on silica gel (gradient elution: chloroform → 
chloroform–methanol 95:5) afforded 0.092 g (29% after two steps) of the title compound. 
1H NMR (500 MHz, DMSO) δ 8.17 (dd, J = 8.2, 1.1 Hz, 1H), 7.71 (dt, J = 8.2, 1.2 Hz, 
1H), 7.49 (ddd, J = 8.7, 7.7, 1.9 Hz, 1H), 7.36 (m, 6H), 6.15 (d, J = 6.6 Hz, 1H), 5.48 (d, 
J = 11.7 Hz, 1H), 5.19 (s, 1H), 4.66 (dd, J = 9.8, 6.3 Hz, 1H), 4.50 (d, J = 11.7 Hz, 1H), 
3.24 (s, 3H), 2.77 (td, J = 10.6, 5.7 Hz, 1H), 1.87 (ddd, J = 14.1, 5.7, 1.7 Hz, 1H), 1.76 
(dd, J = 13.9, 10.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 155.7, 154.2, 135.8, 132.7, 
131.3, 130.1, 128.5, 128.5, 128.2, 128.0, 128.0, 125.9, 119.3, 79.8, 75.3, 68.9, 67.3, 55.9, 
53.9, 51.3, 40.9, 25.8. HRMS (ESI) calcd for C24H21BrN3O5
+ (MH+) 510.0659, found 
510.0658. 
Kinetic Isotope Effect Measurements 
Experiment 1 
 
 
 
 
0.01 M solutions of 3.83ag and 3.83ag-d3 in DMSO-d6 (0.40 mL) with 0.75 mg 
(0.0037 mmol) of DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) as an internal 
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standard were degassed by bubbling nitrogen and irradiated in a carousel UV LED 
photoreactor (seven 2.9 W @ 365 nm LED Engin chips) with reaction progress 
monitored by 1H NMR. Spectra were acquired at five time points: 
• 0 min, 15 min, 20 min, 25 min and 37 min for 3.83ag; 
• 0 min, 37 min, 55 min, 114 min and 193 min for 3.83ag-d3. 
The experiment was carried out two times. In the obtained spectra, the following 
signals were integrated: 
• In all spectra: a peak from the internal standard at 0.80 ppm (integration was 
set to 1.00); 
• Only in the “0 min” spectrum: peaks from photoprecursor (3.83ag/3.83ag-d3) 
at 7.63 ppm (1H), 6.93 ppm (2H); 
• In all spectra, except “0 min”: peaks from the primary photoproduct 
(3.85ag/3.85ag-d3) at 6.20 ppm (1H), 5.57 ppm (1H; in some cases, skipped 
due to overlapping signals), 5.31 ppm (1H);  
• In all spectra, except “0 min”: peaks from the secondary photoproduct 
(3.87ag/3.87ag-d3) at 8.12 ppm (1H; skipped for 3.87ag-d3 due to overlapping 
signals), 6.77 ppm (1H), 6.29 ppm (1H). 
Integration values that correspond to the same compound were averaged. Then, the 
numbers obtained for 3.87ag and 3.87ag-d3 were normalized (the photoprecursors’ 
integrations in the “0 min” spectra were set to 100%) and used to plot “conversion vs. 
time” graphs (Figures 4.1, 4.2). Based on the data from two experiments, linear 
trendlines were found for each secondary product; their slopes (“X Variable 1”) represent 
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relative rates of formation for 3.87ag and 3.87ag-d3, and therefore were used to calculate 
KIE. 
 
 
 
 
 
 
 
 
Figure 4.1: “Conversion vs. time” plot for 3.87ag. 
 
 
 
 
 
 
 
 
 
Figure 4.2: “Conversion vs. time” plot for 3.87ag-d3. 
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𝐾𝐼𝐸(𝑎𝑝𝑝) =
𝑋 𝑉𝑎𝑟. 1 (3.87ag)
𝑋 𝑉𝑎𝑟. 1 (3.87ag‐d3)
=
1.6 × 10−2 ± 6.7 × 10−4
2.2 × 10−4 ± 2.7 × 10−5
= 72 ± 72 × (
6.7 × 10−4
1.6 × 10−2
+
2.7 × 10−5
2.2 × 10−4
) = 72 ± 12 
Experiment 2 
 
 
 
 
 
 
 
 
 
0.237 g (0.756 mmol) of 3.83ag-d was irradiated according to general procedure F. 
The product (which is a mixture of A, B and C) was purified by flash chromatography on 
silica gel (gradient elution: DCM → DCM–methanol 98:2) and analyzed by 1H NMR 
(Figure 4.3). 
The compound A was distinguished from two other components (B and C) based on 
the presence/absence of D in the methylene group at the α-position to the amide nitrogen 
(signal from another CH2 group appeared to be non-first order and therefore was hard to 
analyze). By integrating the methylene signals, contents of A and B + C in the product 
were obtained. 
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Important notes: 
• N–CHD proton in A gives two signals in the spectrum (3.59 and 3.53 ppm), 
because half of these protons are oriented “up” relative to the configuration of 
all other stereocenters, whereas another half has “down” orientation (assuming 
equal distribution of epimers); 
• N–CH2 group signals in B and C are expected to be split with large 2J = 11 Hz 
(see 1H NMR data for 3.87ag); given that this SSCC is not observed, it is 
conceivable that half of these signals overlap with N–CHD peaks from A. 
Figure 4.3: 1H NMR spectrum of the product obtained by irradiation of 3.83ag-d. 
 
0.5 × 𝐀 + 0.5 × (𝐁 + 𝐂) = 52.6 ± 6.9% = 52.6 ± 3.6 
0.5 × (𝐁 + 𝐂) = 2.7 ± 5.0% = 2.7 ± 0.14 
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𝐀 = (52.6 ± 3.6) × 2 − (2.7 ± 0.14) × 2 = (49.9 ± 3.74) × 2 = 99.8 ±
99.8 × (3.74/49.9) =  99.8 ± 7.48 ∝ 94.8 ± 7.11 (𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑) 
𝐁 + 𝐂 = (2.7 ± 0.14) × 2 = 5.4 ± 5.4 × (0.14/2.7) = 5.4 ± 0.28 ∝ 5.1 ±
0.26 (𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑)  
It was assumed that all non-deuterated product (C) originated from the protic 
precursor 3.83ag, an impurity in 3.83ag-d. Therefore, the content of C in the product 
should be equal to the percentage of 3.83ag in the photoprecursor, which was calculated 
from the 1H NMR spectrum of 3.83ag-d by integrating CH3 and CH2D signals 
(Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: 1H NMR spectrum of 3.83ag-d. 
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𝐂 = 𝟏𝐚 =
72320.254/3
72320.254/3 + (367180.916 + 555862.554 + 342107.573)/2
× 100
= 3.7 ± 5% = 3.7 ± 0.19 (𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑) 
With the known content of C, percentage of B and then KIE were calculated: 
𝐁 = (𝐁 + 𝐂) − 𝐂 = (5.1 ± 0.26) − (3.7 ± 0.19) = 1.4 ± 0.45  
𝐾𝐼𝐸 =
𝐀/2
𝐁
=
(94.8 ± 7.11)/2
1.4 ± 0.45
=
47.4 ± 47.4 × (7.11/94.8)
1.4 ± 0.45
=
47.4 ± 3.56
1.4 ± 0.45
= 34 ± 34 × (
3.56
47.4
+
0.45
1.4
) = 34 ± 14 
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Chapter Five:  Conclusions 
In this work, four new photoassisted synthetic methodologies have been presented. 
All of them take advantage of the light-induced process called excited-state 
intramolecular proton transfer (ESIPT), which generates a reactive o-azaxylylene species 
from readily available o-amido-substituted benzaldehydes and aromatic ketones by 
tautomerization. These reactive intermediates dearomatize tethered aromatic moieties and 
thereby lead to complex structures enriched with sp3 carbon atoms. Furthermore, the 
photoproducts contain functional groups suitable for a multitude of post-photochemical 
modifications, which add another layer of complexity to the final compounds. 
Specifically, we have demonstrated the following: 
• Epoxide-outfitted 2,5-diketopiperazino-quinolinols, which result from the 
diastereoselective intramolecular [4+4] reaction between o-azaxylylenes and 
1,3,4-oxadiazoles with subsequent dinitrogen extrusion, can be engaged in 
various modifications providing access to diverse molecular scaffolds. These 
transformations include epoxide ring-openings and extensive rearrangements 
under Schmidt reaction conditions. 
• Amino-o-azaxylylenes participate in diastereoselective [4+2] cycloadditions 
to tethered pyrrole units in enantiopure photoprecursors, which are quickly 
accessed from chiral amino acids. Reactive enamine double bonds present in 
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the photoproducts serve as entry points for subsequent modifications, such as 
1,3-dipolar cycloaddition and intramolecular Friedel–Crafts reaction. 
• Previously undocumented [2+4] topology of photoinduced benzene 
dearomatization can be achieved through the intramolecular cycloaddition to 
ESIPT-generated o-azaxylylenes. This process affords products with electron-
rich 1,3-cyclohexadiene fragments modifiable by cyclic ketal formation, 
hydrolysis to enones and hetero-Diels–Alder reactions. 
• Incorporation of the multifunctional oxalyl linker into precursor systems 
enables the unprecedented photocascade reaction, where the primary 
o-azaxylylene–aniline [2+4] cycloadducts undergo the subsequent secondary 
photoprocess sensitized by α-dicarbonyl fragment, furnishing complex 
architectures with azabicyclo[2.2.2]octene cores. Various functionalities in the 
photoproducts can be utilized for further transformations, such as acid-
promoted cyclizations, epoxidations, and 1,3-dipolar cycloadditions. 
A subset of the compounds obtained during this work (Figure 5.1) clearly 
demonstrates the diversity and complexity of the structures that can be accessed by the 
methodologies described herein. An important aspect of our chemistry is that the 
synthesis of the required photoprecursors is achieved in a modular fashion from simple 
starting materials and involves robust chemical transformations, creating opportunities 
for further diversification of the product library. 
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Figure 5.1: Selected products prepared by the photoassisted methods developed in this 
work. 
To illustrate high levels of diversity and complexity of the molecules produced by our 
photochemistry-based methods, we ran calculations using the DataWarrior software 
developed by Actelion Pharmaceuticals Ltd. [183, 184]. For the array containing eight of 
our compounds (Figure 5.1) and three natural products (for comparison), we computed 
four types of molecular descriptors – abstract “fingerprints” containing information about 
certain structural features. By applying principal component analysis (PCA), the obtained 
data were converted into a three-dimensional plot visualizing the distribution of the 
molecules in the descriptor-defined chemical space (Figure 5.2). This 3D representation 
illustrates that our photoproducts are spread across a considerable area of chemical space, 
supporting the idea about the diversity of generated scaffolds. 
In addition, we calculated molecular complexity indices (Table 5.1). The numbers 
show that our methodology is capable of producing structures being as complex as 
paclitaxel – a molecule that is regarded as one of the most challenging targets for total 
synthesis. 
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Figure 5.2: PCA-calculated distribution of the selected photoproducts (Figure 5.1) 
and natural products (5.1–5.3) in the chemical space defined by four types of descriptors. 
 
Table 5.1: Molecular Complexity Indices for the Selected Photoproducts 
and Natural Products 
Compound Molecular Complexity (low < 0.5 < high) 
3.8b 1.06 
3.27 1.10 
3.39 1.09 
anti-3.60l 1.02 
3.67 1.09 
3.88ck 1.13 
3.101 1.13 
3.106 1.18 
5.1 (penicillin G) 0.88 
5.2 (strychnine) 1.07 
5.3 (paclitaxel) 1.10 
 
3.27 
3.88ck 
3.101 
3.39 
3.8b 
anti-3.60l 
3.67 
3.106 
5.1 
5.2 
5.3 
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Taking everything into account, we believe that our synthetic methods allow for 
probing large regions of unexplored chemical space, and therefore, are suitable for DOS-
based strategy in the drug discovery. For that reason, we have started sending selected 
photoproducts to the National Cancer Institute, where they are evaluated for anti-cancer 
activities. We hope that our efforts in developing new chemical tools for creating small 
molecules can contribute to the discovery of novel therapies. 
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Appendix B:  List of Abbreviations and Acronyms 
ABT  2-(2'-aminophenyl)benzothiazole 
Ac  acetyl 
AIBN  azobisisobutyronitrile 
app  apparent 
aq.  aqueous 
Ar  aryl 
2-BAPBI 2-(2'-benzamidophenyl)benzimidazole 
BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl) 
Bn  benzyl 
Boc  tert-butyloxycarbonyl 
BPT  back proton transfer 
BR  biradical 
nBu  normal-butyl 
tBu  tert-butyl 
Bz  benzoyl 
CAAQ  1-(chloroacetylamino)anthraquinone 
calcd  calculated 
cat.  catalyst (or catalytic amount) 
ccw  counterclockwise 
comb.   combined 
CT  charge transfer 
cw  clockwise 
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DCAQ  1-(dichloroacetylamino)anthraquinone 
DCE  1,2-dichloroethane 
DCM  dichloromethane 
de  diastereoisomeric excess 
DFT  density functional theory 
DIPEA N,N-diisopropylethylamine 
DMAP  4-(N,N-dimethylamino)pyridine 
DMBP  4,4'-dimethoxybenzophenone 
DMF  N,N-dimethylformamide 
DMP  Dess–Martin periodinane 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DOS  diversity-oriented synthesis 
dppb  1,4-bis(diphenylphosphino)butane 
DR  diradical 
DSS  4,4-dimethyl-4-silapentane-1-sulfonic acid 
EDC  N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 
ee  enantiomeric excess 
er  enantiomeric ratio 
ESI  electrospray ionization 
ESICT  excited-state intramolecular charge transfer 
ESIPT  excited-state intramolecular proton transfer 
Et  ethyl 
 237 
FDA  Food and Drug Administration 
GP  general procedure 
h   hour 
HAT  hydrogen atom transfer 
HATU  (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxid hexafluorophosphate 
HMPA  hexamethylphosphoramide 
HOAt  1-hydroxy-7-azabenzotriazole 
HPAQ  1-(heptanoylamino)anthraquinone 
HPLC  high-performance liquid chromatography 
HRMS  high-resolution mass spectrum 
hν  light (irradiation) 
int.  intermediate 
IPA  2-(imidazo[1,2-a]pyridin-2-yl)aniline 
ISC  intersystem crossing 
KIE  kinetic isotope effect 
LDA  lithium diisopropylamide 
LED  light-emitting diode 
LWA  long-wavelength absorption 
LWE  long-wavelength emission 
mCPBA meta-chloroperbenzoic acid 
Me  methyl 
min  minute 
 238 
N  normal or enol from 
NBS  N-bromosuccinimide 
Ni(cod)2 bis(1,5-cyclooctadiene)nickel(0) 
NMO  N-methylmorpholine N-oxide 
NMR  nuclear magnetic resonance 
PBT  2-phenylbenzothiazole 
PCA  principal component analysis 
Pd(dba)2 bis(dibenzylideneacetone)palladium(0) 
PET  photoinduced electron transfer 
Ph  phenyl 
Phth  phthalimide 
PIP  2‐phenylimidazo[1,2‐a]pyridine 
iPr  iso-propyl 
PTSA  p-toluenesulfonic acid monohydrate 
Py  pyridine (or pyridyl) 
QY  quantum yield 
ref.  reference 
RFF  relativistic force field 
rfx  reflux 
RNA  ribonucleic acid 
rt  room temperature 
S0  ground state 
S1  first singlet excited state 
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sat.  saturated 
SSCC  spin-spin coupling constant 
Sulf  sulfonyl 
SWA  short-wavelength absorption 
SWE  short-wavelength emission 
T  tautomeric or keto from 
T1 (T2)  first (second) triplet excited state 
TADDOL α,α,α',α'-tetraaryl-2,2-disubstituted 1,3-dioxolane-4,5-dimethanol 
TCSPC time-correlated single-photon counting 
TEA  triethylamine 
TES  triethylsilyl 
TFA  trifluoroacetic acid 
TFAQ  1-(trifluoroacetylamino)anthraquinone 
TFE  2,2,2-trifluoroethanol 
THF  tetrahydrofuran 
TICT  twisted internal charge transfer 
TMS  tetramethylsilane 
Ts  para-toluenesulfonyl 
U.S.  United States 
UV  ultraviolet 
Var.  variable 
vis.  visible 
vol  volume 
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